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Abstract 
 
Background: High dietary sugar intake is controversially associated with an 
increase in prevalence of type 2 diabetes globally. This has been attributed to the 
impact that sugars have in the development of disease risk factors linked to 
diabetes, cardiovascular disease and others. (Poly)phenols present in our daily 
diet may affect these processes by multiple mechanisms, including effects on the 
digestion, uptake and post-prandial distribution of glucose and fructose.  
Aim: Study the expression of GLUT7 in Caco-2/TC7 intestinal cells and identify 
novel inhibitors of sugar transporters by determining the direct impact of specific 
(poly)phenols and extracts on fructose and glucose uptake by GLUT2 and GLUT7 
transporters, as well as their effect on sugar uptake by the fructose specific 
transporter GLUT5.  
Methods: The Caco-2/TC7 cell model was used to investigate GLUT7 expression. 
For sugar transport studies, X. laevis oocytes were injected with the relevant 
transporter mRNA. After protein expression, oocytes were incubated in a 14C-
glucose/fructose solution containing individual (poly)phenols and extracts. 
Automated capillary Western blotting (Wes) confirmed protein expression on 
oocyte membranes and uptake of internalysed 14C-glucose/fructose was observed 
by liquid scintillation counting.  
Results: The presence of fructose led to a significant increase in GLUT7 
expression, as determined by mRNA (13% increase, p ≤ 0.001) and protein (2.7-
fold increase, p ≤ 0.05) analysis of the Caco-2/TC7 cell model. GLUT5-mediated 
fructose transport was significantly inhibited by German chamomile extract (IC50 of 
 
 
iv 
 
0.73±0.18 mg/ml), sugar-free pomegranate extract (0.48 ± 0.22 mg/ml), apigenin 
(IC50 = 40 ± 4 µM), (–)-epigallocatechin-gallate (EGCG) (IC50= 72 ± 13 µM) and 
hesperidin (IC50 = 264 ± 72 µM). GLUT2-mediated glucose transport was 
significantly inhibited by various compounds and extracts, including quercetin (IC50 
= 7 ± 1 µM), EGCG (IC50 = 72 ± 13 µM) and apigenin (IC50 = 27 ± 4 µM). These 
three compounds also significantly inhibited fructose transport by GLUT2; IC50 = 8 
± 2 µM for quercetin, 93 ± 16 µM for EGCG and 28 ± 10 µM for apigenin. In addition, 
apigenin significantly decreased the uptake of both glucose (IC50 = 38 ± 2 µM) and 
fructose (IC50 = 16 ± 12 µM) by GLUT7.  
Conclusions: The quantitative model used to investigate the molecular 
mechanism of GLUT2, GLUT5 and GLUT7 inhibition by specific (poly)phenols, 
achieved through over-expression of transporters in X. laevis oocytes, identified 
novel inhibitors for each of these individual transporters. In addition, apigenin was 
shown to be a potent inhibitor of sugar transport by all three GLUTs investigated. 
Moreover, fructose was shown to modulate expression of GLUT7 in the Caco-
2/TC7 model. Further characterisation of the lesser known GLUT7, sharing 58% 
sequence similarity to GLUT5, will help highlight any role it may play in regulation 
of sugar uptake. Overall these results suggest that some of these compounds or 
extracts may have potential in interventions aimed at the control of post-prandial 
blood sugar levels in both healthy volunteers and diabetic patients.  
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Chapter 1  
Introduction and research objectives 
 
1.1 Overview 
The monosaccharide D-glucose is the most plentiful ‘simple sugar’ existing in 
nature, and is the main dietary energy producing source for most higher organisms 
(Nelson and Cox, 2008). Although the consumption of sugars is necessary for 
energy and life the development of many health conditions has been associated 
with the ever increasing intake of sugars in the diet. Diabetes mellitus, for instance, 
affects nearly 5% of the world population, with type 2 diabetes (T2DM) accounting 
for 90-95% of cases (Hajiaghaalipour et al., 2015). Many health organizations 
worldwide, including the World Health Organization (WHO) and United Nations 
Food and Agricultural Organization (FAO), have recommended that daily free 
sugar intake should not exceed 10% of the total caloric intake in adults as a 
measure to prevent the development of diabetes and obesity, as well as any risk 
factors associated with these conditions (Laville and Nazare, 2009). The increasing 
health burden associated with excess sugar intake has led to a lot of research 
currently being conducted to try and minimize the health deteriorating effects high 
sugar intake may have in the body. (Poly)phenols are plant derived reducing 
agents that, much like other compounds such as vitamin C and E, act as 
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antioxidants and aid the body in the prevention of oxidative stress and diseases 
such as inflammation and cardiovascular disease which are associated with it 
(Scalbert et al., 2005). Studies have also shown that (poly)phenols are able to 
decrease glucose absorption by the body and have a positive impact on 
carbohydrate metabolism, which in turn helps to controls glycaemic responses, 
secretion of insulin and fasting hyperglycaemia (Hanhineva et al., 2010). 
 
1.2 The health burden of diabetes mellitus and associated 
diseases 
Diabetes mellitus is a chronic condition caused by the body’s lack of insulin 
production or its inability to effectively recognize the availability of insulin. Type 1 
diabetes mellitus (T1DM) is referred to as insulin dependent diabetes mellitus 
(IDDM) and usually develops in early life due to autoimmune impairment of 
pancreatic β cells, which leads to insufficient insulin production. Treatment of 
T1DM is carried out by insulin therapy where insulin dose is balanced in 
accordance to dietary intake (Nelson and Cox, 2008). T2DM is also known as non-
insulin dependent diabetes mellitus (NIDDM) for individuals with T2DM produce 
insulin but become insulin resistant due to damaged insulin recognition and 
response system. The risk of developing T2DM is higher in individuals suffering 
from obesity (Nelson and Cox, 2008). The prevalence of obesity has trebled in the 
last 20 years in the UK alone and has contributed to elevated levels of morbidity 
and mortality (Jennings et al., 2009). In addition, increased dietary intake of sugars 
has been shown to have a corresponding link to increased prevalence of obesity 
in the U.S in the last two decades (Elliott et al., 2002). Diet regulation, therefore, is 
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strongly advised to help control this disease, which is usually managed with 
pharmacological treatments. Physical activity has also been shown to improve, and 
to a certain extent prevent or delay the onset of T2DM as individuals with a weekly 
energy expenditure of 1,000 kcals or above having up to 20% potential reduction 
in risk of T2DM development (Paffenbarger, 1996). Patients living with T2DM are 
also classed as at high risk of developing CVD, most likely due to lipid 
abnormalities, hypertension, and obesity, which are risk factors linked to both 
conditions (Jennings et al., 2009). Throughout the continuation of this report, 
specifically in chapters presenting the research results, the term diabetes is used 
in reference to T2DM, unless otherwise stated. 
 
1.2.1 The role of glucose in the development of diabetes mellitus 
The American Diabetes Association describes diabetes as metabolic diseases 
arising from hyperglycaemia caused by defective secretion and/or action of insulin. 
To that effect, levels of circulating glucose in the blood is a common diagnostic test 
for diabetes (Zeymer, 2006). By definition, diabetes mellitus comes about through 
the body’s inability to produce or recognise insulin, secreted by the pancreatic β 
cells in the presence of glucose, thereby establishing a clear link between this 
condition and glucose (Basciano et al., 2005). Patients with a fasting plasma 
glucose level between 5.6 mmol/L and 6.9 mmol/L are considered to have impaired 
fasting glucose and patients with blood glucose levels between 7.8 mmol/L and 
11.0 mmol/L 2 h following oral glucose tolerance test (OGTT) are considered to 
have impaired glucose tolerance (IGT). Individuals who fit into either of these 
groups are classified as pre-diabetic and are at a higher risk of developing diabetes 
(ADS, 2014). Insulin signalling following carbohydrate intake in T2DM patients is 
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impaired by accumulation of displaced lipids, leading to diminished uptake of 
glucose by skeletal muscles in response to insulin. Excess glucose travels to the 
liver where it contributes to lipogenesis and the increased lipid levels weakens the 
ability of insulin to regulate gluconeogenesis and glycogen synthesis, all 
contributing to the secretion of triglycerides (Samuel and Shulman, 2012). High 
triglycerides levels are associated with obesity and insulin resistance (Ochoa et al., 
2015). 
 
Data from epidemiological studies and surveys from 199 countries worldwide found 
a link between increased fasting plasma glucose and prevalence of T2DM. From 
1980 to 2008 fasting plasma glucose increased by 0.07 mmol/L for men and 0.09 
mmol/L for women every decade, and the number of people with T2DM more than 
double in this same time frame (153 million in 1980 to 347 million in 2008) (Danaei 
et al., 2011). To add to that, food supply data analysed from FAO concluded that 
for each year of exposure to high sugar (more than 300 kcal/person/day) there was 
an 0.053% increase in T2DM prevalence once all control variables were taken into 
account. These findings suggest that prevalence of T2DM can be elevated by 
exposure to sugar in the diets regardless of other factors such as age, exercise 
level and weight (Basu et al., 2013). The Iowa Women’s Health Study, a 
prospective cohort study of over 35.000 postmenopausal women, found that the 
relative risk of developing TD2M was 1.30 for those women who consumed 25.8 
g/day or more of glucose (Meyer et al., 2000). Some diabetic patients are, 
therefore, able to regulate their blood glucose through their diet as well as 
practicing exercise. Nevertheless, for patients with an acute β cell defect simple 
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diet adjustments are not sufficient and these individuals require daily injections of 
insulin to keep their condition under control (Jung et al., 2014). 
 
1.2.2 The role of fructose in the development of risk factors 
associated with diabetes mellitus  
Dietary intake of fructose, mainly from fruits, has been documented for thousands 
of years (Sun and Empie, 2012a). Human ancestral diet, however, was composed 
of high levels of fibre and protein and much lower levels of salts and carbohydrates, 
the latter almost exclusively derived from fruits and vegetables (Konner and Eaton, 
2010). Over three-quarters of the hunter-gatherer societies around the world 
acquired more than 50% of their food from animals, with less than a quarter 
obtaining more than 50% of their sustenance from plants (Cordain et al., 2000). 
These hunter-gatherer groups, although having a high energy consumption from 
carbohydrate (around 20-40%) still consumed less than the current average 
American (about 50%) and very likely used no sweetener apart from honey (Welsh 
et al., 2011). Nevertheless, ever since the industrial revolution, when sugar prices 
dropped and alternative sugar sources were identified, there has been a dramatic 
rise in the consumption of fructose. Daily intake of fructose has increased from 
around 5 g in the 1700s to 180 g by 2009 (Johnson et al., 2009). In other words, 
the consumption of sugars increased by almost 40-fold in 300 years (Douard and 
Ferraris, 2013). This upturn in the amounts of fructose being incorporated into our 
daily diet corresponds with the increase in prevalence of obesity observed since 
around the 1980s in both the UK and USA (Grundy, 1998). Unlike beet and cane 
sugars that are composed of the disaccharide sucrose, formed by a bond between 
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the monosaccharide glucose and fructose molecules, corn sugars have a higher 
percentage of fructose; usually around 55%, but could go up to as high as 90% 
(Guzman-Maldonado and Paredes-Lopez, 1995). High fructose corn syrup 
(HFCS), produced by the enzymatic isomerization of dextrose to fructose, began 
to increase in popularity and be added to foodstuffs such as breakfast cereals, 
condiments and prepared desserts around the 1970s. In 1985 about 35% of 
sweeteners by dry weight was accounted for by HFCS in the food supply (Park and 
Yetley, 1993). Around the same time, intake of fructose accounted for 10% of total 
daily energy intake in adults in the U.S, with similar trends around the world 
(Bialostosky et al., 2002). Over two thirds of fructose consumed came from food 
products and beverages which had the sugar added to them and only about one 
third originated from fruits and other natural sources (Popkin and Nielsen, 2003). 
It is estimated that an individual in the U.S consumes about 600 mL of soft drinks 
every day (Nielsen and Popkin, 2004). Comparison of published data records from 
43 countries suggests that those countries with higher consumption of HFCS have 
a 20% higher prevalence of T2DM than those countries with lower availability of 
HFCS in their foodstuffs (Goran et al., 2013). To add to that, the National Diet and 
Nutrition Survey reported that the daily intake of soft drinks per person per day in 
the UK is of approximately 240 ml and of double this amount in the younger 
population (Bates et al., 2012). Data analysed from four cohort studies suggest 
that the relative risk of developing T2DM was 1.20 per 33 ml of sugar sweetened 
soft drinks per day (p<0.001) and 1.13 per 330 ml artificially sweetened soft drink 
per day (p = 0.02) (Greenwood et al., 2014). It is important to note that the EPIC-
InterAct study reported that those individuals who regularly consumed artificially 
sweetened soft drinks had a higher initial BMI than regular consumers of sugar 
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sweetened soft drinks (28 kg/m2 and 26 kg/m2, respectively), meaning that the 
higher relative risk observed for the artificially sweetened soft drinks category might 
have originated from reverse causality (Forouhi and Wareham, 2014). 
Nonetheless, a hypothesis that the uncoupling of the sweet taste from its energy 
source could trigger appetite, causing a positive energy balance and thereby 
weight gain has been proposed to be the true reason why relative risk of T2DM is 
elevated in the artificially sweetened drinks group. Another hypothesis to explain 
the findings suggests an association between artificially sweetened drinks and an 
overcompensation for the discerned energy saved in other parts of the diet 
(Greenwood et al., 2014).  
 
Absorption of fructose by the body is a facilitated diffusion mechanism and linear 
process. Fructose is metabolized in the intestine, liver and kidney by the enzymes 
fructokinase, aldolase B and triokinase, with most of it being metabolized by the 
liver following oral load (Laville and Nazare, 2009). Metabolism of fructose, unlike 
other carbohydrates, is mainly an insulin-independent process, meaning that 
following fructose ingestion fewer glycaemic excursions are caused. In vitro 
analysis of pancreas and isolated islet demonstrate that fructose, in the absence 
of glucose, is not able to stimulate insulin secretion (Coore and Randle, 1964). Le 
et al showed that fasting fructose concentration in venous blood was elevated from 
0.005 mM to 0.3 mM following ingestion of a soft drink containing 69 g of sucrose 
while glucose concentration rose from 5.5 mM baseline to 6.8 mM with the same 
drink. Insulin release was accompanied by the rise in glucose concentration in the 
blood, peaking at around 30 min before returning to baseline at 90 min. Blood 
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fructose levels returned to baseline after 3 h of sucrose soft drink ingestion (Le et 
al., 2012).  
 
A study by Vozzo et al showed that fructose leads to a higher concentration of 
plasma insulin in T2DM patients and was hypothesised to be a good replacement 
for glucose in the diet of such individuals (Vozzo et al., 2002). Nonetheless, 
different studies have pointed out how excess fructose intake may exacerbate risk 
factors associated with T2DM and cardiovascular disease, as illustrated in Figure 
1.1. For instance, lysis of fructose molecule into pyruvate and dihydroxyacetone-
phosphate (DHAP) by the liver provides the acyl part and the carbon to glycerol of 
the triglyceride (TG) molecule. It is important to note that these lipogenic effects of 
fructose have only been examined in the presence of glucose and insulin. Fructose 
on its own, however, has been shown to stimulate re-esterification of non-esterified 
fatty acids (NEFA), a process that is boosted in the presence of insulin (Laville and 
Nazare, 2009). Fructose is also a strong stimulator of de novo lipogenesis through 
excess substrate (citrate) production and conversion of TG composition into very-
low-density lipoproteins (VLDL) (Lim et al., 2010). A study conducted on 32 
overweight and obese subjects consuming either glucose or fructose sweetened 
drinks, accounting for 25% of total energy intake, for 10 weeks showed that hepatic 
de novo lipogenesis was increased significantly higher following fructose intake 
than glucose intake (75% and 27%, respectively) (Stanhope et al., 2009). 
Accumulation of TG by reduced VLDL clearance can ultimately lead to 
hypertriglyceridemia and insulin resistance, both of which are strong risk factors 
for obesity and T2DM (Laville and Nazare, 2009). Hypertriglyceridemia, in turn, 
causes less leptin, a satiety hormone, to be transported across the blood-brain 
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barrier and is another indirect way by which fructose increases chance of obesity 
development (Banks et al., 2004). Changes in circulating hormone levels following 
a high fructose or high glucose meal was examined in a study of 12 healthy women. 
The study concluded that ghrelin was significantly less suppressed in the women 
who ingested the high fructose meal and their levels of insulin and leptin were also 
lower. This suggests that fructose can disturb the energy balance signalling to the 
brain, thereby leading to potential further energy intake, to a greater extent than 
glucose (Teff et al., 2004). Excess lipids are taken up by the muscle form 
intramyocellular lipids, causing muscle insulin resistance (Laville and Nazare, 
2009). In addition, synthesis of the forkhead box protein O1 (FOXO1) is increased 
in the presence of fructose. In a hepatic insulin resistant environment FOXO1 is 
not phosphorylated and upon entering the nucleus will stimulate production of 
enzymes that increase gluconeogenesis, leading to elevated glucose generation 
and hyperglycaemia (Dong et al., 2008). Usage of ATP molecules for fructose 
phosphorylation by fructokinase allows AMP deaminase I to take phosphate from 
ADP creating uric acid as a waste product. Uric acid acts as an inhibitor of 
endothelial nitric acid synthase (eNOS) in the smooth muscle causing a decrease 
in nitric oxide production and, therefore, an increase in blood pressure (Johnson et 
al., 2007).  
 
 
 
 10 
 
Figure 1-1 Metabolic effects of fructose on liver. Once in the liver fructose 
stimulates production of FOXO1 which in a hepatic insulin resistant state lead 
to increased gluconeogenesis, and thereby higher glucose secretion, leading 
to hyperglycemia. Coupling of AMP deaminase I with a phosphate from the 
phosphorylation of fructose by fructokinase produces uric acid, an inhibitor of 
eNOS, leading to decreased production of the vasodilator nitric oxide and an 
elevation of blood pressure. Fructose also directly causes re-esterification of 
NEFA leading to hepatic insulin resistance. De novo lipogenesis is stimulated 
by fructose through excess citrate production and transformation of 
triglycerides into VLDL. Reduction in clearance rate of VLDL leads to 
hyperglycaemia and insulin resistance. In addition, a higher uptake of lipids 
by the muscle causes muscle insulin resistance. High levels of triglycerides is 
in itself a risk factor for obesity and dyslipidaemia but it also leads to 
decreased leptin delivery to the brain, which in turn can cause further intake 
of fructose, increasing the risk of both conditions (Lim et al., 2010). 
 
A study conducted by Nguyen et al showed a positive correlation between intake 
of sugar-sweetened drinks and hypertension in children (Nguyen et al., 2009). The 
same correlation has been confirmed in adults in a study by Gao et al (Gao et al., 
2007). An animal model study showed that the offspring of fructose fed mice were 
hyperglycaemic upon birth in contrast to control group offspring suggesting a 
potential correlation between maternal fructose intake and development of T2DM 
risk factors (Jen et al., 1991). The Nurse’s health study II, which followed over 91 
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000 women free of diabetes at the start of the study, concluded that those who 
consumed one sugar-sweetened drink every day had a relative risk of developing 
the disease of 1.83 compared to those who consumed sugar-sweetened 
beverages once a month. The sugar-sweetened drinks used in the study were 
supplemented with HFCS and fruit juice consumption was not linked to diabetes 
risk (Hu et al., 2001). It was hypothesised that other components of the fruits, such 
as minerals and fibres, could act as a counterbalance for the potential negative 
health effects of their naturally occurring sugars, a characteristic not present in 
artificially sweetened drinks (Schulze et al., 2004). Further studies need to be 
conducted in order to fully understand the direct effects of fructose on health, 
however, care should be taken when advising dietary replacement of glucose with 
this sugar for T2DM patients, as well as increase awareness of sugar-sweetened 
drinks and other products by general consumers, as it could have serious long term 
deleterious effects on health, as discussed above (Laville and Nazare, 2009). 
 
1.3 Sugar uptake by GLUTs 
GLUT proteins encoded by the SLC2 genes are transporters of monosaccharides 
and polyols across eukaryotic cell membranes (Mueckler and Thorens, 2013). All 
fourteen GLUT transporters are made up of around 500 amino acids and are all, 
apart from HMIT, facilitative transporters (Uldry and Thorens, 2004). Each GLUT 
protein contains 12 transmembrane segments (TM1-12) and a single site for N-
linked glycosylation (Mueckler et al., 1985), (Uldry and Thorens, 2004). The GLUTs 
are grouped into three classes in accordance to sequence similarity; class 1 is 
comprised of GLUT 1-4 and 14, class 2 includes GLUT 5, 7, 9 and 11 and class 3 
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is made up of GLUT 6, 8, 10, 12 and HMIT (Mueckler and Thorens, 2013). A radial 
tree representative of the structural alignment of the members the GLUT family (1-
13) is shown in Figure 1.2 (Uldry and Thorens, 2004).  
 
 
Figure 1-2 Radial tree representative of the structural alignment of the extended 
glucose transporter family (GLUT). This diagram was constructed, by Uldry 
et al, using the clustalW program from the European Bioinformatics Institute. 
The three different classes of this family are clearly distinguishable in this 
representation (Uldry and Thorens, 2004).  
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Figure 1-3 Schematic illustration of the structure of classes 1 and 2 of the GLUT 
family. The extracellular loop containing the N-glycosylation site(s) and the 
protein-containing motif between transmembrane domains 6 and 7, shown in 
this figure, comprise the major differences between classes 1-2 and class 3 
(A). Sugar molecules are transported into the cell by a structural change of 
the transporter’s opening, which shift between outward and inward facing (B) 
(Deng et al., 2015). 
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Classes 1 and 2 differ structurally from class 3 by the location of the N-linked 
glycosylation site, found on the fifth exofacial linker domains in class 3 GLUTs as 
opposed to the first exofacial linker domains in class 1 and 2 GLUTs, and the 
protein-containing motif between transmembrane domains 6 and 7 (Mueckler and 
Thorens, 2013), (Uldry and Thorens, 2004). The GLUTs have an opening facing 
the outside of the cell that picks up sugar molecules, which are released into the 
cell by a shape change that causes an inward opening (Deng et al., 2015), 
(Henderson and Baldwin, 2012). Figure 1.3 A illustrates the overall structure of 
GLUTs from classes 1 and 2, and Figure 1.3 B shows the biding and release of 
sugar molecules by GLUTs. Out of the fourteen GLUT proteins it has been 
experimentally shown that eleven are able to transport glucose (Thorens and 
Mueckler, 2010). Effectively every cell type in the human body expresses one or 
multiple GLUTs and it is thought that by having a surplus of proteins able to 
transport glucose, with differing regulatory and kinetic properties, the body ensures 
it has a good circulation of this sugar as a fuel to maintain itself (Hokayem et al., 
2013). 
 
1.3.1 Sugar transport by GLUT2, GLUT5 and GLUT7 
Active transport of glucose in the small intestine is achieved  by the sodium-
dependent transporter, sodium-glucose cotransporter 1 (SGLT1), on the apical 
membrane, by means of the downward sodium gradient managed by 
Na+/K+/ATPase on the basolateral membrane (Hediger et al., 1987), (Thorsen et 
al., 2014). Complete absorption of dietary sugars involves the facilitative 
transporter GLUT2 which is responsible for glucose, fructose, mannose, 
glucosamine and galactose transport and delivery to the blood (Ferraris, 2001), 
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(Uldry et al., 2002). GLUT2 has low affinity for glucose (KM ~ 17 mM), fructose (KM 
~ 76 mM), galactose (KM ~ 92 mM) and mannose (KM ~ 125 mM), but has high 
affinity for glucosamine (KM ~ 0.8 mM) (Uldry et al., 2002), (Mueckler and Thorens, 
2013). Although GLUT2 is expressed on the basolateral membrane of enterocytes 
it is now widely accepted that in the presence of high glucose levels the transport 
of this sugar is mediated primarily by GLUT2, through trafficking of basolateral 
GLUT2 to the apical surface (Kellett et al., 2008), (Helliwell et al., 2003). In other 
words, in response to high dietary sugar intake the rapid insertion of the low affinity 
and high-capacity transporter, GLUT2, into the apical membrane means that this 
protein accommodates for the higher concentrations of glucose, and becomes the 
major route of this sugar’s absorption (Helliwell et al., 2000), (Affleck et al., 2003). 
Although trafficking of GLUT2 was not confirmed by some groups, a variety of 
experiments performed in cell and rat models support this proposed mechanism 
(Affleck et al., 2003), (Roder et al., 2014), (Helliwell and Kellett, 2002). Live imaging 
analysis of kidney cells also showed a rapid basal-to-apical translocation of GLUT2 
in response to glucose (Cohen et al., 2014). Furthermore, localisation of GLUT2 to 
the apical membrane in rat intestinal models has been shown to be increased at 
high sugar levels (Morgan et al., 2007). Additionally, GLUT2-knockdown mice 
present a diabetic phenotype, experiencing characteristic symptoms of this 
condition, such as hyperglucagonemia and hyperinsulinemia (Thorens, 2001). 
 
Fructose uptake in the gut is primarily mediated by GLUT5, which is specific to 
fructose only, with no ability to transport glucose or galactose (Kane et al., 1997). 
GLUT5 has evolved to be able to recognize fructose in all its forms, having a 
reported efficiency (KM) of 6 mM for this sugar (Burant et al., 1992), (Girniene et 
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al., 2003). Secondary transport of fructose is mediated by GLUT2, which is able to 
recognize fructose in its furanose form (Manolescu et al., 2007b). GLUT2 is also 
responsible for transporting fructose across the basolateral membrane and into the 
blood, following absorption of this sugar on the apical membrane by GLUT5 (Kellett 
and Brot-Laroche, 2005). Expression of GLUT5 is reportedly regulated by 
developmental, hormonal and nutritional influences (Douard and Ferraris, 2008). 
For example, lower levels of GLUT5 expression in children is the likely cause of 
malabsorption following dietary fructose intake (Nobigrot et al., 1997), (Wilder-
Smith et al., 2014). To add to that, studies on adipocytes and in vivo have shown 
increased expression of GLUT5 in the presence of high fructose, suggesting 
expression of this protein is regulated by its substrate (David et al., 1995), (Legeza 
et al., 2014). 
 
Another GLUT that potentially plays a role in the uptake of glucose and fructose in 
the gut is GLUT7, the closest relative to GLUT5 sharing 53% sequence homology 
and 68% amino acid identity to the fructose specific transporter (Li et al., 2004), 
(Scheepers et al., 2005). GLUT7 has high affinity for both glucose and fructose (KM 
< 0.5 mM), and due to the high levels of expression of this protein in the ileum it is 
thought it is potentially responsible for sugar uptake at the end or after a meal, 
when sugar concentrations are lower (Drozdowski and Thomson, 2006), 
(Cheeseman, 2008). Although there is still controversy about the ability of GLUT7 
to transport sugars, expression of human GLUT7 (hGLUT7) in X. laevis oocytes 
have shown that this protein was able to transport fructose and glucose, but not 
galactose (Ebert et al., 2017), (Li et al., 2004). It has been hypothesised that a 
conserved motif, present in the sequences of GLUT2,5 and 7, is responsible for 
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the ability of these proteins to transport fructose (Manolescu et al., 2005), (Doege 
et al., 2001). Even though further characterization of this protein is required, its 
high levels of similarity with GLUT5 suggests it may be an active participant in 
fructose uptake in the gut (Uldry and Thorens, 2004). Figure 1.4 sheds light on the 
transport of sugars from the lumen across the enterocyte by different transporters. 
It can be observed from this figure that the functions of GLUT2,5 and 7 likely 
overlap, namely, GLUT5 is exclusively a high-affinity transporter of fructose, while 
GLUT7 is a high-affinity and low-capacity transporter of this sugars, and GLUT2 
transports both glucose and fructose (Mueckler and Thorens, 2013), (DeBosch et 
al., 2012), (Cura and Carruthers, 2012).  
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Figure 1-4 Illustration of the transport of sugars across the enterocyte by three 
GLUT transporters (GLUTs 2, 5 and 7) and sodium dependent transporter 
SGLT1. GLUT2 is responsible for the facilitative transport of glucose as well 
as fructose across the cell and it is present on both apical and basolateral 
sides. GLUT5 is only expressed on the apical side of the cell membrane and 
will bring fructose into the enterocyte to be transported out by GLUT2. GLUT7 
is thought to contribute to the transport of fructose and glucose across the 
cell. Levels of expression of this protein on apical and basolateral membranes 
require further investigation in addition to the possible ability of this protein to 
transport other less common sugars. SGLT1 is responsible for the active 
transport of glucose through the apical membrane in a sodium dependent 
manner. Na+K+-ATPase on the basolateral membrane keeps the optimal 
gradient for this transporter. GLUT2 on the basolateral membrane will 
transport any glucose brought into the cell by SGLT1 active transporter out 
into the extracellular fluids. (Kellett et al., 2008), (Cheeseman, 2008), 
(Drozdowski and Thomson, 2006) 
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1.4 Overview of (poly)phenols 
(Poly)phenols are naturally occurring plant-derived compounds, present in fruits, 
vegetables, cereals, and beverages composed of plant/fruit extracts (Pandey and 
Rizvi, 2009), (Kim et al., 2016), (Liu, 2013). In plants, (poly)phenols are involved in 
protection against high levels of ultraviolet radiation (Williamson and Manach, 
2005). In addition, (poly)phenols may have an impact on the sensory, optical and 
chemical properties of foodstuffs, such as colour, flavour, and oxidative stability 
(Pandey and Rizvi, 2009). Significant amounts of (poly)phenols are consumed in 
the human diet, and these compounds are thought to have an effect on a variety 
of biological processes, including sugar absorption in the gut (Perez-Jimenez et 
al., 2010), (Nyambe-Silavwe and Williamson, 2016), (Alzaid et al., 2013). Dietary 
consumption of (poly)phenols is of approximately 1 g/day, achieved through 
consumption of unprocessed fruits and vegetables, as well as teas, jams, juices, 
etc (Scalbert and Williamson, 2000). Amounts of daily (poly)phenols consumption 
differs between different populations, for instance in the adult Polish population the 
average consumption of (poly)phenols was determined to be 1771.2 ± 729.5 mg/d 
(Grosso et al., 2014), while in elderly Japanese individuals consumption was 1492 
± 665 mg/d (Taguchi et al., 2015). The same study saw a pronounced variability in 
(poly)phenol consumption between individuals, namely 183–4854 mg/d, with 
beverages like green tea and coffee accounting for over 70% of total (poly)phenol 
consumption (Taguchi et al., 2015). Structurally, (poly)phenols are comprised of at 
least one phenolic hydroxyl group, and the different classes of (poly)phenols are 
determined by the number of phenol rings and how they are bound to one another 
(Spencer et al., 2008). The main classes of (poly)phenols of importance to human 
diet are phenolic acids, flavonoids, stilbenes and lignans (Del Rio et al., 2013), (de 
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Bock et al., 2012). The most abundant and well-studied class of (poly)phenols, 
flavonoids, is divided into different subgroups, all comprised of a basic C6-C3-C6 
structure. The main subgroups of flavonoids are flavonols, flavones, isoflavones, 
flavan-3-ols, flavanones and anthocyanidins (Rodriguez-Mateos et al., 2014). The 
basic three-ring chemical structure of flavonoids, and of its different subgroups, are 
illustrated in Figure 1.5. 
 
Figure 1-5 Basic structure of flavonoids and its subclasses. Flavonoids have a 
common C6-C3-C6 structure and are divided into subclasses of dietary 
importance; namely, flavonols, flavones, isoflavones, anthocyanidins, 
flavanones and flavan-3-ols (Del Rio et al., 2013), (Rodriguez-Mateos et al., 
2014), (Tsao, 2010). 
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The structural arrangement of hydroxyl groups and glycosylation and/or alkylation 
patterns of each subgroup has an impact on their biological activity (Tsao, 2010), 
(Del Rio et al., 2013). Figure 1.6 illustrates examples of chemical structures of 
compounds from the other main classes of (poly)phenols. For instance, phenolic 
acids and their usual C6-C1 structure is represented by gallic acid, the most 
common phenolic acid. The main dietary stilbene is resveratrol, which displays the 
common C6-C2-C6 structure of this class. High concentrations of lignans can be 
found in cereals grains such as flaxseed, for which one of the main components is 
secoisolariciresinol (Del Rio et al., 2013), (Pandey and Rizvi, 2009). 
 
Solubility and stability of (poly)phenols can be increased significantly by 
glycosylation as oxidation of phenolic group is prevented by glycosyl moieties 
(Desmet et al., 2012), (Torres et al., 2011). In addition, biological and 
pharmacological properties of (poly)phenols may also be enhanced by 
glycosylation (Gantt et al., 2011). This is achieved through improved 
pharmacokinetics and potency of compounds, facilitated transport by membrane 
transporters, as well as cell-specific delivery by interaction with carbohydrate 
specific receptors (Murota et al., 2010). Enzymatic glycosylation of (poly)phenols 
is catalysed by glycosyltransferases, which are able to transfers sugar moieties 
from donor molecules to specific aglycons with stereoselectivity (Lairson et al., 
2008). Glycosidases are another class of enzymes that are able to transfer single 
glycosyl moieties or multiple glycosyl groups to (poly)phenolic acceptors (Bojarova 
and Kren, 2011). Several (poly)phenols are naturally found in glycoside form and 
some flavonoid glycosides, such as quercetin rutinoside, have been used in the 
clinical setting (Fang et al., 2013), (Desmet et al., 2012), (Murota et al., 2010).  
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Figure 1-6 Chemical structures of gallic acid, resveratrol and secoisolariciresionol. 
Gallic acid is the most common phenolic acid, while resveratrol is the main 
dietary stilbene. Lignans are found in high concentrations in cereal grains 
such as flaxseed. One of the main componentrs of flaxseed is 
secoisolariciresionol (Del Rio et al., 2013), (Rodriguez-Mateos et al., 2014). 
 
1.4.1 Bioavailability in humans 
The effectiveness of (poly)phenols absorption by the gut, as well as the total 
amount absorbed, can be measured in blood plasma and urine samples (Arts and 
Hollman, 2005). The bioavailability of different (poly)phenols is dependent on the 
food source and nature of attached sugar moieties (Del Rio et al., 2013), (Manach 
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et al., 2004). The amount of absorption varies between individuals, dependent on 
microbial populations and the presence of other dietary components (Scalbert and 
Williamson, 2000). In addition, processing of food material can increase 
bioavailability of (poly)phenols, as was the case for flavonoids in cocoa powder, 
determined by analysis of blood and urine samples (Andújar et al., 2012). To add 
to that, enantiomeric forms of flavan-3-ol in cocoa and green tea have also shown 
to influence bioavailability of these compounds (Rodriguez-Mateos et al., 2014). 
Due to different absorption and metabolism rates, intrinsic activity and excretion 
from the body, the most common (poly)phenol compounds in our diet are not 
necessarily  the most active (Manach et al., 2004).  
 
There are two proposed mechanisms for (poly)phenol absorption. One mechanism 
involves the lactase phloridizin hydrolase (LPH) enzyme, present in the apical 
membrane of the small intestine, which deglycosylates and hydrolyses lactose. 
The very high specificity of this enzyme results in a passive diffusion of aglycone 
compounds into the cell (Day et al., 2000). Alternatively, absorption is achieved via 
a mechanism involving cytosolic β-glucosidase (CBG) (Gee et al., 2000). 
Glucosides are transported into the cell via SGLT1, where it can be hydrolysed and 
catalysed by CBG (Crozier et al., 2010). Before being released into the 
bloodstream, (poly)phenol aglycones are conjugated in the intestine, then carried 
in the bloodstream to the liver for subsequent phase II metabolism and further 
processing (Scalbert et al., 2002). (Poly)phenols that are not absorbed and 
metabolised by the gut pass to the colon, where microflora cleaves (poly)phenol 
glucosides into aglycones for absorption, and consequential transport to the liver 
(Crozier et al., 2010). In summary, absorption of dietary (poly)phenols is achieved 
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through hydrolysis by intestinal enzymes or colonic microflora, conjugation in the 
intestine, and subsequent processing in the liver (Scalbert et al., 2002). Once 
absorbed, (poly)phenols will accumulate in the target tissue and prompt biological 
processes (Bahadoran et al., 2013). Plasma concentrations of (poly)phenols after 
dietary intake are usually nM, with concentrations of 1 µM generally being reached 
after consumption of 10-100 mg of a single compound (Scalbert and Williamson, 
2000), (Manach et al., 2004). More recently, however, more sensitive analytical 
methods have shown that plasma concentrations of (poly)phenols might be higher 
than previously identified. For instance, a study on rats showed a plasma luteolin 
concentration ranging from 6.88-29 µM (Li et al., 2015). Furthermore, a study 
investigating the effect of flavonoids on platelet aggregation identified the 
concentration of flavonoids in circulation to be of 0.6-122 µM (Bojic et al., 2012).  
 
1.4.2 Attenuation of disease risk factors by (poly)phenol rich extracts 
and pure compounds 
Evidence from several studies show that various (poly)phenols and (poly)phenol-
rich foods have a protective effect against chronic diseases, including CVD, 
diabetes and cancer (Del Rio et al., 2013). Table 1.1 lists examples of the positive 
impacts on disease risk factors, in humans, achieved through the consumption of 
(poly)phenol rich extracts. These same extracts, as well as pure compounds 
present in high amounts in the extracts, were used in sugar uptake inhibition 
studies presented in Chapters 4-6. For instance, although many bioactive 
chemicals are present in green tea catechins, such as (–)-epigallocatechin-gallate 
(EGCG), are particularly abundant (Higdon and Frei, 2003). In addition, two of the 
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major reported flavonoid constituents of German chamomile are apigenin and 
quercetin, the latter directly involved in the reduction of blood glucose levels in rats 
(Kato et al., 2008). Furthermore, epicatechin and procyanidins are present in high 
amounts in cocoa and oleuropein is the main constituent of Bonolive extract. 
Composition of all extracts is shown in Chapter 2 (refer to section 2.1). 
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Table 1-1 Examples of disease factor attenuation by (poly)phenolic extracts 
Extracts Impact on disease risk factors References 
Bonolive  
(oleuropein) 
 
↓ inflammation 
↓ LDL-cholesterol oxidation 
↑ HDL-cholesterol  
↓ CHD risk 
(Martin-Pelaez et al., 
2013) 
(Impellizzeri et al., 2011) 
 
Black tea ↓ LDL-cholesterol  (Davies et al., 2003) 
Cocoa ↑ HDL-cholesterol  
↓ blood pressure 
↓ relative risk of CVD 
(Mellor et al., 2010) 
(Buijsse et al., 2010) 
Coffee ↓ fasting glycaemia  
↓ LDL-cholesterol oxidation 
↑ endothelial function 
(Pimentel et al., 2009) 
(van Dam and Feskens, 
2002)  
(Manach et al., 2004) 
(Buscemi et al., 2010) 
Eucalyptus Leaf 
Extract (ELE) 
↓ sucrose activity 
↓ fructose transport* 
(Toda et al., 2001) 
(Sugimoto et al., 2005)* 
German chamomile  ↓ cholesterol  
↓ blood glucose levels 
(McKay and Blumberg, 
2006) 
(Kato et al., 2008) 
(Zemestani et al., 2016) 
Green tea  ↓ blood pressure 
↓ LDL-cholesterol  
↓ all-cause mortality  
(Kim and Kim, 2013) 
(Nantz et al., 2009) 
(Maron et al., 2003) 
Citrus 
(poly)phenols: 
hesperidin & 
hesperetin 
↓ hepatic TG accumulation 
↓ synthetic enzyme activity 
↓ cholesterol  
(Jung et al., 2006) 
(Cha et al., 2001) 
Pomegrante ↓ fasting & post-prandial glucose 
↓ glycaemic response  
↓ gluconeogenesis  
↓ inflammation 
↑ glycogen synthesis 
(Jafri et al., 2000) 
(Viuda-Martos et al., 
2010) 
(Banihani et al., 2013) 
(Parmar and Kar, 2008) 
* study conducted using mice model 
. 
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1.4.3 Effect of (poly)phenols on postprandial glycaemia  
 
The glycaemic index (GI) can be defined as the indexing of a glycaemic response 
from a specific quantity of available carbohydrate in a test food to the same quantity 
in a standard foodstuff, when consumed by the same individual (Jenkins et al., 
2002). In other words, the GI is the blood glucose response of 50 g of 
carbohydrates expressed as a percentage of the same quantity of carbohydrates 
from a reference food (Wolever et al., 1991). The GI is a rank of the glycaemic 
potential of carbohydrates present in various foods in a ‘gram for gram’ of 
carbohydrate approach (Marsh et al., 2011).  
 
Prolonged consumption of high GI foods has been shown to play a role in the 
development of T2DM, obesity and CVD (Ludwig, 2002), (Bornet et al., 2007). 
Furthermore, serological biomarkers associated with increased relative risk of CHD 
were elevated after the consumption of a high-glycaemic load diet (Mathews et al., 
2015). Low-GI foods, therefore, have been associated with a protection against 
these chronic diseases. Observational studies suggest that low-GI foods are able 
to reduce hyperglycaemia and hyperinsulinemia, as well as potentially increasing 
satiety, when compared to higher-GI foods (Aston, 2006). These observations are 
in agreement with the hypothesis that higher postprandial glycaemia is ‘a universal 
mechanism for disease progression’ (Barclay et al., 2008).    
 
The hormonal control of blood glucose is a critical process in our physiology as 
failure to maintain energy homeostasis can lead to metabolic syndrome, a disorder 
associated with obesity, hyperglycaemia, impaired glucose tolerance, 
 
 
 28 
hypertension, dyslipidaemia and a predisposition to T2DM development 
(Hanhineva et al., 2010). Therefore, slowing down the digestion or absorption of 
carbohydrates can have beneficial effects to overall health, by helping to reduce 
disease risk factors (Barclay et al., 2008). This could be achieved by reducing the 
consumption of high-GI foods and/or incorporating components in our diet that may 
reduce postprandial glucose (Hanhineva et al., 2010). Dietary (poly)phenols, for 
instance, may have the potential to slow down blood glucose spikes by inhibiting 
carbohydrate digestion and rapid sugar absorption (McDougall et al., 2005), 
(Williamson, 2013). For instance, (poly)phenolic compounds present in green tea, 
strawberry, raspberry, blueberry and blackcurrant have been shown to significantly 
inhibit both α-amylase and α-glucosidase, digestive enzymes that are responsible 
for sugar production (Nyambe-Silavwe et al., 2015), (McDougall et al., 2005). 
These enzymes are also the targets for a common anti-diabetic drug, acarbose, 
used in many countries worldwide. For this reason, it is believed that a long-term 
consumption of specific (poly)phenols could have a comparable effect to acarbose 
at reducing the risk/progression of diabetes (Williamson, 2013). 
 
Consumption of (poly)phenols has been shown to be beneficial to glycaemic 
control in several studies. For instance, a meta-analysis including over 280,000 
participants and more than 18,000 incidents of T2DM showed that relative risk of 
diabetes was 0.91 between the highest intake of flavonoids group and the lowest 
intake of flavonoids group (Liu et al., 2014). The same meta-analysis found that 
green tea consumption significantly decreased fasting blood glucose levels and 
lowered concentrations of glycohemoglobin (HbA1c), an early glycation product 
and marker of chronic glycaemia (Liu et al., 2014). Moreover, a meta-analysis of 
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22 trials, consisting of 1,584 participants, concluded that green tea consumption 
led to reductions in fasting glucose (Zheng et al., 2013). A meta-analysis of 24 
trials, including 1,106 individuals, showed that cocoa consumption significantly 
improved insulin sensitivity (Shrime et al., 2011). In addition, short-term intake of 
cocoa also significantly reduced insulin resistance, as determined in a meta-
analysis of 42 trials including over 1,290 individuals (Hooper et al., 2012). A 
systemic review of 36 trials measuring changes in HbA1c following exposure to 
(poly)phenol supplementation showed a significant reduction in HbA1c in T2DM 
patients without any other intervention at glycaemia (Palma-Duran et al., 2017). 
Furthermore, analysis of data from 3 longitudinal studies identified that 
consumption of three servings/week of fruits, in particular grapes, apples and 
blueberries, significantly lowered T2DM risk (Muraki et al., 2013). To add to that, a 
meta-analysis of 9 studies showed that oral consumption of aloe vera significantly 
reduced fasting blood glucose and HbA1c (Dick et al., 2016). 
 
1.4.4 Effect of (poly)phenols on sugar uptake by GLUTs 
Certain (poly)phenols have also shown to have an impact on postprandial 
glycaemia control by inhibiting sugar absorption, through inhibition of GLUT 
transporters. For instance, the flavonoids quercetin and phloretin have shown to 
be potent inhibitors of GLUT2, in the oocyte and cell model (Kwon et al., 2007). 
Furthermore, acute exposure of anthocyanin-rich berry extract significantly 
decreases glucose uptake by GLUT2 in Caco-2 cell model (Alzaid et al., 2013). To 
add to that, a (poly)phenol-rich intervention, comprised of green tea and berry 
extracts, had an impact on post-prandial blood glucose in vivo by significantly 
reducing the area under the curve (Nyambe-Silavwe and Williamson, 2016). 
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Inhibition of the fructose specific transporter GLUT5 is achieved by 
epigallocatechin gallate (EGCG), one of the main compounds in green tea (Slavic 
et al., 2009). To date, there have been no inhibitors of GLUT7 identified, which call 
for further studies to be carried out in order to determine further inhibitors of these 
three transporters. In this project, the direct inhibition of GLUT2, 5 and 7, expressed 
in the gut and able to transport fructose, by specific (poly)phenols was investigated. 
Table 1.2 below summarizes the pure compounds and extracts known to inhibit 
sugar uptake by GLUT2 and GLUT5. Sugar uptake experiments presented in this 
table were conducted on the X. laevis oocyte model or on both oocyte and cell 
model. Data from sugar inhibition studies performed for this project, presented in 
Chapter 4 and 5, which has been published and is included in the table below. 
 
Table 1-2 GLUT2 and GLUT5 inhibition by (poly)phenolic compounds and 
(poly)phenol rich extracts 
GLUT2 Reference 
Phloretin, myricetin, fisetin, quercetin, 
isoquercitrin**  
(Kwon et al., 2007) 
Green tea and German chamomile tea** (Villa-Rodriguez et al., 
2017a) 
Phloretin, quercetin, apigenin, mycicetin, EGCG, 
EGC, ECG 
(Johnston et al., 2005) 
Quercetin* (Song et al., 2002) 
Pomegranate** (Kerimi et al., 2017) 
 
GLUT5 Reference 
EGCG, ECG* (Slavic et al., 2009) 
* Sugar uptake inhibition studies performed in X. laevis oocyte model. 
** Sugar uptake inhibition studies performed in X. laevis oocyte and Caco-2 cell 
models. 
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1.5 Research models 
1.5.1 Caco-2/TC7 intestinal cell model 
The Caco-2 cell system is a well characterized and frequently used in vitro model 
of intestinal absorption, as it allows for transport mechanisms to be investigated, 
as well as the ability of chemicals to cross the intestinal barrier (Angelis and Turco, 
2011). As characteristics of Caco-2 cell line, such as transport properties and 
permeability, have been shown to be dependent on culture conditions, several 
clones from this cell line have been isolated (Delie and Rubas, 1997), (Briske-
Anderson et al., 1997). The TC7 clone was shown to have a more homogeneous 
distribution of proteins functional in the gut across the different passage numbers, 
making it an attractive clone for mimicking the in vivo intestinal environment (Turco 
et al., 2011), (Chantret et al., 1994). In addition, Caco-2/TC7 cells express high 
levels of sugar transporters critical for intestinal sugar uptake, including SGLT1, 
GLUT2 and GLUT5 (Sambuy et al., 2005). Previous studies have looked at the 
effect of high glucose and fructose levels in the expression of GLUT2 and GLUT5, 
respectively (Mahraoui et al., 1994), (Gouyon et al., 2003). In this project, the Caco-
2/TC7 cell model was used to investigate any changes in expression of GLUT7, 
also expressed in the intestine, in the presence of different sugars as potential 
substrates. Additional information on this cell model is discussed in Chapter 3. 
 
1.5.2 Xenopus laevis oocytes  
A 1971 study Gurdon et al showed that oocytes extracted from the South-African 
clawed frog Xenopus laevis synthesized haemoglobin following microinjection with 
mRNA (Gurdon et al., 1971). The oocytes have accumulated stores of enzymes, 
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organelles and proteins that are normally used after fertilization which are recruited 
for heterologous proteins, making them very good single-cell models for protein 
expression following microinjection with mRNA (Gurdon et al., 1973), (Bianchi, 
2006). Mammalian cells express many different sugar transporters, leading to a 
high basal sugar transport activity. Therefore, it is challenging to determine 
substrate specificity and kinetics of transport of a single specific sugar transporter 
(Bentley et al., 2012). For this reason, Xenopus laevis oocytes have been 
extensively used in the characterization of transport kinetics and substrate 
specificity of an individual transporter, through over-expression of transporters 
(Nishimura et al., 1993), (Colville et al., 1993), (Kwon et al., 2007). Basal sugar 
transport activity is low in X. laevis oocytes, making it an ideal model for functional 
characterization of heterologously expressed sugar transporters using 
radiolabelled sugar substrates. In general, the transport properties observed by 
heterologously expressed GLUTs in oocytes are similar to the known 
characteristics of these transporters in mammalian tissues (Bentley et al., 2012). 
Furthermore, following translation of injected mRNA X. laevis oocytes are also able 
to modify the synthesized proteins in a manner similar to their normal post-
translational modification. These modifications are thought to take place in the 
endoplasmic reticulum (ER) system of the oocyte stimulated by primary and 
secondary structural signals of the protein (Deacon and Ebringer, 1979).   
 
Other adavantages of X. laevis oocytes include the fact that they are readily 
harvested from the female ovary and are built to survive for long periods of time 
outside the body, needing only to be kept in a simple salt solution with antibiotics 
to prevent infection. In addition, because of their large size (1-1.2 mm in diameter) 
 
 
 33 
these cells are straightforward to microinject, and their low expression of 
endogenous membrane transporters and channels means that multiple 
simultaneous mRNA products can be injected into one oocyte and that standard 
electrophysiological techniques can easily be performed (Bianchi, 2006) 
 
Figure 1-7 Xenopus laevis oocyte developmental stages and representation of 
undigested ovary and digested oocytes. Oocytes are large cells (1-1.2 mm in 
diameter) that have a characteristic black pigmented region (animal pole and 
a white non-pigmented region (vegetal pole) (A) (Ferrell, 1999). Following the 
enzymatic digestion of the ovary, stage V-VI oocytes are manually selected 
for subsequent microinjections (B).  
 
Oocytes are immature eggs stored in the abdominal cavity of the adult female in 
clumps called ovarian lobes, which are made up of oocytes, connective tissue, 
blood vessels and follicle cells. Oocytes are large individual cells of 1-1.2 mm in 
diameter and with a surface area of 18-30 mm2 (Broer, 2010). Oocytes go through 
six maturation stages (I-VI), as shown in Figure 1.7 A, of which stage V-VI oocytes 
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are generally used for heterologous expression and electrophysiological studies 
due to their larger size. The oocytes have a characteristic black pigmented region 
and a white non-pigmented region, corresponding to the animal pole and vegetal 
pole, respectively (Bianchi, 2006). The yolk is concentrated to the vegetal pole of 
the egg while the animal pole contains the germinal vesicle, or enlarged nucleus 
(Halley-Stott et al., 2010). A layer of follicular cells separates the oocytes from the 
external environment, which reportedly  interferes with electrophysiological 
recordings and is removed prior to microinjections by treatment with collagenase 
(Miledi and Woodward, 1989b), (Miledi and Woodward, 1989a). Enzymatic 
digestion also significantly facilitates the microinjection procedure as the 
micropipette encounters less resistance. Figure 1.7 B shows the X. laevis ovary 
before digestion with collagenase, as well as the digested oocytes and their 
characteristic features. Expression of exogenous proteins in oocytes is most 
commonly achieved through injection of transcribed RNA into the oocyte cytoplasm 
(Bianchi, 2006). In this project, mRNA encoding human GLUT2, 5 and 7 was 
injected into oocytes for expression of these proteins. Sugar uptake experiments 
in the presence of different (poly)phenols and/or extracts was then carried out and 
quantified using radiolabelled sugars.  
 
1.6 Research rationale, aims and objectives 
1.6.1 Research rationale and purpose 
As discussed above, excess dietary sugar consumption contributes to the 
exacerbation of disease risk factors associated with the development of diabetes 
and CVD. Increase in consumption of fructose, specifically, has been correlated to 
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an increase in prevalence of obesity in both the UK and USA (Grundy, 1998). In 
addition, excess fructose intake has also been directly associated with 
development of disease risk factors such hyperglycaemia, hyperinsulinemia, 
hypertension and hyperlipidaemia (Elliott et al., 2002), (Lim et al., 2010), (Laville 
and Nazare, 2009), (Johnson et al., 2007). Many of these disease risk factors are 
also linked to the body’s failure to maintain energy homeostasis, suggesting that 
slowing down carbohydrate digestion or absorption may help reduce disease risk 
factors and have a beneficial effect on overall health (Hanhineva et al., 2010), 
(Barclay et al., 2008). Research has shown that (poly)phenols, acquired from many 
different foodstuffs, have a positive effect on the reduction of many of the disease 
risk factors associated with CVD and diabetes, including having the potential to 
slow down blood glucose spikes by inhibiting carbohydrate digestion and sugar 
absorption (Williamson, 2013), (McDougall et al., 2005), (Hanhineva et al., 2010), 
(Shrestha et al., 2009). Taking these observations into account, this project 
focused on investigating the inhibition potential of specific (poly)phenols and 
extracts on sugar transporters, expressed in the gut and able to transport fructose. 
Ultimately, the compounds or extracts identified in this study as having the ability 
to inhibit one or more of the sugar transporters in the intestine could potentially be 
incorporated in interventions aimed at improving health markers, and control of 
fructose uptake and post-prandial distribution of sugars in both healthy volunteers 
and patients with CVD or diabetes. 
 
1.6.2 Project aims 
This research aimed to further characterize the lesser known GLUT7 by exploring 
the changes in expression of this protein in the presence of different sugars. 
 
 
 36 
Furthermore, another main aim of this project was to set up a quantitative model 
to investigate molecular mechanisms of GLUT2, GLUT5 and GLUT7 inhibition by 
specific (poly)phenols, to validate and instigate cell culture and in vivo work.  
 
1.6.3 Project objectives 
Mammalian cells express many different sugar transporters, making it challenging 
to determine substrate specificity and kinetics of transport of a specific sugar 
transporter (Bentley et al., 2012). The Xenopus laevis oocyte model makes the 
isolation of each of these transporters possible, allowing for the characterization of 
transport kinetics and substrate specificity of each individual transporter. In 
addition, the Caco-2/TC7 intestinal cell model allowed for the investigation of the 
basal levels of GLUT7 expression, as well as any changes in expression brought 
about by the presence of different sugars. In summary, the main objectives of this 
project were: 
 To determine the levels of GLUT7 expression in Caco-2/TC7 intestinal 
model cells. 
 To identify changes in GLUT7 protein and mRNA expression caused by 
culture of Caco-2/TC7 intestinal model cells in the presence of different 
sugars. 
 To design plasmid constructs for heterologous expression of human 
GLUT2, 5 and 7, and their subsequent expression in the X. laevis oocyte 
model. 
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 To investigate the potential inhibitory effects of (poly)phenols and extracts 
on each individual transporter by conducting uptake experiments using 
radiolabelled sugars. 
 To identify common inhibitors for the three transporters investigated. 
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Chapter 2  
General Methods 
 
2.1 Extracts and pure compounds used in inhibition studies  
2.1.1 Materials 
All solvents used for the methods described in this section were purchased from 
Thermo Fisher Scientific, Paisley, UK, unless otherwise stated. Ultrapure water 
was supplied from the Millipore Milli-Q Integral system (resistivity of 18.2 MΩ x cm 
at 25 °C) and used in aqueous solvents.  
Compounds utilized in sugar uptake inhibition experiments were obtained from 
Sigma-Aldrich, Dorset, UK and were as follows; 2,5-Anhydro-D-mannitol (41107-
82-8), acarbose (56180-94-0), apigenin (520-36-5), (-)-Epigallocatechin gallate 
(EGCG) (989-51-5) and (-)-Epicatechin (490-46-0) derived from green tea (≥ 98%), 
cytochalasin B (C6762), epicatechin (490-46-0), flavone (525-82-6), galangin (548-
83-4), hesperetin (69097-99-0), hesperidin (520-26-3), kaempferol (520-18-3), 
phloretin (60-82-2) and quercetin (117-39-5).  
Extracts used in the sugar uptake inhibition studies were as follows; German 
chamomile and green tea plant extracts were supplied by PhytoLab & Co 
(Vestenbergsgreuth, Germany). Pomegranate extract was acquired from CEBAS-
CSIC, Spain. Oleuropein-rich Bonolive extract was kindly supplied from BioActor, 
Ferrer HealthTech, Netherlands. Coffee extract was derived from Nescafe Green 
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Blend instant coffee and Yorkshire tea was used for experiments with black tea. 
GLUT5 specific inhibitor 1-O-Benzyl-2-N,3-O-carbonyl-α-L-sorbofuranosylamine 
(L-sorbose-Bn-OZO) was kindly supplied by Professor Arnaud Tatibouet from the 
Université d’Orléans, France. Procyanidins (DP2-DP8) were purified from freeze 
dried apples using HPLC methods (Hollands et al., 2017) by Dr Paul Needs (IFR, 
Norwich, UK) and provided within the BACCHUS FP7 project as study material by 
Dr Paul Kroon. 1 kg of eucalyptus leaves were purchased from Justingredients, 
Monmouthshire, UK.  
All the extracts used in sugar uptake inhibition studies in Chapters 4-6, including 
the name of supplier and main (poly)phenolic composition, are listed in Table 2.1 
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Table 2-1 List of extracts used in inhibition studies, including the supplier and main (poly)phenolic composition 
Extract name Supplier Analysis Composition 
Bonolive BioActor Performed by supplier 40% oleuropein 
Black tea Yorkshire tea Not analysed Previous documentation suggests black tea is primarily 
made up of thearubigins, with this phenolics accounting 
for almost 60% of solids found in a typical sample (Butt 
et al., 2014) 
Baking 
Chocolate 
Standard 
Reference 
Material 
National Institute of 
Standards and 
Technology 
Described below in 
section 2.1.5 (Robbins 
et al., 2012) 
171.6 ± 21 µM DP1; 52.1 ± 7 µM DP2; 36.4 ± 10 µM 
DP3; 32.7 ± 17 µM DP4; 7.5 ± 2 µM DP5; 1.3 ± 0.04 µM 
DP6; 1.7 ± 0.5 µM DP7; 0.6 ± 0.1 µM DP8; 1.4 ± 1 µM 
DP9; 1.0 ± 0.8 µM DP10 
Cocoa  Lindt Excellence 85% 
Cocoa Dark Chocolate 
Described below in 
section 2.1.5 
120.6 ± 2.4 µM DP1; 99.8 ± 1.9 µM DP2; 39.1 ± 0.8 µM 
DP3; 17.3 ± 1.7 µM DP4; 9.7 ± 0.2 µM DP5; 3.3 ± 0.3 
µM DP6 
Coffee Nescafe Green Blend Performed by Dr. N. 
Kraut (Kraut, 2014) 
In 4 g (1 cup): 160 ± 8.4 µmol 3-caffeoylquinic acid; 
103 ± 6.0 µmol 4-caffeoylquinic acid; 
467 ± 9.2 µmol  5-caffeoylquinic acid  
Eucalyptus 
Leaf Extract 
(ELE) 
leaves were purchased 
from Justingredients 
Not analysed  Not entirely identified but isolated components include 
hydrolysable tannins and favonol glycosides (Sugimoto 
et al., 2005) 
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German 
chamomile 
PhytoLab & Co Performed by Dr. J. 
Villa-Rodriguez (Villa-
Rodriguez et al., 
2017b) 
12.32% apigenin-7-O-glucoside; 
0.28% apigenin 
0.13% luteolin-7-O-glucoside; 
0.07% 4,5-dicaffeoylquinic acid  
Green tea PhytoLab & Co Performed by Dr. H. 
Nyambe (Nyambe, 
2016) 
199.8 ± 6.7 mg/g (-)-Epigallocatechin gallate (EGCG);  
124.4 ± 9.3 mg/g (-)-Epigallocatechin;  
34.4 ±1.9 mg/g (-)-Epicatechin gallate; 
23.3 ± 2.4 mg/g (-)-Epicatechin  
Pomegrante CEBAS-CSIC Performed by Dr. H. 
Nyambe (Nyambe-
Silavwe and 
Williamson, 2016) 
121 mg/g punicalagin; 
6 mg/g puricalin;  
5.9 mg/g ellagic acid hexose;  
101 mg/g ellagic acid  
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2.1.2 Preparation of Eucalyptus Leaf Extract (ELE) by reflux extraction 
of eucalyptus leaves 
Eucalyptus leaves were extracted following methods previously reported 
(Sugimoto et al., 2005). In short, 25 g of leaves were extracted in 250 mL 1:2 
ethanol-water (1:2 v/v) under reflux for 2 h. Ultrapure water, supplied from the 
Millipore Milli-Q Integral system (resistivity of 18.2 MΩ x cm at 25 °C), was used in 
the reflux system. The resulting liquid was filtered with a common paper filter and 
centrifuged for 20 min at 3,000 g. Supernatant was dried in in a centrifugal 
evaporator (Genevac Ltd, Ipswich, UK) and reconstituted in DMSO to 5 mg/mL. 
 
2.1.3 Defatting of dark chocolate product for extract preparation  
Defatting of dark chocolate product was conducted as previously described 
(Robbins et al., 2009). Namely, the dark chocolate product Lindt Excellence 85% 
Cocoa Dark Chocolate was snap-frozen using dry ice and ethanol, and 20 g was 
ground to a powder. Defatting of ground chocolate powder was achieved by adding 
5 g of powder to 45 mL of hexane (H/0406/PB17) and sonicating for 5 min at 50 
°C. The suspension was then centrifuged at 885.4 x g for 5 min and hexane 
supernatant decanted to waste. Sonication and centrifugation steps were carried 
out twice more and sample was placed in the fume cupboard overnight to allow for 
all residual hexane to evaporate. 
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2.1.4 Preparation of dark chocolate extract 
A flavanol-rich extract from fat-free Lindt Excellence 85% Cocoa Dark Chocolate 
product was prepared as previously described (Robbins et al., 2009). In short, an 
extraction solution of acetone (A/0606/17), water and acetic acid (A/0360/PB15) 
was prepared (70:29.5:0.5 v/v/v) and a volume of 10 mL was added to 3.4 g of fat-
free chocolate powder. The suspension was firstly shaken by hand then vortexed 
for ~ 2 min, in order to facilitate dispersion of the sample, before being sonicated 
for 5 min at 50 °C and centrifuged at 885.4 x g for 5 min. The supernatant was 
collected and passed through a strong mixed-mode cation exchange solid phase 
extraction cartridge (30 µm particle size, MCX 186000252, Walters Oasis, 
Hertfordshire, UK) after cartridge condition and equilibration, according to 
manufacturer’s instructions, and then filtered through a 0.45 µm pore sized 
polytetrafluoroethylene (PTFE) membrane syringe filter with 25 mm diameter 
(6874-2504, Sigma-Aldrich, Dorset, UK). Filtrate was collected, diluted and placed 
in a HPLC vial (03-FIVA, Thermo Fisher Scientific, Paisley, UK) for 
chromatographic analysis.   
 
2.1.5 HPLC-FLD protocol for chocolate extract analysis 
The flavanol profile of dark chocolate extract was analysed using an Agilent 1200 
series with fluorescence detection, as previously described (Robbins et al., 2012). 
In summary, a Phenomenex Develosil Diol 100 Å column (particle size of 5 µm, 
250 × 4.6 mm) and a Phenomenex Cyano SecurityGuard cartridge (4 x 3.0 mm), 
installed in accordance with the SecurityGuard cartridge kit, were held at a 
temperature of 35 °C. The flow rate was set to 1 mL/min, injection volume of 5 µL, 
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and autosampler was set to and held at 5 °C. The mobile phase was a binary 
gradient of solvents A, consisting of 2% acetic acid in acetonitrile (A/0626/17) (98:2 
v/v) and B, consisting of acetic acid in aqueous methanol (M/4058/17) (95:3:2 
v/v/v). The starting condition of mobile phase was 7% B, held isocratic for 3 min. 
Solvent B was then ramped to 37.6% for 57 min and subsequently to 100% for 3 
min. This condition of 100% solvent B was held for 7 min before returning to the 
starting condition of 7% solvent B for 6 min. A post run equilibration was held for 
10 min at 7% solvent B. Changes in mobile phase conditions during the total run 
time of 86 min are listed in Table 2.2. Fluorescence detection was conducted with 
excitation set at 230 nm and emission set at 321 nm. Varying dilutions of 
epicatechin were prepared in order to create a calibration standard curve relative 
to known concentrations of epicatechin. Photomultiplier (PMT) level was set to 9. 
Calibration curve linearity was maintained for the prepared epicatechin 
concentrations, ranging from 0.02 mM to 0.5 mM, and linear regression analysis 
was performed to obtain the R-squared and gradient values. The concentration of 
each flavanol (µM) present in the chocolate extract was calculated using the 
epicatechin calibration curve and the individual relative response factors for each 
fraction (DP1-10), as reported previously (Robbins et al., 2012). Chocolate extract 
analysis was performed with an increased gain setting (i.e., PMT 12), as well as 
the PMT 9, to ensure proper dynamic range and enable better measurement of all 
procyanidins. Flavanol concentration values were adjusted for the change in gain 
setting by normalization with a correction factor, namely, the average ratio 
difference in concentration from fractions of same sample analysed at PMT 9 and 
12. 
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Table 2-2 Specific conditions of the mobile phase during the full length of the run. 
Run time (min) % solvent B 
0 7 
3 7 
60 37.6 
63 100 
70 100 
76 7 
86 7 
 
The profile obtained for the defatted chocolate extract, from monomer to decamer, 
was compared against Baking Chocolate Standard Reference Material (2384) 
kindly supplied by the National Institute of Standards and Technology (USA). Fat-
free chocolate reference standard was prepared and analysed in the same 
manner, described above (refer also to section 2.1.2), as the chocolate extract. 
 
2.2 General methods applied to Caco-2 and Caco-2/TC7 cell 
model 
2.2.1 Materials 
Cell culture materials were purchased from Sigma-Aldrich, Dorset, UK, unless 
otherwise stated. Ultrapure water, supplied from the Millipore Milli-Q Integral 
system (resistivity of 18.2 MΩ x cm at 25 °C), was used for rinsing cells on the 
immunostaining protocol. Buffers used in the methods described below were tris 
buffered saline (TBS) buffer (1706435, Bio-Rad, Hemel Hempstead, UK), 
phosphate buffered saline (PBS) (P4417), PBS with calcium chloride and 
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magnesium chloride (PBS+) (D1283) and Hank’s balanced salt solution (HBSS) 
(55021C). Sugars added to growth medium in protein and gene expression 
analysis were as follows: D-fructose (F/1950/50, Thermo Fisher Scientific, Paisley, 
UK), D-galactose (BP656-500, Thermo Fisher Scientific, Paisley, UK), D-sucrose 
(10638403, Thermo Fisher Scientific, Paisley, UK), sorbitol (W302902) and L-
glucose (G5500). 
 
2.2.2 Caco-2 and Caco-2/TC7 basic cell culturing  
Caco-2/TC7 cells kindly donated by Dr M. Rousset  (U178 INSERM, Villejuif, 
France) were routinely cultured in 25 mM glucose Dulbeccos’s modified Eagle’s 
DMEM Medium (D5671) supplemented with 20% (v/v) fetal bovine serum  (FBS) 
(F7524), 2% (v/v) Glutamax™ (35050, Thermo Fisher Scientific, Paisley, UK), 2% 
(v/v) non-essential amino acids (M7145), 100 U/mL penicillin and 0.1 mg/mL 
streptomycin (P0781) at 37 °C with 10% CO2 in a humidified atmosphere. Caco-2 
cell line (HTB-37) was obtained from ATCC (Manassas, USA). This cell line was 
cultured in the same conditions as Caco-2/TC7 with the following alterations; 
cultured in 5.5 mM glucose Dulbeccos’s modified Eagle’s Medium (D5546), 
supplemented with 15% (v/v) FBS, with 5% CO2 in a humidified atmosphere. Both 
Caco-2 and Caco-2/TC7 cells were sub-cultured at ∼ 90% confluence, through 
detachment with 0.25% trypsin (T4049), and seeded on flasks at a density of 1 × 
104 cm−2 and medium was replaced every two days. Cells were used between 
passage number 28 and 45. Transepithelial electrical resistance (TEER) is a good 
indicative of cell layer differentiation state, as with the formation of tight functions 
the TEER of a cell layer is increased. Therefore, to confirm integrity of cell layer 
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TEER was measured prior to cell scraping for mRNA and/or protein analysis. A 
TEER value of 200 Ω or above was deemed acceptable.  
 
2.2.3 GLUT7 gene expression analysis 
Caco-2/TC7 cells were seeded on 6-well Transwell plates (0.4 μM pore size, 
polycarbonate, Corning, UK) at a density of 6 × 104 cm−2 and kept for 21 days in 
the conditions listed above. During the first 7 days post-seeding cells were grown 
in asymmetric conditions, namely, FBS was only included in the medium added to 
the basolateral side of each well in the Transwell plates. Throughout the whole 
differentiation period cells were grown in glucose-only medium or medium 
supplemented with 25 mM of one of the following sugars; fructose, sorbitol, 
galactose, L-glucose and sucrose on apical side only, or both apical and 
basolateral sides. Medium was replaced every second day. At day 21, cells were 
washed twice with ice-cold PBS solution, scraped, and mRNA material was 
extracted from cells using the Aurum Total RNA Mini Kit (Bio-Rad 732-6820, Hemel 
Hempstead, UK), following manufacturer’s instructions. Reverse transcription of 
RNA to cDNA was performed using the Applied Biosystems high capacity RNA to 
cDNA kit (4387406, Life Technologies, USA) and PCR reaction to quantitatively 
determine gene expression was performed using TaqMan’s duplexed FAM/VIC 
assays in a QX100 Droplet digital PCR system (Bio-Rad), as previously described 
(McDermott et al., 2013). In short, triplicate reactions of 20 µL stock sample 
solution were prepared by adding 9 µL total transcribed nucleic acids (5 ng), 1µL 
GLUT7 (SLC2A7) FAMTM-labelled TaqMan primer (Hs01013553_m1, Thermo 
Fisher Scientific, Paisley, UK) and 10µL of ddPCR Supermix for Probes (Bio-Rad). 
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TBP (TATA box binding protein) (Hs00427620_m1, Thermo Fisher Scientific, 
Paisley, UK) was added to final stock sample solution to act as a reference. 
Droplets were generated through the PCR reactions, as per manufacturer’s 
instructions, by the QX100 Droplet generator (Bio-Rad) and then transferred to a 
96-well PCR plate, which was subsequently sealed at 180 °C using a PX1 PCR 
plate sealer (Bio-Rad). End point PCR was conducted in a C1000 Touch thermal 
cycler (Bio-Rad) under the following conditions; 95 °C (10 min), 39 cycles of 94 °C 
(0.5 min) followed by 57.8 °C (1 min), 98 °C (10 min) and cooling at 12 °C. The 
fluorescence produced by the droplets was quantified by the QX100 droplet reader 
(Bio-Rad). Concentrations of target and reference DNA (copies/µL) were 
presented as a ratio. All reactions were performed in duplex mode. All data were 
analysed with the QuantaSoft software (Kosice, Slovakia). General principle 
droplet making and quantification is represented in Figure 2.1.  
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Figure 2-1 Representation of general principle of droplet making and 
quantification. Once droplets are formed and PCR is conducted individual 
droplets are passed through a two-colour detection system that determines 
which droplets are positive/negative for presence of target. (Adapted from 
Bio-Rad digital PCR workflow) 
 
2.2.4 Immunofluorescence staining 
Caco-2/TC7 cells were seeded at a density of 6 x 104 cm-2 on Millicell cell culture 
inserts (12-well, PET 0.4 mm pore size, Millipore) and maintained in conditions 
described above for 21 days, with media changed every two days. Cells were fixed 
with the addition of 4% para-formaldehyde in PBS to each well and insert. Inserts 
were then placed on a small volume of 5 µg/mL Fluorescein labelled Wheat Germ 
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Agglutinin (WGA) (Fl-1021, Vector Laboratories, Peterborough, UK) in HBSS and 
incubated at 37 °C for 10 min. Cells were washed three times with PBS+ and 
permeabilized with 0.1% Triton-X100 for 20 min at room temperature before being 
incubated with GLUT2 (ab95256, Abcam, Cambridge, UK), GLUT5 (sc271055, 
Santa Cruz Biotechnology, Dallas, TX, USA)  or GLUT7 (NBP1-81821, Novus 
Biologicals, Littleton, CO, USA) primary antibody at a 1:50 dilution for 1 h, also at 
room temperature. Three washes with PBS were performed on the cells which 
were then incubated with either Cy3-conjugated AffiniPure donkey anti-mouse IgG 
(415-165-150, Jackson ImmunoResearch, USA) or anti-rabbit IgG (711-165-152, 
Jackson ImmunoResearch, USA) secondary antibodies at a dilution of 1:300. Cells 
were washed three times with PBS, stained with 2 µg/mL 4',6-diamidino-2-
phenylindole (DAPI) for 5 min, rinsed with water, and mounted onto microscopy 
slides using ProLong Gold antifade reagent mounting medium (P36930, Thermo 
Fisher Scientific, Paisley, UK). Images were obtained from a Zeiss LSM 700 
Inverted Confocal Microscope. Cells imaged without the WGA cell membrane 
marker were permeabilized once fixed and processed for imaging in the same way 
as described above, with the exception that Alexa Fluor 488-conjugated AffiniPure 
donkey anti-rabbit IgG (711-545-152, Jackson ImmunoResearch, USA), at a 
dilution of 1:300, was used in the secondary antibody incubation step.  
 
2.2.5 Cell surface protein biotinylation 
Cells were seeded onto 6-well Transwell plates and maintained for 21 days, as 
described previously. During the first 7 days post-seeding, cells were grown in 
asymmetric conditions with no FBS added to the apical medium. Throughout the 
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whole differentiation period, cells were grown in glucose-only medium or medium 
supplemented with 25 mM fructose on the apical side only, or on both apical and 
basolateral sides. A change of media was done every second day. Cell surface 
biotinylation was performed using Pierce Cell Surface Protein Isolation Kit (89881, 
Thermo Fisher Scientific, Paisley, UK) according to manufacturer’s instructions. 
The general principle for this method is illustrated in Figure 2.2. In brief, cells were 
washed twice with ice cold PBS+ before being incubated with Sulfo-NHS-SS-Biotin 
for 30 min, on ice, on a low speed shaker. Quenching solution was added to each 
well and cells were then washed twice with TBS. Cells were scraped and lysed in 
60 mM octylglucoside/150 mM NaCl/ 20 mM Tris solution (pH 7.4), containing 
protease inhibitors (P8340), for 30 min on ice, then cell debris was pelleted by 
centrifugation at 14,000 x g for 5 min. Clarified supernatant was transferred into a 
new tube and protein concentration for each cell lysate was determined using 
LabTech-Nanodrop ND100 spectrophotometer. Meanwhile, NeutrAvidin Agarose 
beads were added to Pierce Spin Columns (69725, Thermo Fisher Scientific, 
Paisley, UK) and columns were then washed twice with TBS and lysis buffer. 
Lysates were added to their corresponding filter columns, at comparable protein 
concentrations, and incubated at room temperature on a rotator at low speed for 1 
h. Filter columns were washed twice with TBS and then treated with Rapid PNGase 
F (P0710S, New England Biolabs, Ipswich, USA) for 15 min at 37 ˚C. Biotinylated 
membrane fractions were eluted with SDS-PAGE sample buffer containing 0.5 M 
dithiothreitol (DTT) following a 20 min incubation at 37 ˚C with this elution solution. 
Samples were stored at -80 ˚C. 
 
 
 
53 
 
 
Figure 2-2 Cell surface biotinylation procedure summary. Cultured Caco-2/TC7 
cells were labelled with Sulfo-NHS-SS-Biotin for 30 min on ice. Quenching 
solution is added to the cells which were washed, harvested and lysed. Cell 
proteins bound to biotin were isolated with NeutrAvidin Biotin-binding protein 
with the use of a filter spin column. Purified biotinylated membrane protein 
extract was eluted with SDS-PAGE elution buffer containing 0.5 M DTT. 
 
2.2.6 Protein analysis 
Expression of GLUT7 on biotinylated membrane cell samples was determined with 
ProteinSimple’s automated Western blot system ‘Wes’ according to manufacturer’s 
instructions with the exception of denaturing of samples, which was done at 37 ˚C 
for 15 min as GLUTs have shown a tendency to degrade at higher temperatures. 
Cell lysate samples were treated with Rapid PNGase F (P0710S, New England 
Biolabs, Ipswich, USA) for 15 min prior to the denaturing step. GLUT7 antibody 
(NBP1-81821, Novus Biologicals, Littleton, CO, USA) dilution was 1:10 and 
NaKATPase antibody dilution was 1:100. Optimal loading concentration for cell 
lysate samples was 0.4 mg/mL and membrane fraction biotinylated samples were 
loaded without dilution.  
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2.2.7 Statistical analysis 
Protein and gene expression experiment results were interpreted as a ratio of 
loading controls. Each data point represents the mean of three biological 
replicates, and three technical replicates in gene expression assays, ± SEM. Cells 
cultured in standard medium containing only glucose were used as controls for all 
experiments, for which results were normalized to. Data from biological replicates 
were combined by normalizing each individual experiment by the control and 
ANOVA was performed to determine any statistical difference. Two tailed 
homoscedastic Student’s t-test was used to award significance to specific 
conditions normalized to the glucose control. 
 
2.3 Molecular biology  
2.3.1 Materials 
Bacterial competent cells used for transformations were Stellar™ Competent 
Cells (E. coli HST08 strain) (636763, Clonetech, Saint-Germain-en-Laye, France). 
Agar powder (L2897, Sigma-Aldrich, Dorset, UK) was solubilized with Ultrapure 
water, supplied from the Millipore Milli-Q Integral system (resistivity of 18.2 MΩ x 
cm at 25 °C), and autoclaved. Under a flame, antibiotics were added to melted 
agar and poured onto D x H 120 mm x 20 mm petri dishes (CLS430591, Sigma-
Aldrich, Dorset, UK) which were left to set at room temperature then stored at 4 °C 
for up to 14 days. Before use all agar plates were warmed, upside down, at 37 °C. 
Ampicillin (BP1760-5, Thermo Fisher Scientific, Paisley, UK) was used to make 
Amp+ plates, and Spectinomycin (22189-32-8, Sigma-Aldrich, Dorset, UK) was 
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utilised to make Spc+ plates. Luria-Bertani (LB) broth (71751, Lennox-Novagen, 
Hertfordshire, UK) was solubilized in Ultrapure water and autoclaved before use.  
Gels used for electrophoresis were made up using agarose (EP-0010-05, 
Eutogentec, Hampshire, UK) in 1% Tris base, acetic acid and EDTA (TAE) buffer 
(diluted with Ultrapure water from 50x TAE buffer, 161-0743, Bio-Rad, 
Hertfordshire, UK) with SYBR Safe DNA Gel Stain (S33102, Thermo Fisher 
Scientific, Paisley, UK). Size of DNA products was compared against a 1 kb DNA 
HyperLadder (BIO-33025, Bioline, London, UK).  
RNA denaturing gels were made by dissolving 0.75 g agarose in 36 mL Ultrapure 
water and adding 5 mL 10x MOPS buffer (BP2900500, Thermo Fisher Scientific, 
Paisley, UK) and 9 mL 37% formaldehyde (C5300-1, Bio Basic, Ontario, Canada). 
The size of mRNA products was determined against a ssRNA Ladder. All gel 
images were obtained from exposing the gel on a Dark Reader Transilluminator 
(DR-46B, Clare Chemical Research, Dolores, CO, USA) and imaging on a 
DigiDoc-It Imaging System darkroom (76-0311-01, UVP, Cambridge, UK).  
Universal and customized primers used for sequencing reactions of each vector 
are listed in Tables 2.3 and 2.4, respectively.  
Glycerol stocks were made by adding 500 µL 50% glycerol to 500 µL cells in LB 
broth into a Cryotube Vial (368632, Thermo Fisher Scientific, Paisley, UK). All 
glycerol stocks were stored at – 80 °C. Glycerol (G/P450/05, Thermo Fisher 
Scientific, Paisley, UK) was diluted with Ultrapure water to 50% and autoclaved 
before use. 
Complete sequence of expression vector and plasmid constructs can be found in 
the appendix. 
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Table 2-3 List of universal primers, and their sequence, used for sequencing 
reactions of each vector. 
Universal 
primer name 
Sequence Plasmid 
T7 5’ - TAA TAC GAC TCA CTA TAG 
GG - 3’ 
SLC2A5 in 
pANT7_cGST, 
GLUT7pGEM-HE 
SP6 5’ - GAT TTA GGT GAC ACT ATA 
G - 3’ 
pBF 
GLUT5pBF 
GLUT2pBF 
GLUT7pBF 
CMV-Forward 5’ - CGC AAAT GGG CGG TAG 
GCG TG - 3’ 
pcDNA3.2/v5-DEST 
hGlut2  
M13-Forward 5’ - GTA AAA CGA CGG CCA G - 
3’ 
SLC2A7 in pENTR223.1 
M13-Reverse 5’ - CAG GAA ACA GCT ATG AC - 
3’ 
pcDNA3.2/v5-DEST 
hGlut2 
SLC2A7 in pENTR223.1 
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Table 2-4 List of customized primers, and their sequence, used for sequencing 
reactions of each vector. 
Primer name Sequence Plasmid 
pBF-Forward 5' - CGC TCA ACT TTG GCA GGG 
ATC CG - 3' 
GLUT5pBF 
GLUT2pBF 
GLUT7pBF 
pBF-Reverse 5’ - GTG TTC TTG AGG CTG GTT 
TAG TGG - 3’ 
GLUT5pBF 
GLUT2pBF 
GLUT7pBF 
GLUT5_1703-
F 
5' - CAG CAT CGT CTG TGT CAT 
CTC CTA CG - 3' 
SLC2A5 in 
pANT7_cGST 
GLUT5pBF 
GLUT5_1068-
F 
5' - GTG GTG CCC CAG CTC TTC 
ATC ACT G - 3' 
GLUT5pBF 
GLUT2_509-F 5' - TTG GAG TTG GCG CTG TAA 
AC - 3' 
pcDNA3.2/v5-DEST 
hGlut2, 
GLUT2pBF  
GLUT7_1390-
F 
5' - GGC TAC AAC CTC TCT GTG 
GT - 3' 
GLUT7pGEM-HE 
SLC2A7 in 
pENTR223.1 
GLUT7pBF 
GLUT7_2124-
F 
5' - CTC CTC TCC ATC ATC GTG 
CT - 3' 
GLUT7pBF 
GLUT7_2254-
F 
5' - CTG GCG TCG TCA ACA TAG 
TG - 3' 
GLUT7pGEM-HE 
GLUT7pBF 
GLUT7_841-F 5' - CTC CTC TCC ATC ATC GTG 
CTC ATG G - 3' 
GLUT7pBF 
 
 
2.3.2 Propagation of pBF expression vector and human GLUT2, 5 and 
7 gene containing vectors 
Plasmid vector pBF (SP6 promoter), an amphibian expression vector widely used 
in heterologous expression of proteins in X. laevis oocytes that contains specific 
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characteristics contributing to mRNA stability, was kindly provided by Dr. Jonathan 
Lippiat (Faculty of Biological Sciences, University of Leeds, UK) Human GLUT5 
gene was obtained from SLC2A5 in pANT7_cGST plasmid (DNASU, Tempe, 
USA), human GLUT2 gene was derived from pcDNA3.2/v5-DEST hGlut2 plasmid 
(Addgene, Cambridge, MA, USA) and human GLUT7 gene was acquired from 
SLC2A7 in pENTR223.1 plasmid (DNASU, Tempe, USA). GLUT7 mRNA was also 
prepared from GLUT7pGEM-HE plasmid (T7 promoter), kindly supplied by Debbie 
O'Neill of Prof. Chris Cheeseman’s group (Department of Physiology, Alberta 
University, Canada). All vectors were sequenced with universal primers for their 
promoter or specific regions, as well as specific primers designed against the 
different areas of the gene of interest, to confirm sequence provided. A list of 
primers used for sequencing of each vector is listed above in Table 2.4. The 
vectors, excluding SLC2A7 in pENTR223.1 plasmid, were transformed into 
competent cells (E. coli HST08 strain), according to supplier’s instructions. Cells 
were spread over an Ampicillin containing agar plate (Amp+ agar plate) and 
incubated overnight at 37 ˚C before being added to 250 mL LB broth, containing 
250 µL Ampicillin, and incubated overnight on a shaker at  37 ˚C and 190 rpm. A 
portion of purchased glycerol stock from SLC2A7 in pENTR223.1 plasmid was 
spread over a Spectinomycin containing agar plate, incubated overnight at  37 ˚C, 
then added to LB broth with Spectinomycin and incubated overnight in the same 
conditions described above. Contents of each LB broth flask were put through a 
EndoFree Plasmid Maxikit (12362, Qiagen, Les Ulis, France) for plasmid DNA 
extraction. Nucleic acid concentration was measured using a LabTech-Nanodrop 
ND100 spectrophotometer. 
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2.3.3 Design of plasmid constructs by insertion of human GLUT genes 
into pBF expression vector 
 
2.3.3.1 Recombinant hGLUT5 plasmid construct (GLUT5pBF) 
Expression vector, pBF, was linearized with XbaI (RG181 Promega, Madison, WI, 
USA). Primers were designed to contain a short end region homologous to each 
end of the GLUT5 gene sequence, as available in SLC2A5 in pANT7_cGST 
plasmid, as well as a region homologous to linear pBF. Specific primers containing 
homologous ‘sticky-ends’ were as follows; forward primer 5’-GGT TAA CTA GTC 
CGA ACC ACG GGG ACG TG- 3’ and reverse primer 5’ -CGA TGA ATT CTA TCA 
CAA CTG TTC CGA AG- 3’. Primers were added to SLC2A5 in pANT7_cGST 
plasmid and CloneAmp HiFi PCR premix (639298, Clonetech, Saint-Germain-en-
Laye, France) and PCR was conducted in a C1000 Touch thermal cycler (Bio-Rad) 
under the following conditions; 98 ˚C (1 min), 35 cycles of 95 ˚C (0.5 min), 60 ˚C 
(0.5 min) and 72 ˚C (2 min), followed by 72 ˚C (4 min) and cooling/hold at 4 ˚C. 
Figure 2.3 below illustrates, in general terms, the process of ligation of GLUT gene 
insert into pBF expression vector. Electrophoresis was performed on linear pBF 
and PCR product on a 1% agarose gel for 45 min at 70 V in 1% TAE buffer. DNA 
was extracted from gel band products using Zymoclean Gel DNA recovery kit 
(D4002, Zymo Research, Cambridge, UK). The DNA products were ligated 
together to produce GLUT5pBF using In-Fusion HD Cloning kit (638909, 
Clonetech, Saint-Germain-en-Laye, France). The insert was transformed into 
bacterial competent cells and incubated overnight, as described above (refer to 
1.3.1). Individual colonies were extracted and added to 5 µL of water. A streak 
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plate of colonies was created by gently running the end of each pipette tip used to 
extract colonies onto an Amp+ plate. Colonies were boiled at 95 ˚C for 5 min and 
PCR was performed with the addition of GoTaq Green Master Mix (M7123, 
Promega, Southampton, UK), pBF-Reverse primer and GLUT5_1703-Forward 
primer in a C1000 Touch thermal cycler (Bio-Rad). Electrophoresis was performed 
on PCR products, as above, and colonies that produced individual bands (product 
size equal to number of base pairs between two primers; 466 base pairs, and 
number of base pairs from start of GLUT5_1703-Forward primer until the end of 
sequence; 3244 base pairs) were propagated from the streak plate in 5 mL LB 
broth, containing 5 µL ampicillin, and incubated overnight on a shaker at  37 ˚C 
and 190 rpm. Plasmid DNA extraction was performed using Qiaprep Spin Miniprep 
Kit (27106, Qiagen, Les Ulis, France) and nucleic acid concentration was 
measured using a LabTech-Nanodrop ND100 spectrophotometer. Sequencing 
confirmed which colonies were positive for the presence of the GLUT5 gene. A 
chosen positive GLUT5pBF colony was propagated from streaked plate in 250 mL 
LB broth plus Ampicillin and DNA was then extracted, as described above (see 
2.3.1). A glycerol stock of this GLUT5pBF clone was prepared and stored at - 80 
˚C.  
 
 
61 
 
 
Figure 2-3 Ligation of insert (GLUT gene) into pBF expression vector. pBF is 
digested with XbaI restriction enzyme at a specific site, creating ‘sticky-
ends’. Primers are designed to have homology to linear pBF as well as 
GLUT sequence; in this example, GLUT5pBF primers are shown. PCR of 
GLUT containing plasmid is performed, followed by ligation of products with 
linear pBF vector.   
 
2.3.3.2 Recombinant hGLUT2 plasmid construct (GLUT2pBF) 
Primers were designed, as described previously, to contain homologous ends to 
linear pBF expression vector as well as GLUT2 sequence. Specific primers with 
homologous ‘sticky-ends’ were as follows; forward and reverse primers were 5’ -
CCG GGT TAA CTA GTC CCA CTG CTT ACT GGC TTA TC- 3’ and  5’ -TAT CGA 
TGA ATT CTA TCA GGG TTC CTT CCG GTA TTG TC- 3’, respectively. 
Expression vector was linearized and PCR was performed on SLC2A5 in 
pANT7_cGST plasmid with the homologous end primers, as described above 
(refer to 2.3.2.1), under the following conditions; 95 ˚C (1 min), 30 cycles of 98 ˚C 
(10 sec), 65 ˚C (15 sec) and 72 ˚C (10 sec), followed by 72 ˚C (2 min) and 
cooling/hold at 4 ˚C. Much the same as the methods described above (see 2.3.2.1) 
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electrophoresis of linear product and PCR product was performed, followed by 
DNA extraction from agarose gel and ligation of DNA products, with subsequent 
transformation into competent bacterial cells. Colonies extracted from Amp+ plates 
were added to 5 mL LB broth with 5 µL Ampicillin and incubated overnight on 
shaker at  37 ˚C and 190 rpm. Plasmid DNA extraction was performed using 
Qiaprep Spin Miniprep Kit and nucleic acid concentration was measured using a 
LabTech-Nanodrop ND100 spectrophotometer. Glycerol stocks were prepared for 
each colony by adding 500 µL 50% glycerol to 500 µL propagated DNA in LB broth. 
DNA from all extracted colonies was digested with HindIII restriction enzyme 
(R60471, Promega, Madison, WI, USA). Electrophoresis was performed on 
digested plasmid DNA and positive colonies for GLUT2pBF (those that produced 
a two band product, one for restriction site on the pBF sequence and one for 
restriction site on the GLUT2 sequence) were sequenced to confirm the presence 
of the GLUT2 gene. DNA from one chosen positive GLUT2pBF colony was 
propagated from its glycerol stock in 250 mL LB broth plus Ampicillin, followed by 
DNA extraction, as described above (see 2.3.1). A glycerol stock of this GLUT2pBF 
clone was prepared and stored at - 80 ˚C.  
 
2.3.3.3 Recombinant hGLUT7 plasmid construct (GLUT7pBF) 
This construct was made using the same methods described in the previous 
section (refer to 2.3.2.2), with the following exceptions; primers containing 
homologous ends to linear pBF and GLUT7 sequence were designed and are as 
follows; forward primer 5' - CCG GGT TAA CTA GTC GTT GTA AAA CGA CGG 
CCA GT - 3' and reverse primer 5' - TAT CGA TGA ATT CTA TCA CCA GGA AAC 
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AGC TAT GAC CAT - 3'. PCR was conducted on SLC2A7 in pENTR223.1 plasmid 
using homologous end primers under the following conditions; 30 cycles of 98 ˚C 
(10 sec), 55 ˚C (15 sec) and 72 ˚C (0.5 min), followed by cooling/hold at 4 ˚C.  
 
2.3.4 Confirmation of G7pGEM-HE plasmid sequence 
In order to confirm the presence of hGLUT7 gene in the GLUT7pGEM-HE plasmid, 
the DNA extracted following the propagation of the plasmid was digested with KpnI 
(R6341, Promega, Madison, WI, USA) and HindIII restriction enzymes. 
Electrophoresis of the digest on a 1% agarose gel was performed. A two band 
product (one for each restriction enzyme) was sequenced to confirm presence of 
the GLUT7 gene. The primers used for sequencing of this vector are listed in Table 
2.3.  
 
2.3.5 Isolation of mRNA encoding hGLUT2, hGLUT5 and hGLUT7 
genes 
Restriction enzymes were utilized to digest each individual recombinant plasmid; 
PmlI (R05325, New England Biolabs, Ipswich, USA) was used to linearize 
GLUT2pBF plasmid, MluI (RG381, Promega, Madison, WI, USA) was used to 
linearize GLUT5pBF plasmid, either PmlI and MluI were used to linearize 
GLUT7pBF, and GLUT7pGEM-HE was digested with NheI (R6501, Promega, 
Madison, WI, USA). Linear DNA products, with the exception of GLUT7pGEM-HE, 
were added to SP6 polymerase mMESSAGE mMACHINE® (AM1340, Ambion, 
Applied Biosystems, Warrington, UK) in vitro transcription kit and capped RNA 
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products were obtained, according to manufacturer instructions. A T7 polymerase 
mMESSAGE mMACHINE® (AM1344, Ambion, Applied Biosystems, Warrington, 
UK) in vitro transcription kit was used to produce mRNA derived from linear 
GLUT7pGEM-HE product. A general template for the in vitro transcription method 
described here is presented in Figure 2.4. Concentration of the mRNA products 
was measured using LabTech-Nanodrop ND100 spectrophotometer. The size of 
each product was determined by electrophoresis of a small quantity of mRNA on 
a 1.5% agarose 2.2 M formaldehyde RNA denaturing gel for 70 min at 75 V in 1x 
MOPS buffer. Gel was stained with SYBR Gold Nucleic Acd Stain (S11494, 
Thermo Fisher Scientific, Paisley, UK) for 30 min before being imaged.  
 
Figure 2-4 General template for in vitro transcription reaction of plasmid 
constructs. GLUT gene inserts were all inserted between a specific single 
restriction enzyme (RE) site and the promoter (T7 or SP6). Vector is 
linearized at the RE site and the transcription begins on the first base of 
promoter region, ending when template terminates and enzyme falls off it. 
This set up allows for generation of multiple specific RNA transcripts. 
(Beckert and Masquida, 2011)  
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2.4 Microinjection of mRNA into oocytes and sugar uptake 
experiments 
2.4.1 Materials 
Xenopus laevis ovary from adult females were received from the European 
Xenopus Resource Centre, University of Portsmouth, UK. Materials utilized for this 
method were purchased from Sigma-Aldrich, Dorset, UK, unless otherwise stated. 
Before and following digestion, oocytes were washed in a filter sterilised salt 
solution entitled OR2, containing 82.5 mM NaCl (433209), 2.5 mM KCl (7447-40-
7, Thermo Fisher Scientific, Paisley, UK), 1 mM MgCl2 (M8266), 5 mM HEPES 
(7365-45-9) at pH 7.4. Once digested and/or microinjected, oocytes were kept in 
calcium containing ND96-ACT filter sterilized salt solution containing 96 mM NaCl, 
2 mM KCl, 1.8 mM CaCl2 (10043-52-4, Thermo Fisher Scientific, Paisley, UK) 1 
mM MgCl2, 5 mM HEPES at pH 7.4 with the addition of 50 µg/mL tetracycline 
(BP912-100, Thermo Fisher Scientific, Paisley, UK), 100 µg/mL amikacin 
(BP2643-1, Thermo Fisher Scientific, Paisley, UK) and 100 µg/mL ciprofloxacin 
(33434-100MG-R, Sigma-Aldrich, Dorset, UK). Solutions were made up using 
ultrapure water, supplied from the Millipore Milli-Q Integral system (resistivity of 
18.2 MΩ x cm at 25 °C), which was also used in the control water microinjections.  
Radiolabelled sugars used in uptake experiments were as follows: 2-[14C(U)]-
Deoxy-D-Glucose ([14C] deoxy-D-glucose) [Specific Activity: 250-350 mCi (9.25-
13.0 GBq)/mmol, 50 µCi (1.85 MBq)] (NEC720A050UC) and D-[14C(U)]-Glucose 
([14C] glucose) [Specific Activity: 250-360 mCi (9.25-13.3 GBq)/mmol, 250 µCi 
(9.25 MBq)] (NEC042X250UC) were purchased from PerkinElmer, Waltham, MA, 
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USA. D-[14C(U)]-Fructose ([14C] fructose) [in ethanol:water (9:1) solution, 100 
μCi/mL, 50 µCi (1.85 MBq)] was purchased from Moravek Inc., Brea, CA, USA.  
Incubation solutions were made up with the following sugars, D-fructose 
(F/1950/50), D-glucose (50-99-7) and 2-deoxy-D-glucose (154-17-6) purchased 
from Thermo Fisher Scientific (Paisley, UK).  
 
2.4.2 Preparation of Xenopus laevis oocytes for microinjection and 
expression of recombinant hGLUT2, hGLUT5 and hGLUT7 
Xenopus laevis oocytes were isolated and microinjected as described previously 
(Kwon et al., 2007). Briefly, approximately one quarter of the ovary was manually 
cut, placed into a 50 mL tube and washed three times with calcium free OR2 
solution. The ovary was incubated in 1 mg/mL collagenase A (10103578001) in 
OR solution at room temperature for 90 min or until fully digested. The digest was 
washed with OR2 solution and subsequently kept at 18˚C in ND96-ACT medium, 
containing antibiotics, until microinjection. One day post digestion stage V-VI 
oocytes were visually selected from digest using a pasteur pipette and 
microinjected with 50 nl of protein mRNA or water, to be used as controls, using 
an air pressure injector (PV 820, Pneumatic PicoPump, WPI) (Figure 2.5).  
Microinjection tips were made using a programmable micropipette puller (PMP 
100, MicroData instrument Inc.) from custom made narrow glass cylinders (20.3 
cm in length, 10 µL maximum volume). Following microinjections oocytes were 
kept at 18˚C in ND96-ACT medium with antibiotics for 24 h (GLUT5 injected 
oocytes), 48 h (GLUT2 injected oocytes) or 120 h (GLUT7 injected oocytes) before 
 
 
67 
 
experiments were carried out. Media with antibiotics was changed every day to 
every second day for GLUT7 microinjected oocytes. 
 
Figure 2-5 Oocyte microinjection setup. Micropipettes were made from narrow 
glass cylinders using a micropipette puller and then secured onto the 
micropipette holder. Oocytes were placed onto a holding piece under a 
microscope for magnified visualisation [10x magnification eyepiece, 2x 
(dual) built-in objective lens]. Oocytes were microinjected, using the 
manipulation controls on the micropipette holder, by an air pressure injector. 
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2.4.3 [14C] Fructose uptake by GLUT5 
Following microinjection with protein mRNA or water Xenopus oocytes were 
incubated in 6 mM or 100 µM fructose solution with 14C-fructose at a concentration 
of 0.5 µCi/mL. Incubations solutions were made up in the presence and absence 
of increasing concentrations of the compounds/extracts being tested. In cases 
where the stock solution of compound being tested was made using solvents 
(DMSO or ethanol), the equivalent amount of solvent was added to all control sugar 
incubation solutions. Incubations were carried out at 25 ˚C for 5 min (100 µM 
fructose incubation solution) or 15 min at 37 ˚C (6 mM fructose incubation solution). 
All uptake experiments were carried out with three to six replicates of three 
oocytes. After the termination of the incubation period, oocytes were washed with 
ice cold fructose solution, at the same molarity as the incubation solution, and 
homogenised in 0.3 M sucrose (10638403, Thermo Fisher Scientific, Paisley, UK),  
plus 10 mM sodium phosphate (7601-54-9) and protease inhibitor mixture (P8340) 
solution. In order to separate the yolk and pellet cell debris the homogenized 
samples were spun at 3,000 g for 15 min at 4˚C. The supernatant was then 
centrifuged at 48,000 g for 1 h at 4 ˚C to pellet the membranes, which were re-
suspended in the same solution used for the homogenisation step and stored at – 
20 ˚C until protein expression analysis. The supernatant of the second 
centrifugation step was added to a vial containing 5 mL of scintillation fluid and 
sample radioactivity counts were measured using Packard Tri-Carb 1900 TR Liquid 
Scintillation Counter. Samples not used for protein analysis were homogenized and 
added directly to the vials for counting as neither the yolk or cell debris interfere 
with this process. Protein concentration for membrane extract sample was 
determined using LabTech-Nanodrop ND100 spectrophotometer. 
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2.4.4 [14C] Fructose and [14C] Glucose uptake by GLUT2 
Uptake experiments in Xenopus oocytes expressing GLUT2 were carried out in the 
same manner as described above (see 2.4.3), with the following changes; 
concentration of glucose and fructose incubation solutions was 100 µM and 
incubations were carried out at 25 ˚C for 5 min. Homogenization of each three 
oocyte replicate was performed with 1% sodium dodecyl sulfate (SDS) (A1112, 
AppliChem, Darmstadt, Germany).  
 
2.4.5  [14C] Deoxy-D-glucose, [14C] Fructose and [14C] Glucose uptake 
by GLUT7 
Uptake experiments in Xenopus oocytes expressing GLUT7 were carried out in the 
same manner as described above (see 2.4.3), with the following changes; 
concentration of sugar incubation solutions was 100 µM and incubations were 
carried out at 25 ˚C for 30 min. Homogenization of each three oocyte replicate was 
performed with 1% SDS. Uptake experiments were carried out with six replicates 
of three oocytes or three replicates of 10 oocytes. 
 
2.4.6 Protein analysis of X. laevis membrane extracts by Western blot 
Western blot analysis of oocyte membrane extracts was performed as described 
previously (Manolescu et al., 2007a). In short, oocyte membrane samples of 
GLUT5 injected oocytes, as well as positive control TC7 cell lysate samples, were 
denatured following addition of 4X Laemmli reducing buffer (1610747, Bio-Rad, 
Hemel Hempstead, UK) for 15 min at 37 °C. All samples were resolved using SDS-
 
 
70 
 
PAGE Mini-PROTEAN TGX Stain-Free precast 10% gels (4568033, Bio-Rad, 
Hemel Hempstead, UK) for 30 min at 200 V and subsequently transferred to 
Immun-Blot PVDF membranes (1620175, Bio-Rad, Hemel Hempstead, UK)  by 
electrophoresis. Immunoblotting was performed with primary anti-GLUT5 antibody 
(ab36057, Abcam, Cambridge, UK) at a 1:250 dilution, followed by secondary anti-
mouse antibody (ab125323, Abcam, Cambridge, UK) at a 1:10.000 dilution. 
Membrane was washed three times with Tris buffered saline (TBS) buffer 
(1706435, Bio-Rad, Hemel Hempstead, UK) with Tween 20 (1706531, Bio-Rad, 
Hemel Hempstead, UK). Membranes are then incubated with 50:50 peroxide and 
luminol from Clarity Western ECL substrates kit (1705060, Bio-Rad, Hemel 
Hempstead, UK) for 5 min away from light. In a dark room membrane was exposed 
onto a photographic film revealing the bands produced by GLUT5 protein 
expression. Alternatively, membranes were imaged with ChemiDoc XRS+ (Bio-
Rad, Hemel Hempstead, UK) western blot digital imaging system, according to 
manufacturer instructions. 
 
2.4.7 Protein analysis of X. laevis membrane extracts by Wes 
Expression of hGLUT2, hGLUT5 and hGLUT7 in Xenopus oocyte membranes was 
determined with ProteinSimple’s automated western blot system ‘Wes’ according 
to manufacturer’s instructions, as formerly reported (Ziegler et al., 2016), with the 
exception of sample denaturing condition, which was done at 37 ˚C for 15 min. 
Membrane extracts of hGLUT2 and hGLUT7 injected oocytes were treated with 
Rapid PNGase F (P0710S, New England Biolabs, Ipswich, USA) for 15 min prior 
to denaturing step. GLUT2 antibody (ab95256, Abcam, Cambridge, UK) dilution 
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was 1:50, as was the dilution of GLUT5 antibody (sc271055, Santa Cruz 
Biotechnology, Dallas, TX, USA) used for protein detection on oocyte membrane 
samples. Optimal loading concentration for GLUT2 oocyte membrane samples 
was 0.4 mg/mL and 0.2 mg/mL was used for GLUT5 oocyte membrane samples. 
GLUT7 antibody (NBP1-81821, Novus Biologicals, Littleton, CO, USA) dilution was 
1:10. Membrane extracts of hGLUT7 expressing oocytes were used undiluted. 
 
2.4.8 Statistical analysis 
Sugar uptake experimental results are all representative of three to six replicates 
of three oocytes, or three replicates of 10 oocytes, per individual condition. Water 
injected control oocytes were used in every experiment and individual condition. 
Each data point represents the mean of all replicates ± SEM normalized to the 
mean of its respective control replicates, unless controls are included in the figures. 
Two tailed homoscedastic Student’s t-test was used to award significance, as 
previously reported (Manolescu et al., 2005). Uptake of sugar per oocyte 
(pmol/oocyte/incubation time) was determined by using a standard curve, 
produced for each experiment and every condition, and taking into consideration 
the concentration of sugar incubation solution. Firstly, radioactive counts (CPMA) 
were converted into ng/µL by diving it by the slope of its respective standard curve. 
The result was adjusted for the amount of sugar available for uptake (in pmol) and 
by the maximum volume of the average oocyte (~ 0.52 mm3 or 0.52 µL), and 
divided by the number of oocytes in each replicate. IC50 were determined by 
identifying the concentration of the added compound at which the uptake of sugar 
was decreased by half.   
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Chapter 3  
Characterization of hGLUT2, hGLUT5 and hGLUT7 using the 
Caco-2/TC7 cell culture model 
 
3.1 Abstract 
A common cell culture model of the small intestine, namely the Caco-2/TC7 cell 
model, was used to investigate changes in GLUT7 expression in response to the 
presence of different sugars, with the aim to further characterize the substrates of 
this transporter. Cells were seeded onto Transwell filters and cultured throughout 
the differentiation period in media supplemented with 25 mM of different sugars on 
the apical side only, or on both apical and basolateral sides. There was a significant 
increase in GLUT7 mRNA expression (13%, p ≤ 0.001) in cells grown in the 
presence of fructose, on both apical and basolateral sides, when compared to 
glucose control. In addition, a significant rise in total protein expression (2.7-fold, p 
≤ 0.05) was observed in cells grown under the same conditions. Localization of 
GLUT7 on the apical and basolateral membranes was determined using cell 
surface biotinylation and confocal imaging. Nonetheless, protein expression at the 
cell surface was unchanged in the presence of fructose. As levels of expression of 
GLUTs are reportedly increased in the presence of their substrates, it can be 
extrapolated from these findings that fructose is a substrate of the GLUT7 
transporter. Further investigations are required in order to fully understand the role 
of GLUT7 on the regulation of sugar uptake in the gut.  
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3.2 Introduction 
The Caco-2 cell system is a well characterized and frequently used in vitro  model 
of intestinal absorption, commonly used to examine transport mechanisms and the 
ability of specific chemicals or compounds to cross the intestinal barrier (Angelis 
and Turco, 2011). Seeding of these cells on semi-permeable membranes (eg. 
transwell filters) enables them to differentiate and polarize in long-term culture, 
forming a monolayer with tight junctions, and properties which mimic the intestinal 
barrier (Turco et al., 2011). Caco-2 cell line characteristics have been shown to be 
highly dependent on culture conditions leading to reports on variability of transport 
properties and permeability (Delie and Rubas, 1997), (Briske-Anderson et al., 
1997). Therefore, several clones from this cell line have been isolated, including 
the TC7 clone, which was acquired from a late passage of the parental cell line 
(Chantret et al., 1994). This clone was shown to have more homogenous 
distribution of proteins functional in the small intestine across different passage 
numbers, as well as more developed intercellular junctions and characteristic 
transporter and some brush border enzymes expression profile (Turco et al., 2011), 
(Chantret et al., 1994).   
 
It is known that Caco-2/TC7 cells express different sugar transporters, critical for 
sugar transport, including SGLT1, GLUT2 and GLUT5 (Sambuy et al., 2005), 
(Alzaid et al., 2013), and studies have looked at the effect of high glucose and 
fructose levels in the expression of GLUT2 and GLUT5, respectively (Mahraoui et 
al., 1994), (Gouyon et al., 2003). In addition, data has shown that GLUT5 
expression is higher in adipocytes cultured in the presence of fructose, proposing 
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a stimulation, albeit not conclusive, of transport by the protein substrate itself 
(Legeza et al., 2014). Furthermore, the GLUT2 basolateral to apical membrane 
trafficking proposed by Kellett et al was confirmed in a live cell imaging study with 
liver cells, where translocation of GLUT2 from basal to apical membrane was 
prompted by high glucose levels (Cohen et al., 2014). As localization of 
transporters is critical for function, confocal microscopy was used in this chapter to 
look at GLUT transporter cellular distribution in Caco-2/TC7 cells (Grefner et al., 
2014), (Kipp et al., 2003). Images of Caco-2/TC7 cells incubated with anti-GLUT2, 
5 and 7 antibodies were taken with the aim to determine precise localization of 
each protein in the cells and further characterize the lesser known GLUT7 protein. 
GLUT7 is reportedly expressed on the apical membrane of intestinal cells 
(Cheeseman, 2008), (Douard and Ferraris, 2008) and has been shown to transport 
both glucose and fructose when expressed in oocytes (Li et al., 2004), (Chapter 
6). Nevertheless, the effects of any substrates on the expression levels of GLUT7 
remains to be investigated. Therefore, this chapter examines changes in GLUT7 
mRNA expression levels in the presence of fructose, sucrose, L-glucose, sorbitol 
and galactose, when compared to glucose. In addition, the effect of fructose on 
total and surface protein expression is determined.  
 
Caco-2/TC7 cells used for experiments presented in this chapter were cultured on 
transwell filters (Figure 3.1 B), with the aim of mimicking the environment 
encountered by enterocytes in vivo. Briefly, cells are seeded onto transwell filters 
and placed into a well allowing separation of apical and basolateral medium. This 
imitates the situation in vivo, where sugars are absorbed into the cell from the 
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lumen by transporters on the apical membrane and released into the blood on the 
basal membrane (Lodish et al., 2008). Basolateral membranes refer to the 
basal/lateral domains of the enterocyte (Figure 3.1 A). 
 
Figure 3-1 Representation of enterocyte and culture of Caco-2/TC7 cells on 
transwell filters. Membranes of enterocyte (apical, lateral and basal) are 
marked with their locations (A). Characteristics of culture of Caco-2/TC7 
enterocytes, seeded onto a transwell filter, and exposed to media on apical 
and basolateral compartments (B).  
 
3.3 Determination of location of GLUTs on cellular membranes 
by immunostaining 
Mammalian intestinal cells, Caco-2/TC7, were cultured following methods 
described in Chapter 2 (section 2.2.2). In order to establish the precise localisation 
of each GLUT transporter on cellular membranes, fixed cells were imaged using 
inverted confocal microscopy following immunofluorescence staining (refer to 
section 2.2.4, Chapter 2). Cells were stained with membrane marker wheat germ 
agglutinin (WGA) (emitting green fluorescence), nuclear stain DAPI (emitting blue 
fluorescence) and Cy3-conjugated donkey anti-rabbit/mouse secondary antibody 
(emitting red fluorescence). Detection of proteins was performed by incubating the 
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cells with primary anti-GLUT2, 5 or 7 antibody, followed by incubation with 
secondary antibody, which is conjugated to Cy3, allowing detection (red 
fluorescence). Images are presented as a range from apical membrane (far left) to 
basal membrane (far right). As a negative control, primary antibody was emitted, 
resulting in absence of Cy3 fluorescnce (Figure 3.2). 
 
Figure 3-2 Negative control for immunofluorescence detection for GLUTs in 
differentiated Caco-2/TC7 monolayers. Cells were incubated with nuclear 
stain DAPI (blue), membrane marker wheat germ agglutinin (WGA) (green), 
no primary antibody and Cy3-conjugated donkey anti-rabbit secondary 
antibody (red). Scale bar (10 µm) is shown in the lower left corner of first DAPI 
image and applies to all images. Images from left to right represent sections 
through the cell from the apical to basal side of enterocyte. Images represent 
one of 3 biological replicates. 
 
 
 
78 
 
Immunostaining with anti-GLUT5 primary antibody detected GLUT5 (red 
fluorescence), predominantly on the apical membrane of the enterocyte, and with 
less intensity on lateral domain. Virtually no GLUT5 was detected on the basal 
membrane (Figure 3.3). This is in agreement with data suggesting that fructose is 
transported into the cell by GLUT5, present at high levels on the apical membrane 
(Burant et al., 1992), (Drozdowski and Thomson, 2006), (Reinicke et al., 2012). 
 
Figure 3-3 Immunofluorescence detection of GLUT5 in differentiated Caco-2/TC7 
monolayers. Cells were incubated with nuclear stain DAPI (blue), membrane 
marker wheat germ agglutinin (WGA) (green), mouse anti-GLUT5 primary 
antibody and Cy3-conjugated donkey anti-mouse secondary antibody. 
GLUT5 is shown in red, predominantly on the apical membrane. Scale bar 
(10 µm) is shown in the lower left corner of first DAPI image and applies to all 
images. Images from left to right represent sections through the cell from the 
apical to basal side of enterocyte. Images represent one of 3 biological 
replicates. 
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Immunostaining with anti-GLUT2 primary antibody detected GLUT2 (green 
fluorescence) across both apical and basal/lateral membranes of the enterocyte 
(Figure 3.4). This corroborates the findings by Kellett et al, who conclude that the 
main route for glucose absorption into cells is by translocation of GLUT2 
transporter to the cell apical surface in response to high glucose levels (Kellett and 
Helliwell, 2000). Presence of GLUT2 on basolateral membrane was shown in 
studies using liver cells and rat intestinal models (Cohen et al., 2014), (Helliwell 
and Kellett, 2002), (Cheeseman, 1993). Immunostaining images of GLUT2 
incubated with WGA produced a granular staining, making visualization of the 
protein less clear, and this is why immunostaining was carried out without the 
membrane marker. Immunostaining images of GLUT2 with WGA can be found in 
the appendix.  
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Figure 3-4 Immunofluorescence detection of GLUT2 in differentiated Caco-2/TC7 
monolayers. Cells were incubated with nuclear stain DAPI (blue) and rabbit 
anti-GLUT2 primary antibody and Cy3-conjugated donkey anti-rabbit 
secondary antibody. GLUT2 is shown in green, ranging from both the apical 
to the basal membranes. Scale bar (10 µm) is shown in the lower left corner 
of first DAPI image and applies to all images. Images from left to right 
represent sections through the cell from the apical to basal side of enterocyte. 
Images represent one of 3 biological replicates. 
 
Lastly, immunostaining with anti-GLUT7 primary antibody showed GLUT7 
localization (green fluorescence) mainly on the apical membrane of the enterocyte 
(Figure 3.5). A fainter detection of this protein was localized on the lateral 
membrane, with little localisation of this protein on basal membrane. The possibility 
of GLUT7 being expressed on the apical brush border membrane, due to the high 
sequence similarity with GLUT5, has been previously proposed (Cheeseman, 
2008), (Li et al., 2004). In addition, immunohistochemistry assays using rat tissue 
localized GLUT7 to the apical membrane of the small intestinal epithelial cells 
(Cheeseman, 2008). Nevertheless, the presence and/or localisation of GLUT7 in 
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Caco2-TC7 cells has not previously been reported. As for GLUT2, immunostaining 
images of GLUT7 incubated with WGA did not produce images with good 
visualization, and so, immunostaining was carried out without the membrane 
marker. Immunostaining images of GLUT7 with WGA can be found in the 
appendix. 
 
 
Figure 3-5 Immunofluorescence detection of GLUT7 in differentiated Caco-2/TC7 
monolayers. Cells were incubated with nuclear stain DAPI (blue) and rabbit 
anti-GLUT7 primary antibody and Cy3-conjugated donkey anti-rabbit 
secondary antibody. GLUT7 is shown in green, predominantly on the apical 
side. Scale bar (10 µm) is shown in the lower left corner of first DAPI image 
and applies to all images. Images from left to right represent sections through 
the cell from the apical to basal side of enterocyte. Images represent one of 
3 biological replicates. 
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3.4 Characterization of hGLUT7 through quantitative protein and 
mRNA analysis 
GLUT7 has been previously reported to transport both glucose and fructose and it 
has also been determined that glucose uptake by this transporter was significantly 
inhibited in the presence of fructose (Li et al., 2004), (Chapter 6). In order to further 
characterize GLUT7 and investigate the role of fructose on mRNA levels and 
protein expression, cells on Transwell filter plates were cultured during the 
differentiation stage in medium supplemented with 25 mM fructose or other sugars 
either on the apical side only or on both apical and basolateral sides (refer to 
Chapter 2 section 2.2 for full protocols).  
 
3.4.1 Quantification of hGLUT7 mRNA following cell differentiation in 
the presence of different sugars 
Methods used in the quantification of mRNA were described in Chapter 2 (refer to 
section 2.2.3). Differences in mRNA levels when cells were grown in media 
supplemented with different sugars, were quantified using TATA-box binding 
protein (TBP), a general transcription initiator in mammalian cells (Lodish et al., 
2008) as a housekeeping gene control. A preliminary analysis of GLUT7 mRNA 
levels present in Caco-2/TC7 and Caco-2 showed that the former expressed 3.7-
fold more GLUT7 than Caco-2 cells (p ≤ 0.01) (Figure 3.6). This highlighted the 
differences in protein expression between the parental cell line Caco-2 and its 
clone TC7, as previously reported for other intestinal transporters (Chantret et al., 
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1994), (Turco et al., 2011). For this reason all further investigations were carried 
out with Caco-2/TC7 cells only.  
 
Figure 3-6 GLUT7 mRNA expression in differentiated Caco-2/TC7 and Caco-2 
intestinal cell lines. TBP was multiplexed with GLUT7 as a housekeeping 
gene and results are shown as a ratio of the individual copy numbers for each 
gene. Ratio of GLUT7 to TBP showed that differentiated Caco-2/TC7 cells 
had 3.7-fold more mRNA of this protein than Caco-2 cells. Each data point 
represents the mean of 3 technical replicates from 1 biological sample, 
analysed in triplicates, ± SD. **  p ≤ 0.01 
 
Expression of GLUT7 in Caco-2/TC7 cells grown in media supplemented with 25 
mM of either fructose, sorbitol, galactose, L-glucose or sucrose on apical side only 
during cell differentiation period (21 days) remained unchanged when compared 
to glucose control (Figure 3.7 A). On the other hand, cells grown in media 
supplemented with fructose on both apical and basolateral sides showed a 
significant increase (13%, p ≤ 0.001) in GLUT7 expression when compared to 
glucose control (Figure 3.7 B). No other sugar had a significant impact on GLUT7 
expression when added to growth media on both apical and basolateral sides.   
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Figure 3-7 GLUT7 mRNA expression in differentiated Caco-2/TC7 intestinal cells 
following growth in media supplemented with different sugars. TBP was 
multiplexed with GLUT7 as a housekeeping gene and results are shown 
normalized to the glucose control, and as a ratio of the individual copy 
numbers for each gene. Fructose, sorbitol, galactose, L-glucose and sucrose 
added to apical media did not lead to any change in GLUT7 expression (A). 
A significant increase in GLUT7 expression (13%) was observed when media 
for both apical and basolateral sides was supplemented with fructose. No 
other sugar had the same effect (B). Each data point represents the mean of 
3 biological replicates and 3 technical replicates, analysed in triplicates, ± 
SEM. ***  p ≤ 0.001 
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Because of some variation in expression between the biological replicates, results 
in each experiment were normalized to the respective glucose control. Selected 
results from the effect of fructose, as well as one additional biological replicate, are 
presented in Figure 3.8 below to allow for a better comparison. From this figure it 
looks like the GLUT7 mRNA levels also increased when cells were cultured in 
apical medium supplemented with fructose. However, potentially due to variation 
in expression between replicates a significance could not be attributed to these 
results.  
 
Figure 3-8 GLUT7 mRNA expression in differentiated Caco-2/TC7 intestinal cells 
following growth through the differentiation phase in media supplemented 
with fructose. TBP was multiplexed with GLUT7, as a housekeeping gene, 
and results are shown as a ratio of the individual copy numbers for each gene. 
Fructose added to apical media only did not lead to a change in GLUT7 
expression. However, a significant increase in GLUT7 expression (13%) was 
attributed to fructose supplementation in media for both apical and basolateral 
sides (apical and BL). Each data point represents the mean of 4 biological 
replicates and 3 technical replicates, analysed in triplicates, ± SEM. ***  p ≤ 
0.001 
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3.4.2 Quantification of total and cell surface hGLUT7 protein 
expression following cell differentiation in the presence of 
different sugars 
Protein expression was measured using ProteinSimple capillary automated 
western blotting (Wes). Differences in protein expression levels were measured by 
normalizing to Na+/K+ ATPase (NaKATPase), an ion pump present in the plasma 
membranes of all animal cells (Lodish et al., 2008). Amount of protein localised to 
the surface was quantified following cell surface biotinylation (refer to Chapter 2, 
section 2.2.5). Initially, a standard curve was constructed with different amounts of 
Caco-2/TC7 cell lysate to test linearity of both the GLUT7 and NaKATPAse 
antibodies and a loading sample concentration of 0.4 mg/ml was found optimal for 
signals of both antibodies (Figure 3.9 A). Antibody dilutions were 1:100 for 
NaKATPase and 1:10 for GLUT7. Cell surface biotinylation samples were used un-
diluted. All results are shown as a ratio of the area of the peak obtained for GLUT7 
protein to the area of the peak representative of the NaKATPase protein (Figure 
3.9 B).  
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Figure 3-9 Standard curve for GLUT7 and NaKATPase antibodies and example of 
protein detection by multiplexed antibodies. Standard curved showed that 
both antibodies have linearity at protein concentrations of Caco-2/TC7 lysate 
between 0.1 – 0.6 mg/mL (A). Example of protein detection in Caco-2/TC7 
lysate analysed with multiplexed GLUT7 and NaKATPase antibodies, at a 
lysate loaded concentration of 0.5 mg/ml (B). GLUT7 antibody dilution was 
1:10, and NaKATPase antibody dilution was 1:100. Detected protein size for 
GLUT7 was 49 kDa, and 101 kDa for NaKATPase. 
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Figure 3-10 GLUT7 protein expression in differentiated Caco-2/TC7 intestinal cells 
following growth through the differentiation phase in media supplemented 
with fructose. NaKATPase was multiplexed with GLUT7, as a housekeeping 
gene, and results are shown as a ratio of the individual peak area for each 
protein. Fructose added to apical medium only (apically only) did not lead to 
a change in total GLUT7 protein expression. A significant increase in total 
GLUT7 expression (2.7-fold) was found after apical and basolateral media 
fructose supplementation (A). Surface protein expression was not changed 
significantly with either treatment (B). Each data point represents the mean 
of 3 biological replicates and 2 technical replicates, ± SEM. *  p ≤ 0.05 
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GLUT7 protein expression, measured in crude cell lysate, was significantly 
increased (by 2.7-fold, p ≤ 0.05) following addition of with 25 mM fructose to apical 
and basolateral growth media compared to glucose control (Figure 3.10 A). 
Analysis of lysates from cells grown with apical fructose supplementation showed 
no change in protein expression. Furthermore, there was no significant change 
detected in surface GLUT7 protein expression on apical or basolateral sides 
following supplementation either with fructose apically or on both sides, when 
compared to glucose control (Figure 3.10 B). These results suggest that fructose 
increased GLUT7 expression in the total lysate, however, this did not translate into 
an increase in protein levels on the cell surface. 
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Figure 3-11 GLUT7 surface protein expression in differentiated Caco-2/TC7 
intestinal cells. Analysis of surface biotinylation samples (apical and 
basolateral (BL) fractions), after treatment with PNGase (P) and mock 
treatment (M), by capillary automated western blotting. Results show that 
protein detection, on both apical and basolateral membranes, is greatly 
improved following treatment with PNGase. Detected protein size for GLUT7 
was 47-49 kDa. Antibody dilution was 1:10. Biotinylation samples were un-
diluted. 
 
Imaging results presented above show poor expression of both GLUT7 and GLUT5 
on cellular basal membranes, with a good detection of both on apical domain. 
Interestingly, cell surface biotinylation was able to detect a strong expression of 
GLUT7 on basolateral membrane, as well as on the apical membrane. This could 
be attributed to treatment of samples with the glycosidase PNGase prior to protein 
analysis, which significantly increased the detection of GLUT7 (Figure 3.11). On 
the other hand, analysis of samples from cell surface biotinylation of differentiated 
Caco-2/TC7 cells detected presence of GLUT5 on apical cellular membrane only 
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(Figure 3.12). These differences in the localization highlights a potential difference 
in the function of both transporters.  
 
Figure 3-12 GLUT5 surface protein expression in differentiated Caco-2/TC7 
intestinal cells. Analysis of surface biotinylation samples by capillary 
automated western blotting show GLUT5 protein expression on the apical 
membrane only. Detected protein size for GLUT5 was 59 kDa, with antibody 
dilution of 1:50. Biotinylation samples were un-diluted. 
 
3.5 Summary and discussion of results 
Immunostaining was used to detect expression of GLUT2, GLUT5 and GLUT7 in 
Caco-2/TC7 cells. GLUT2 transporter was expressed across the enterocyte, being 
present on the apical as well as the basal membranes. This agrees with the 
concept that in conjunction with SGLT1, GLUT2 is responsible for the absorption 
of glucose after translocation to the apical membrane from the basal domain 
(Kellett and Helliwell, 2000). Nevertheless, a recent sugar uptake study in GLUT2-
knockout mice showed no decrease in glucose uptake in the absence of this 
transporter (Roder et al., 2014). Although in this study GLUT2 was detected on the 
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apical membrane of brush border membrane fractions, it was attributed to a 
contamination with basolateral membrane (Roder et al., 2014). There is currently 
an ongoing debate about the contribution to glucose uptake attributed to GLUT2 
directly, with some studies showing glucose uptake predominantly by SGLT1 
(Gorboulev et al., 2012), whereas other show GLUT2 as the primary transporter of 
this sugar (Helliwell et al., 2003), (Kellett and Helliwell, 2000). Nonetheless, at least 
at high glucose concentrations, it has become generally accepted that GLUT2 is in 
fact present on apical membranes and does contribute to the uptake of glucose 
(Morgan et al., 2007), (Wright et al., 2007), (Thorens and Mueckler, 2010), (Cohen 
et al., 2014). Further evidence of the ability of GLUT2 to transport glucose, as well 
as fructose, into cells can be concluded from uptake experiments by oocytes 
expressing this transporter (Kwon et al., 2007), (Uldry and Thorens, 2004), 
presented in Chapter 5. 
 
Two different methods were used to determine cellular localization of GLUT2, 
GLUT5 and GLUT7. Immunostaining showed, primarily, that both GLUT5 and 
GLUT7 transporters are localized to the apical membrane of the enterocytes, with 
only faint detection on basal membrane. In agreement, cell surface biotinylation 
confirmed the presence of GLUT5 on the apical membrane only, whereas 
biotinylated GLUT7 was detected both on apical and basolateral membranes 
(Reinicke et al., 2012), (Drozdowski and Thomson, 2006), (Burant et al., 1992). 
Differences in localization of GLUT7 between the two methods could be explained 
by the need for de-glycosylation in order to increase GLUT7 antibody binding, as 
the presence of glycosylation could mask the epitope from recognition. 
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Biotinylation samples are treated with the glycosidase PNGase prior to protein 
analysis, whereas immunostaining is performed on untreated cells, which could be 
leading to less GLUT7 than is available being recognized. Treatment of fixed cells 
with PNGase prior to confocal imaging could potentially increase the detectability 
of GLUT7 on the basolateral side when using this method. Nonetheless, the 
difference in distribution of GLUT5 and GLUT7 highlights the different functions of 
these proteins, regardless of their structural similarities. For instance, GLUT5 
transports fructose only, while GLUT7 is able to transport both glucose and 
fructose, as determined by uptake experiments in oocytes discussed in Chapters 
4 and 6.  
 
To date, GLUT7 has been shown to transport glucose and fructose only, with no 
uptake of galactose, xylose or deoxy-D-glucose observed by GLUT7-expressing 
oocytes (Li et al., 2004). It has been reported that expression of GLUT2 is 
increased in the brush border membrane at high glucose concentrations in rat 
models (Kellett and Helliwell, 2000). Live cell imaging, in liver cell lines, showed a 
rapid translocation of GLUT2 from basal to apical membrane in response to 
glucose stimulation, a process regulated by PKC (Cohen et al., 2014). Similarly, 
GLUT5 expression has been shown to be higher in adipocytes cultured in the 
presence of fructose compared to glucose, suggesting the substrate for this protein 
stimulates its own uptake (Legeza et al., 2014). Based on these observations, it 
could be hypothesised that high levels of substrate elevate the expression of GLUT 
transporters. Therefore, with the aim to further characterize the lesser known 
GLUT7 transporter, mRNA and protein levels were measured following culture of 
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Caco-2/TC7 intestinal cells in the presence of different sugars. There was a 
significant increase in mRNA levels (13%, p ≤ 0.001) when cells were cultured in 
25 mM fructose on both apical and basolateral sides, compared to glucose. No 
other sugars had a significant effect on GLUT7 mRNA levels. In agreement, protein 
expression was also increased by the same treatment (2.7-fold, p ≤ 0.05). 
Nonetheless, surface protein levels were unchanged in cells grown in media 
supplemented with fructose. It can be concluded from these novel findings, 
therefore, that the presence of fructose increases expression levels of GLUT7 at 
the mRNA and total protein levels, but not surface proteins. This could be attributed 
to an inefficient mechanism of translocation of the protein to the cell surface, or re-
internalisation of protein once cells were no longer exposed to this sugar, namely, 
during the biotinylation procedure. Furthermore, as sugars are transported from 
the apical to the basolateral side the total amount of fructose gets diluted in the 
system when cells are cultured in only apical medium supplemented with fructose, 
which could be masking any potential differences in GLUT7 expression by the 
presence of this sugar. Addition of higher concentrations of fructose to the apical 
medium, equalizing to a final total concentration of 25 mM following transport 
across the apical membrane, would give a more direct comparison between 
GLUT7 expression levels in cells cultured in apical versus apical and basolateral 
fructose supplemented media. To add to that, a fructose-only experimental 
condition, such as when cells are periodically depleted of glucose, as well as 
alternating low/high fructose during different or short exposure periods, could help 
determine the direct role of fructose on GLUT7 expression level. 
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Studies on Caco-2/TC7 cell models, as well as liver cell lines, showed that in the 
presence of insulin the expression of GLUT2 at the apical cell surface is reduced, 
whereas GLUT5 expression remains unchanged (Cohen et al., 2014), (Tobin et 
al., 2008). Future investigations on the effects of insulin on GLUT7 localisation 
would help characterize this protein further and highlight the potential similarities 
between GLUT7 and GLUT2, as localization results from biotinylated samples 
suggest a similar pattern for this two GLUTs. Although phloretin does not inhibit 
glucose uptake by GLUT7-expressing oocytes (Chapter 6), this compound has 
been shown to inhibit GLUT2 translocation by inhibiting PKC activity (Cohen et al., 
2014). Further investigations on the effect of apigenin, the only compound shown 
to decrease the uptake of fructose by GLUT7-expressing oocytes (Chapter 6), on 
GLUT7 expression in the Caco-2/TC7 cell model should be carried out under 
different conditions (eg., sodium free and in the presence of insulin) to shed light 
on the potential GLUT7 protein mechanisms of inhibition. Differentiated Caco-2 
and Caco-2/TC7 cell monolayers have been previously used in sugar transport 
inhibition studies in the presence of (poly)phenols  (Villa-Rodriguez et al., 2017b), 
(Johnston et al., 2005), but these cells, as for the intestine in vivo, express a variety 
of GLUTs and other sugar transporters, which makes them unsuitable for 
determination of the role of individual transporters. Therefore the Xenopus laevis 
expression system was used to elucidate effects of (poly)phenols as inhibitors on 
individual functional GLUTs, as described in the following chapters (Chapter 4, 5 
and 6). 
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Chapter 4  
Fructose uptake inhibition of heterologously expressed 
hGLUT5 by (poly)phenols 
 
4.1 Abstract 
The prevalence of type 2 diabetes (T2DM) has been linked to increasingly high 
intakes of sugars through the diet. Excess fructose, in particular, increases serum 
triglyceride and LDL-cholesterol in humans, and promotes hepatic insulin 
resistance, hyperinsulinemia and hyperglycemia. The impact of specific plant 
derived (poly)phenols and food extracts on fructose transport by GLUT5, a 
membrane bound protein with specificity for fructose only, was investigated 
through expression of human GLUT5 (hGLUT5) in X. laevis oocytes. Analysis of 
oocyte membrane extracts microinjected with hGLUT5 mRNA show expression of 
this protein at the cell surface (size: 60 kDa). In addition, the uptake of 14C-fructose 
by GLUT5 was significantly inhibited by its known specific inhibitors L-sorbose-Bn-
OZO (L-sorbose) and 2,5-anhydro-D-mannitol (a-mannitol), as expected. A 
reduction in fructose uptake by GLUT5 of more than 50% (p ≤ 0.01) was attributed 
to a-mannitol when added to incubation solutions containing high and low 
concentrations of fructose. At low fructose concentration, German chamomile 
(Matricaria recucita) tea extract and sugar-free pomegranate extract inhibited the 
uptake of fructose by GLUT5 (IC50 of 0.73±0.18 mg/ml and 0.48 ± 0.22 mg/ml for 
German chamomile and pomegranate extract, respectively). Furthermore, fructose 
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transport by GLUT5 was decreased in the presence of pure compounds apigenin 
(IC50 = 40 ± 4 µM), EGCG (IC50= 72 ± 13 µM) and hesperidin (IC50 = 264 ± 72 µM), 
at incubation conditions of low fructose concentration. These results suggest that 
specific extracts and pure compounds may have potential to be used in 
interventions aimed at the control of post-prandial blood sugar levels in both 
healthy volunteers and diabetic patients. 
 
4.2 Introduction 
Excessive ingestion of fructose has been associated with increased prevalence of 
obesity, which in turn is one of the most well documented risk factors of type 2 
diabetes (T2DM), metabolic syndrome and cardiovascular disease (CVD) (Bantle, 
2009). Fructose has been shown to directly contribute to the amplification of 
disease risk factors by elevating total LDL-cholesterol and deceasing VLDL 
clearance in the body (Elliott et al., 2002). Other examples of disease risk factor 
development pathways activated by the presence of fructose include pathways 
leading to hepatic insulin resistance, hyperinsulineamia, hyperglycemia and leptin 
resistance, as previously discussed in Chapter 1 (Lim et al., 2010).  
 
In the body, fructose is transported across membranes by the membrane bound 
facilitative transporter GLUT5, which has specificity for fructose only, with no ability 
to transport glucose or galactose (Kane et al., 1997), (Manolescu et al., 2007b). 
Expression of GLUT5 is mainly observed in the small intestine, but this protein is 
also found in the brain, musculoskeletal tissue, kidney, liver, testis and adipocyte 
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(Lim et al., 2010), (Thompson et al., 2016), (Wilder-Smith et al., 2014). A Km of 6 
mM has been reported for GLUT5-mediated fructose uptake in a study 
investigating the specificity of GLUT5 for fructose through expression of this protein 
on Xenopus laevis oocytes (Burant et al., 1992). Six other GLUT transporters have 
the ability to transport fructose, with GLUT2 being the second major transporter of 
this sugar after GLUT5 (Manolescu et al., 2007b). Nevertheless, unlike GLUT5, 
GLUT2 has shown to recognize glucose, glucosamine as well as galactose, and to 
be inhibited by phloretin and cytochalasin B (Manolescu et al., 2007b), (Krupka, 
1985), (Uldry et al., 2002). Healthy individuals have been reported to be able to 
absorb up to 25 g of fructose, with higher doses leading to malabsorption and 
intolerance (Rao et al., 2007). Dietary fructose absorption is mostly regulated in 
the small intestine, where GLUT5 is found in great abundance (Blakemore et al., 
1995), (Dyer et al., 2002). Expression of GLUT5 has been reported to be regulated 
by developmental,  hormonal as well as nutritional influences (Douard and Ferraris, 
2008). For instance, in the prenatal stage, levels of intestinal GLUT5 mRNA, as 
well as fructose transport rates, are low (Buddington and Diamond, 1989). Fructose 
malabsorption in young children, following the consumption of honey and fruit juice 
containing fructose, is likely associated with the low expression levels of GLUT5 
(Nobigrot et al., 1997), (Wilder-Smith et al., 2014). Cui et al have investigated the 
role of specific genes on fructose modulation in vivo, hypothesising that 
corticosteroids play a major role in regulating intestinal GLUT5 (Cui et al., 2004). 
To add to that, studies have confirmed that GLUT5 is regulated by its substrate, 
fructose, with increased levels of GLUT5 mRNA available following consumption 
of a diet high in this sugar in vivo (David et al., 1995). Adipocytes cultured in the 
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presence of fructose also showed a higher expression of GLUT5 (Legeza et al., 
2014).  
 
Due to its expression in insulin-sensitive tissues in humans, such as skeletal-
muscle and adipocytes, the interest in GLUT5 expression levels in association with 
diseases has increased over the recent years. Although the link between excess 
dietary fructose consumption and development of disease risk factors is widely 
accepted, as is the importance of GLUT5 for fructose transport, the direct link 
between GLUT5 and the development of diseases such as diabetes in these 
tissues remains to be determined (Douard and Ferraris, 2008). Nevertheless, 
diabetic patients have exhibited increases in GLUT5 mRNA and protein expression 
in skeletal muscle as well as in the intestine (Stuart et al., 2007), (Dyer et al., 2002). 
Furthermore, studies have shown a correlation between GLUT5 expression and 
diabetes, or diabetic complications, in fat tissue of rodent models (Hajduch et al., 
1998). Chronic exposure of fructose has been indirectly linked with obesity and 
hyperinsulinemia, even though fructose does not lead to an acute increase in 
insulin levels. This has been proposed to be caused by the significantly higher 
levels of expression of GLUT5 in diabetic human and animal models when 
compared to non-diabetic controls (Basciano et al., 2005), (Litherland et al., 2004). 
To add to that, a study by Litherland et al on obese rats concluded that GLUT5 
expression, as well as rate or fructose transport, are dependent on insulin 
sensitivity, supporting the hypothesis of a potential role for GLUT5 in increased 
circulating fructose detected during diabetes (Litherland et al., 2004). Other 
disease risk factors, namely fructose-induced hypertension, have also been 
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directly associated with GLUT5 as seen in a study conducted on GLUT5-deficient 
mice, which demonstrated a malabsorptive phenotype and resistance to 
hypertension induced by fructose, when compared to wild-type mice (Barone et al., 
2009).  
 
GLUT5-mediated fructose uptake inhibition is not achieved in the presence of 
quercetin, phloretin or cytochalasin B, examples of competitive inhibitors of 
facilitative glucose transport by GLUT2 transporter (Burant et al., 1992), (Song et 
al., 2002). A study by Slavic et al showed that epigallocatechin gallate (EGCG) was 
an effective GLUT5-mediated fructose transport inhibitor, when protein was 
expressed in Xenopus laevis oocytes (Slavic et al., 2009). Other reports have 
demonstrated that plant products rubusoside and astragalin-6-glucoside also 
inhibited GLUT5 protein in proteoliposomes (Thompson et al., 2015). The same 
group showed GLUT5-mediated fructose transport inhibition by the chemical N-
[4(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine (MSNBA) in 
proteoliposomes (Thompson et al., 2016). To date, the only other known specific 
inhibitors of GLUT5 are the sugar analogues L-sorbose-Bn-OZO and 2,5-anhydro-
D-mannitol, both of which were engineered to specifically inhibit GLUT5 (Girniene 
et al., 2003), (Tatibouet et al., 2000). A study on adipocyte differentiation showed 
less lipid accumulation in L-sorbose-Bn-OZO  treated cells compared to control in 
medium with no added fructose (Du and Heaney, 2012).  Furthermore, the 
compound 2,5-anhydro-D-mannitol demonstrated high affinity for GLUT5 and 
significantly inhibited fructose uptake in human breast adenocarcinoma cell line, 
MCF-7 (Tanasova et al., 2013). 
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The membrane bound GLUT5 transporter evolved to recognize different 
configurations of fructose (furanose and pyranose), while excluding glucose 
completely, thereby becoming exclusively specific to fructose (Tatibouet et al., 
2000), (Cura and Carruthers, 2012). The role of GLUT5 in fructose transport and 
its overexpression pattern in diseases such as diabetes highlights the importance 
of this protein for potential therapeutic interventions (Thompson et al., 2015). Plant-
derived compounds, (poly)phenols, present in our daily diet, have been reported 
to have a positive impact on carbohydrate metabolism by a number of different 
mechanisms, including controlling post-prandial sugar distribution and regulating 
sugar digestion (Hanhineva et al., 2010). As described above, some (poly)phenols, 
such as EGCG, have shown to have an impact on fructose uptake by GLUT5. In 
this chapter, the effects of specific (poly)phenols and plant extracts  on GLUT5-
mediated fructose transport, and their potential as bioactives in disease prevention 
interventions, were investigated through uptake experiments performed on X. 
laevis oocytes expressing GLUT5. Extracts and compounds used in the uptake 
experiments presented in this chapter were selected based on their reported 
impacts on disease risk factors associated with excess fructose intake. 
 
4.3 Validation of GLUT5pBF plasmid construct functionality 
 
4.3.1 Confirmation of adequate placement of hGLUT5 gene in 
expression vector 
Human GLUT5 gene was inserted into pBF expression vector, commonly used in 
heterologous expression of proteins in X. laevis oocytes, following the methods 
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described in Chapter 2 (see section 2.3). The successful ligation of gene of interest 
and the expression vector was determined through PCR of plasmid construct 
colonies with two primers; one designed against a region of the pBF sequence 
(pBF-reverse) and one homologous to the sequence of GLUT5 gene 
(GLUT5_1703-Forward). A positive product for presence of GLUT5 gene produced 
clear individual DNA bands of size corresponding to the number of base pairs (bp) 
between the two primers, as well as the number of bp from start of GLUT5_1703-
Forward until the end of the sequence when analysed on gel electrophoresis, as 
can be seen in Figure 4.2. Serving as a control, PCR was also performed on pBF 
plasmid, which produced no DNA products. Fifteen individual colonies were 
extracted, and those considered positive for the presence of GLUT5 gene and were 
sequenced to confirm exact sequence (refer to Chapter 2 section 2.3.1 for list of 
primers used). Exact position of each primer, as well as basic structure of plasmids, 
are shown in Figure 4.1.  
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Figure 4-1 Illustration of the GLUT5pBF and pBF plasmids and primer location for 
PCR validation of positive colonies for GLUT5 presence. Representation of 
the full GLUT5pBF plasmid and all its different attributes, including SP6 
promoter (green) region and PolyA tail (light purple), as well as location of the 
inserted GLUT5 gene (orange) (A). Representation of the pBF plasmid and 
its characteristics, prior to the insertion of the GLUT5 gene, including the 
location of pBF reverse primer (dark purple) (B). Representation of primer 
location (dark purple) on GLUT5pBF plasmid sequence (C).  
 
The two primers used to perform PCR for positive colony validation are shown in 
dark purple in Figure 4.1 B and C, above. The size of DNA products expected to 
be observed in gel electrophoresis was calculated by determining the number of 
base pairs between either end of the two primers (466 bp), in dark purple on Figure 
4.1 C, as well as the number of base pairs from the beginning of GLUT5_1703 
forward primer up until the end of the sequence (3244 bp). The exact location of 
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the GLUT5 sequence (orange) in reference to the other characteristics of the pBF 
plasmid are shown in Figure 4.1 A. The gene was inserted in between the SP6 
promoter region (green), where in vitro transcription of mRNA starts, and MluI 
restriction site (pink), where transcription ends (Beckert and Masquida, 2011). To 
add to that, GLUT5 is also located before the PolyA region (light purple), a stretch 
of sequence that contains only adenosine. The PolyA tail is crucial for the stability 
of mRNA and is important for the translation process. It also acts as an identifying 
element for mRNA nuclear export (Fuke and Ohno, 2008). The same figure shows 
the site of the specific primers with homology to pBF and GLUT5 sequences (light 
grey) used in the ligation of the two vectors (refer to Chapter 2, section 2.3.3.1). 
These characteristics are derived from amphibian expression vector pBF (Figure 
4.1 B). The different attributes of this plasmid aids the expression of heterologous 
proteins from microinjected mRNA in the host, X. laevis. For this reason, the 
molecular biology methods were set up to incorporate the GLUT genes into the 
sequence of this specific expression vector. Full sequences of the pBF expression 
vector and of the GLUT5pBF construct can be found in the appendices. 
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Figure 4-2 Gel electrophoresis image of PCR of GLUT5pBF colonies after ligation 
of GLUT gene to expression vector. Primers used were pBF-reverse and 
GLUT5_1703- Forward. A colony positive for the presence of GLUT5 gene 
produced a clear individual band [colony 1, 5, 6 (A) and 13 (B)], whereas 
negative colonies and control (c, pBF plasmid) (A) produced no products. 
Product sizes are equal to number of base pairs between two primers (466 
bp) and number of base pairs from start of GLUT5_1703-Forward primer until 
the end of sequence (3244 bp). Size of products was determined against a 
DNA hyperladder (HL). 
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Figure 4.2 shows the DNA products from PCR reaction of colonies with pBF-
reverse and GLUT5_1703- Forward primers. Colonies 1, 5, 6 and 13 (Figure 4.2 A 
and B) were considered positive for the presence of GLUT5 as they produced 
products around 400 bp and 3000 bp in size, which are comparable to the expected 
product sizes of 466 bp and 3244 bp. Control PCR of pBF plasmid without GLUT5 
insert produced no products, as expected. Sequencing results from positive 
colonies for the presence of GLUT5 gene showed that the sequence of all four 
colonies matched the expected sequence for GLUT5pBF. One single colony was 
randomly chosen for propagation (colony 5) and used for all subsequent 
experiments. 
 
4.3.2 Confirmation of specificity and quality of mRNA product 
The in vitro transcription (IVT) reaction was carried out with linearized GLUT5pBF 
plasmid obtained from digestion with MluI restriction enzyme, as its restriction site 
is located after the gene of interest (refer to Chapter 2, section 2.3.5 for details). 
The mobility of circular plasmid DNA in agarose gels is dependent on various 
factors, including the type and concentration of agarose gel, current strength, and 
density of superhelical twists. Supercoiled DNA is tightly compact and occupies 
less space in the gel, therefore migrating at a faster rate than relaxed linear DNA 
(Sambrook and Russell, 2001). Figure 4.3 A illustrates the migration pattern of 
circular GLUT5pBF (circ.) and of linear digest (lin.). Circular plasmid produces two 
distinct band products; the higher molecular weight band corresponding to nicked 
DNA and the lowered molecular weight band indicating supercoiled DNA. Linear 
GLUT5pBF digest migrates through the gel at a slower rate than circular DNA and 
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produces a band at a size comparable to that of the full plasmid sequence (4620 
bp). The mRNA product of IVT reaction is analysed in a denaturing RNA gel (see 
Chapter 2 section 2.3.5) confirming that its size matched the expected size 
obtained from the sequence (2031 bp) (Figure 4.5 B). The presence of 
formaldehyde in agarose gel maintains RNA in the denatured state by preventing 
intra-strand base pairing, making the visualisation of mRNA product possible 
(Sambrook and Russell, 2001). 
 
Figure 4-3 Gel electrophoresis of linearized GLUT5pBF construct and denaturing 
gel of GLUT5 mRNA product. GLUT5pBF plasmid was linearized by digestion 
with MluI restriction enzyme before IVT reaction. Circular GLUT5pBF plamid 
(circ.) produces bands on gel characteristic of its structure, whereas linear 
plasmid (lin.) produces a single band corresponding in size to the full 
sequence of the plasmid (4620 bp) (A). After IVT reaction the mRNA product 
was run on a formaldehyde denaturing gel to confirm that its size matched  
that expected from sequence of the plasmid (2031 bp) (B). The size of the 
products was determined against a DNA hyperladder (HL) (A) and ssRNA 
ladder (B). Gel electrophoresis confirming linearization of plasmid and RNA 
denaturing gel of mRNA products were performed for every new mRNA 
sample prepared.  
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4.4 Validation of X. laevis model functionality 
4.4.1 Fructose uptake by GLUT5-expressing oocytes and inhibition by 
known specific inhibitors 
The uptake of fructose by GLUT5-expressing oocytes was measured using 
different concentrations of fructose and 14C-fructose in an incubation solution. The 
optimal specific radioactivity was determined to be 0.5 µCi, which remained 
unchanged for all uptake experiments. Two fructose concentrations were used to 
carry out GLUT5 uptake experiments, namely 6 mM and 100 µM. A time course 
experiment measuring uptake of fructose over time was used to determine the 
optimal incubation time for the initial uptake experiments, all conducted with 6 mM 
fructose incubation solution. Although there was no significant difference between 
uptake at the different time points tested the highest uptake, with the least 
variability, was attributed to a 15 min incubation period. Results of this time course 
experiment are presented in Figure 4.4. GLUT5 km for fructose has been reported 
to be around 6 mM (Manolescu et al., 2007a), hence why this particular 
concentration was used for initial experiments. Incubations were carried out at 37 
°C to try and mimic the temperature conditions of the body, where this protein is 
active. Oocyte incubation conditions for the initial fructose uptake experiments 
were, therefore, 6mM fructose for 15 min at 37 °C. Water injected oocytes were 
used as controls in all uptake experiments. Results of uptake by GLUT5-
expressing oocytes are shown normalized to the uptake observed by their 
respective water injected controls, unless otherwise stated. 
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Figure 4-4 Fructose (6 mM) uptake time course experiment. One day post GLUT5 
mRNA microinjection oocytes were incubated in 6 mM fructose solution 
containing [14C] fructose over 5-30 min at 37 °C. Each data point represents 
the mean of 3 replicates (of 3 oocytes), normalized to control for each 
condition, ± SEM. There was no statistical difference between the incubation 
times tested, however, the highest uptake and less variability was attributed 
to 15 min incubation. All 6 mM fructose uptake experiments were carried out 
for 15 min at 37 °C. 
 
The possible effects of solvents on oocytes, in particular ethanol and DMSO, were 
investigated by addition of increasing concentrations of each solvent in a fructose 
incubation solution. Radiolabelled 14C-fructose used in uptake experiments is 
available in ethanol:water (9:1) solution, meaning standard incubation solution 
contains 1.25% of ethanol. There were no significant changes in fructose with the 
addition of up to 11.25% ethanol (Figure 4.5 A) or up to 10% DMSO (Figure 4.5 B). 
In addition, the oocytes seemed to be visually unaffected. All uptake experiments 
for which added compounds were stored in either DMSO or ethanol, the equivalent 
amount of the solvent was added to the standard fructose only incubation solution. 
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Figure 4-5 Effect of solvents on oocytes. One day post GLUT5 mRNA 
microinjection oocytes were incubated in 6 mM fructose solution containing 
[14C] fructose with and without ethanol (1.25-11.25%) (A) and DMSO (0-10%) 
(B) for 15 min at 37 °C. There was no significant change in uptake of fructose 
by the oocytes in the presence of either solvent (A) (B). Oocytes were visually 
unaffected. Each data point represents the mean of 3 replicates (of 3 
oocytes), normalized to control for each condition, ± SEM. 
 
The addition of 6 mM of the GLUT5 specific inhibitor of L-sorbose-Bn-OZO (L-
sorbose) to fructose incubation solution significantly decreased the uptake of this 
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sugar in oocytes microinjected with GLUT5 mRNA by 53%, p ≤ 0.01 (Figure 4.6 
A). Similarly, 7.6 mM 2,5-anhydro-D-mannitol (a-mannitol), another compound 
synthesised to specifically inhibit GLUT5, significantly decreased the uptake of 
fructose in hGLUT5-expressing oocytes by 54%, p ≤ 0.001 (Figure 4.6 B). 
 
Alternative GLUT5 fructose uptake experiments were carried out at a fructose 
incubation solution concentration of 0.1 mM, as previously reported in similar 
oocyte uptake experiments (Li et al., 2004). Incubation time was decreased to 5 
min and experiments were carried out at 25 °C. There was a significant difference 
between fructose uptake by GLUT5 mRNA injected oocytes and water injected 
control oocytes, as for previous uptake experiments at higher fructose 
concentration. Moreover, addition of 7.6 µM 2,5-anhydro-D-mannitol (a-mannitol) 
significantly reduced GLUT5-mediated fructose uptake by 61% (p ≤ 0.01) (Figure 
4.6 C). Inhibition of fructose uptake observed by this inhibitor was comparable at 
both fructose incubation solution concentrations, therefore, determining that the 
oocyte model is functional and that oocytes were able to translate the protein from 
hGLUT5 mRNA and transported it to the membrane, where it is active as a 
transporter. 
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Figure 4-6 Inhibition of GLUT5 fructose uptake by known inhibitors. One day post 
GLUT5 mRNA microinjection oocytes were incubated in 6 mM fructose 
solution containing [14C] fructose with and without 6 mM L-sorbose-Bn-OZO 
(L-sorbose) (A) and 7.6 mM 2,5-anhydro-D-mannitol (a-mannitol) for 15 min 
(B) or incubated in a 0.1 mM fructose solution containing [14C] fructose with 
and without 7.6 µM 2,5-anhydro-D-mannitol (a-mannitol) for 5 min (C). 
Internalized sugar uptake was determined by scintillation spectrometry for 
protein expressing oocytes (black bars) and water injected controls (open 
bars). Net change in uptake, Δ, (grey bars) was determined by normalizing 
the uptake observed by GLUT5 to control uptake. The mean ± SEM of three 
(A and B) or six (C) replicates (of 3 oocytes) is shown per individual condition. 
L-sorbose-Bn-OZO reduced GLUT5 uptake of fructose by 53% (A) and 2,5-
anhydro-D-mannitol decreased fructose uptake by GLUT5 by 54% (B) when 
incubated in 6 mM fructose. 2,5-anhydro-D-mannitol reduced GLUT5-
mediated fructose uptake by 61% when incubated in 0.1 mM fructose (C). ** 
p ≤ 0.01 and *** p ≤ 0.001. 
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4.4.2 Determination of expression of recombinant hGLUT5 on oocyte 
membrane extracts 
Expression of GLUT5 on oocyte membranes post microinjection with protein 
mRNA was observed by traditional western blot techniques (refer to Chapter 2 
sections 2.4.3 and  2.4.6). Membranes extracts from 10 oocytes (Figure 4.7 A) and 
3 oocytes (Figure 4.7 B) injected with GLUT5 mRNA or water were compared to 
positive control TC7 cell lysate. Images confirm that GLUT5 was expressed on 
GLUT5 mRNA injected oocyte membranes (G5) and positive control (TC7) but not 
in water injected control membrane extracts (C).   
 
Figure 4-7 Western blot image of the expression of GLUT5 on oocyte membrane 
extracts. Membrane extract derived from oocytes injected with GLUT5 mRNA 
(G5) or water (C), two days following microinjections, were compared to 
positive lysate TC7 lysate (TC7) for expression of GLUT5. Membrane extracts 
from 10 oocytes, imaged at exposure time of 5 s, show expression of GLUT5 
on mRNA injected membrane extracts and positive control, but not in control 
injected extracts (A). Similarly, membrane extracts of three oocytes, imaged 
at exposure time of 1 min, confirms expression of protein in mRNA injected 
membrane extracts (G5, 2 replicates) and positive control (TC7) only (B). TC7 
lysate concentration was 0.2 mg/ml; oocyte membrane concentrations were 
0.5 mg/ml. This image is one of 7 replicates. 
 
GLUT5 expression on oocyte membranes was also investigated through capillary 
automated Western blot system, Wes (see Chapter 2 section 2.4.7). Two days post 
microinjection with GLUT5 mRNA oocyte membranes were extracted and 
analysed on Wes under varying protein concentrations (0.4-0.02 mg/ml). A gel 
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image of the decreasing concentrations of protein shows a correlation between 
concentration and signal produced (Figure 4.8 A), also noticeable in 
electropherogram (Figure 4.8 C). Lower loading concentrations of protein 
produced a cleaner signal and less non-specific binding. An alternative sample of 
oocyte membranes extracted one day post microinjection with GLUT5 mRNA was 
compared to a membrane extract of water injected control oocytes and showed 
protein detection in mRNA injected samples only (Figure 4.8 B). This data is also 
presented as an electropherogram (Figure 4.8 D), showing no protein detection in 
water injected control membrane samples.   
 
Figure 4-8 Confirmation of expression of GLUT5 on oocyte membrane extracts by 
wes. Membranes extracted from three oocytes two days post injection with 
GLUT5 mRNA, as well as water injected control membranes, were analysed 
using automated capillary Western blot (Wes). Analysis of a membrane 
extract sample is shown as a gel-like image at varying protein concentrations 
(0.4-0.02 mg/ml) (A) and as an electropherogram of the same samples (C). 
An alternative oocyte membrane sample of mRNA injected oocytes was 
compared to that of water injected controls, both at 0.2 mg/ml, and showed 
GLUT5 expression on mRNA injected membranes extract only (B, D). This 
data is shown as a gel image (B) as well as electropherogram (D). The 
detected protein size for GLUT5 was 60 kDa. Antibody dilution was 1:50. This 
image represents one of 4 replicates. 
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Previous reports of uptake experiments in GLUT5 expression oocytes were 
conducted after two days post microinjection with mRNA (Kwon et al., 2007) (Slavic 
et al., 2009). Membranes were extracted from three oocytes one to four days post 
microinjection with GLUT5 mRNA, in order to assess at what point the protein 
expression was at its highest. GLUT5 protein expression was comparably high 
after 24 hrs and four days post microinjection, as can be observed in a gel like 
image and electropherogram (Figure 4.9 A and B). Although GLUT5 was still 
detectable after two and three days post microinjection, its expression was not as 
pronounced as in the other days. For this reason, all further uptake experiments 
with GLUT5 were performed only 24 hrs after microinjection, as opposed to 48 hrs.   
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Figure 4-9 Determination of level of GLUT5 expression on oocyte membrane 
extracts by wes. Membranes were extracted from three oocytes one to four 
days post injection with GLUT5 mRNA and analysed using automated 
capillary Western blot (Wes). Analysis of membrane extract samples is shown 
as a gel-like image (A) and as an electropherogram of the same samples (B). 
GLUT5 protein expression was at its highest after 1 day (G5 day1) and four 
days (G5 day4) post microinjection. Protein was still detected but at a lower 
expression after 2 days (G5 day2) and three days (G5 day3) post 
microinjection. All samples were loaded at a concentration of 0.1 mg/ml. 
Detected protein size for GLUT5 was 58-59 kDa. Antibody dilution was 1:50. 
 
GLUT5 antibody used for both protein detection techniques was raised against an 
internal region of the human protein and recognizes a product of 49-60 kDa in size. 
Optimal GLUT5 antibody dilution of 1:50 for Wes experiments was determined by 
Dr. S. Tumova. 
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4.5 Uptake experiment results and discussion 
In order to attribute inhibition of GLUT5-mediated fructose transport by a specific 
compound or extract oocytes expressing this transporter were incubated in a 
fructose solution, containing 14C-fructose, in the presence and absence of each 
compound/extract. Uptake inhibition experiments were conducted using plant 
extracts that from the literature have shown to have an impact on disease risk 
factors associated with excess fructose consumption (refer to Chapter 1). In 
addition, extracts which were being used, or would in the future be used, in human 
studies conducted by other individuals in the research group were also tested (e.g. 
German chamomile, green tea and pomegranate) (Villa-Rodriguez et al., 2017a), 
(Nyambe-Silavwe and Williamson, 2016). This was done with the aim to validate 
results and to attribute inhibition to specific transporters. Initial incubation 
conditions were as follows; 6 mM 14C-fructose for 15 mins at 37 °C. Table 4.1 
shows all the compounds/extracts tested for inhibition using these experimental 
conditions. Nevertheless, following inhibition experiments with GLUT2-expressing 
oocytes (Chapter 5) it became apparent that another experimental condition might 
be more suited, namely, 0.1 mM fructose for 5 mins at 25 °C. Specific radioactivity 
of radiolabelled fructose (0.5 µCi) remained unchanged for both conditions. 
Because of the amount of time necessary to microinject the oocytes and to conduct 
the experiments only a few of the extracts and compounds could be re-tested using 
the revised experimental condition (these are marked in Table 4.1 with an asterisk). 
Once extracts that significantly decreased the uptake of GLUT5 were identified 
pure compounds were then tested, using the revised 0.1 mM fructose for 5 mins at 
25 °C experimental condition only.  
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Table 4-1 Compounds/extracts used in GLUT5-mediated fructose uptake inhibition 
studies described in this chapter 
Compound/ extract Experimental condition 
2,5-anhydro-D-mannitol * 6 mM fructose for 15 mins at 37 °C 
0.1 mM fructose for 5 mins at 25 °C 
Acarbose * 6 mM fructose for 15 mins at 37 °C 
0.1 mM fructose for 5 mins at 25 °C 
Apigenin 0.1 mM fructose for 5 mins at 25 °C 
Bonolive * 6 mM fructose for 15 mins at 37 °C 
0.1 mM fructose for 5 mins at 25 °C 
Black tea 6 mM fructose for 15 mins at 37 °C 
Baking Chocolate Standard 
Reference Material 
6 mM fructose for 15 mins at 37 °C 
 
Cocoa 6 mM fructose for 15 mins at 37 °C 
Coffee 6 mM fructose for 15 mins at 37 °C 
EGCG 0.1 mM fructose for 5 mins at 25 °C 
Eucalyptus Leaf Extract (ELE) 6 mM fructose for 15 mins at 37 °C 
Epicatechin 6 mM fructose for 15 mins at 37 °C 
German chamomile * 6 mM fructose for 15 mins at 37 °C 
0.1 mM fructose for 5 mins at 25 °C 
Green tea * 6 mM fructose for 15 mins at 37 °C 
0.1 mM fructose for 5 mins at 25 °C 
Hesperidin 0.1 mM fructose for 5 mins at 25 °C 
Hesperetin 0.1 mM fructose for 5 mins at 25 °C 
L-sorbose-Bn-OZO 6 mM fructose for 15 mins at 37 °C 
(Poly)phenol mixture: 
apigenin, flavone, galangin and 
kaempferol 
6 mM fructose for 15 mins at 37 °C 
Pomegrante 6 mM fructose for 15 mins at 37 °C 
0.1 mM fructose for 5 mins at 25 °C 
Procyanidins 6 mM fructose for 15 mins at 37 °C 
Quercetin 0.1 mM fructose for 5 mins at 25 °C 
* uptake inhibition studies conducted with both experimental conditions 
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4.5.1 Effect of extracts on fructose uptake by GLUT5 
The effect of dark chocolate extract (see section 2.1.3 of Chapter 2 for details) and 
Baking Chocolate Standard Reference Material (kindly supplied by the National 
Institute of Standards and Technology, USA) on GLUT5-mediated fructose 
transport was determined by the incubation of oocytes in 6 mM fructose solution 
with increasing concentrations of the chocolate extract (Figure 4.10 A) and in the 
presence of cocoa reference standard (Figure 4.10 B). There was no significant 
change in uptake in the presence of either extract.  
 
The flavanol profile of dark chocolate extract, as well as that of chocolate reference 
standard material, were analysed following HPLC-FLD protocol (Chapter 2 section 
2.1.4). Concentrations (µM) of each flavanol for both samples were calculated 
using an epicatechin calibration curve (Figure 4.11 A) and individual relative 
response factors for each fraction. The flavanol profile of dark chocolate extract 
consisted of monomer to hexamer (DP1-DP6) only (Figure 4.11 B, C), whereas the 
chocolate reference standard material’s flavanol profile ranged from monomer to 
decamer (Figure 4.11 B, D), matching previously reported analysis (Robbins et al., 
2012). The monomer (DP1, epicatechin) was the most abundant in both samples, 
with lower concentrations of other oligomeric fractions.  
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Figure 4-10 Effect of cocoa extracts on fructose uptake by GLUT5. One day post 
GLUT5 mRNA microinjection oocytes were incubated in 6 mM fructose 
solution containing [14C] fructose with increasing concentrations of dark 
chocolate extract (cocoa) (0-1 mg/ml) (A) and in the presence of chocolate 
reference standard material (cocoa ref. standard) (B) for 15 min at 37 °C. 
There was no significant change in uptake of fructose by the oocytes in the 
presence of either extract under these conditions (A) (B). Each data point 
represents the mean of 3 replicates (of 3 oocytes), normalized to control for 
each condition, ± SEM. 
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Figure 4-11 Analysis of flavanol profile of chocolate extracts using HPLC-FDL. 
Epicatechin calibration curve (A) and relative response factor values were 
used to calculate the concentration of each fraction in both sample (mean ± 
SEM of three replicates) (B). Dark chocolate extract produced a profile 
consisting of monomer to hexamer (C), while chocolate reference material 
produced a full monomer to decamer profile (D). Favanol profiles were 
obtained at PMT level12. Expanded inserts in (C) and (D) were obtained for 
pentamer to decamer by magnification and isolation of these fractions in the 
original image. Monomer (DP1) is not shown due to difference in signal 
intensity.  
 
Uptake of fructose by GLUT5 expressed in oocytes was further investigated with 
coffee, black tea and eucalyptus leaf extract (ELE) (see Chapter 2, section 2.1.2) 
by addition of increasing concentrations of each extract to 6 mM fructose 
incubation solution (Figure 4.12). Coffee extract composition was rich in 
caffeoylquinic acids, composed majorly of 3-, 4- and 5-caffeoylquinic acids. The 
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amount of each caffeoylquinic acid in 4 g of instant coffee (equivalent to 1 cup) 
were 160 ± 8.4, 103 ± 6.0 and 467 ± 9.2 µmol for 3-, 4- and 5-caffeoylquinic acids, 
respectively (Kraut, 2014). Based on previous documentation the composition of 
black tea is thought to be primarily made up of thearubigins, with this phenolics 
accounting for almost 60% of solids found in a typical black tea sample (Butt et al., 
2014). Composition of ELE has not been entirely identified, however, isolated 
components include hydrolysable tannins and favonol glycosides (Sugimoto et al., 
2010). There was no significant change in fructose uptake in the presence of any 
of these three extracts.  
 
Figure 4-12 Effect of extracts on fructose uptake by GLUT5. One day post GLUT5 
mRNA microinjection oocytes were incubated in 6 mM fructose solution 
containing [14C] fructose with increasing concentrations of coffee (0-1 mg/ml) 
(A), black tea (0-1 mg/ml) (B) and ELE (0-1 mg/ml) (C) for 15 min at 37 °C. 
There was no significant change in uptake of fructose by the oocytes in the 
presence of any of the three extracts under these conditions (A) (B) (C). Each 
data point represents the mean of 3 replicates (of 3 oocytes), normalized to 
control for each condition, ± SEM. 
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Additional extracts used to investigate their potential effects on GLUT5-mediated 
fructose uptake were green tea, German chamomile, pomegranate and Bonolive 
(Figure 4.13). As previously, increasing concentrations of these extracts were 
added to 6 mM fructose incubation solution. There was no significant change in 
fructose uptake in the presence of any of the four extracts under the incubation 
conditions tested. 
 
The main active components of green tea are (-)-Epigallocatechin gallate (EGCG) 
(199.8 ± 6.7 mg/g), (-)-Epigallocatechin (124.4 ± 9.3 mg/g), (-)-Epicatechin gallate 
(34.4 ±1.9 mg/g) and (-)-Epicatechin (23.3 ± 2.4 mg/g), as analysed by HPLC 
(Nyambe-Silavwe and Williamson, 2016). The most abundant phenolic compounds 
present, percentage wise, in dry weight of the German chamomile extract are 
apigenin-7-O-glucoside (12.32%), apigenin (0.28%), luteolin-7-O-glucoside 
(0.13%) and 4,5-dicaffeoylquinic acid (0.07%) (Villa-Rodriguez et al., 2017a). 
Bonolive extract, kindly supplied by BioActor, is composed in its vast majority by 
oleuropein, this compound accounting for 40% of the extract composition. 
Pomegranate extract is composed mainly of punicalagin (121 mg/g), puricalin (6 
mg/g), ellagic acid hexose (5.9 mg/g) and ellagic acid (101 mg/g) (Nyambe, 2016). 
All sugars were removed from pomegranate extract through solid phase extraction 
(SPE) by Dr. Hilda Nyambe, to make a sugar-free extract.  
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Figure 4-13 Effect of extracts on fructose uptake by GLUT5. One day post GLUT5 
mRNA microinjection oocytes were incubated in 6 mM fructose solution 
containing [14C] fructose with increasing concentrations of green tea (0-0.5 
mg/ml) (A), German chamomile (0-1 mg/ml) (B), sugar-free pomegranate (0-
1 mg/ml) (C) and Bonolive (0-1 mg/ml) (D) for 15 min at 37 °C. There was no 
significant change in uptake of fructose by the oocytes in the presence of any 
of the extracts under these conditions (A) (B) (C) (D). Each data point 
represents the mean of 3 replicates (of 3 oocytes), normalized to control for 
each condition, ± SEM. 
 
The same four extracts mentioned above were used to investigate fructose uptake 
by oocytes expressing GLUT5 under different incubation conditions, namely, 
incubation at 25 °C for 5 min in a 0.1 mM fructose solution containing [14C] fructose. 
Oleuropein-rich extract Bonolive (Figure 4.14 D) and green tea extract (Figure 4.14 
A) still had no effect on fructose transport under these varying conditions. German 
chamomile (Figure 4.14 B) and sugar-free pomegranate extract (Figure 4.14 C), 
however, significantly decreased the uptake of fructose by GLUT5. IC50 values 
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were 0.73 ± 0.18 mg/ml and 0.48 ± 0.22 mg/ml for German chamomile and sugar-
free pomegranate extracts, respectively. 
 
 
Figure 4-14 Effect of extracts on fructose uptake by GLUT5. One day post GLUT5 
mRNA microinjection oocytes were incubated in 0.1 mM fructose solution 
containing [14C] fructose with increasing concentrations of green tea (0-0.5 
mg/ml) (A), German chamomile (0-1 mg/ml) (B), sugar-free pomegranate (0-
1 mg/ml) (C) and Bonolive (0-1 mg/ml) (D) for 5 min at 25 °C. There was no 
significant change in uptake of fructose by the oocytes in the presence of 
green tea or Bonolive extracts under these conditions (A) (D). GLUT5-
mediated fructose uptake was significantly decreased in the presence of 
German chamomile (IC50 = 0.73 ± 0.18 mg/ml) (B) and sugar-free 
pomegranate (IC50 = 0.48 ± 0.22 mg/ml) (C). Each data point represents the 
mean of 6 replicates (of 3 oocytes), normalized to control for each condition, 
± SEM. * p ≤ 0.05, *** p ≤ 0.001 and **** p ≤ 0.0001. 
 
Results obtained from uptake experiments with extracts show that variability 
between replicates is substantial. This variability could be attributed to the 
individual oocytes in each replicate, as biological variability is expected. This also 
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includes the ability of each oocyte to express the protein from the injected mRNA. 
Differing batches of oocytes, derived from different female ovaries, also play a 
considerable role in variability. It has been reported that husbandry and housing of 
the animals affect the quality of oocytes for membrane transport experiments. To 
add to that, a significant change was observed in the deterioration of oocytes 
derived from specific husbandry conditions over the summer months, adding a 
seasonal variation component (Delpire et al., 2011) (Conn, 1991). Oocytes at stage 
V-VI of development were visually selected for uptake experiments, as 
endogenous transporter activity is not only variable between batches of oocytes 
but also in oocytes of different developmental stages (Miller and Zhou, 2000). 
Nonetheless, as the method of selection is purely visual, it is possible that oocytes 
in transition to or from stage V-VI were selected for uptake experiments, adding 
another factor that could contribute to variability between experiments. There were 
no significant changes in fructose uptake when experiments were carried out with 
incubation conditions that included a longer incubation time, at higher temperature 
and fructose concentration. Nevertheless, a significant decrease in GLUT5 
medicated fructose transport was achieved in the presence of two extracts, 
previously used in uptake experiments, when incubation time and fructose 
concentrations were decreased and temperature lowered. Possible explanations 
for this includes the possibility that at a higher sugar concentration the radiolabelled 
sugar is less likely to be picked up by the transporter. In addition, human GLUT 
transporters are active in the body where the average temperature is around  37 
°C. However, the host, responsible for the expression in this case, is kept at lower 
temperatures. Even though there were no visual damages to the oocytes at  37 °C 
this could have affected the uptake and/or provoked variation. Lastly, a longer 
 
 
128 
 
incubation time poses the risk of a plateau in uptake being reached, meaning an 
inhibition could go undetected. Although the radiolabelled counts were lower under 
these alternative conditions (0.1 mM fructose for 5 min at 25 °C) there was still a 
clear and significant difference between mRNA and water injected samples. 
 
4.5.2 Effect of pure compounds on fructose uptake by GLUT5 
Extracts, even though rich in a combination of (poly)phenols, can contain a lot of 
impurities, which may or may not affect how sugar is transported by the 
transporters on the membrane of the oocyte. For this reason, uptake experiments 
were carried out in the presence of several pure compounds. There was no 
inhibition of GLUT5-mediated fructose uptake observed in the presence of dark 
chocolate extract or chocolate reference standard. Nevertheless, the actual 
amounts of individual procyanidins were considerably low in both extracts (refer to 
section 3.5.1). In order to investigate the effect of individual components of the 
chocolate extracts on fructose uptake, experiments were carried out in the 
presence of each individual procyanidins from monomer to octamer, as well as 
pure epicatechin (Figure 4.15 A and B). Uptake experiments were also performed 
with a mixture of individual (poly)phenols, containing apigenin, flavone, galangin 
and kaempferol at 50 µM each. In addition, specific GLUT5 inhibitor L-sorbose-Bn-
OZO (at 6 mM) was added to the incubation solution as well as this (poly)phenol 
mixture to explore the possibility that presence of compounds could be standing in 
the way of the binding site of inhibitors. These uptake experiments were carried 
out under the following conditions; 6 mM fructose incubation solution, at 37 °C for 
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15 min.  There was no significant change in fructose uptake in the presence of any 
of the pure compounds mentioned above, under the incubation conditions tested. 
 
Figure 4-15 Effect of pure compounds on fructose uptake by GLUT5. One day post 
GLUT5 mRNA microinjection oocytes were incubated in 6 mM fructose 
solution containing [14C] fructose with increasing concentrations of 
epicatechin (0-1 mg/ml) (A), in the presence of procyanidins, monomer to 
octamer (B), in the presence (poly)phenol mixture of apigenin, flavone, 
galangin and kaempferol, at 50 µM (C) and in the presence of (poly)phenol 
mixture with 6 mM specific inhibitor, L-sorbose-Bn-OZO (Lsorbose) (D) for 15 
min at 37 °C. There was no significant change in uptake of fructose by the 
oocytes in the presence of epicatechin (A), procyanidins (B) or (poly)phenol 
mixture (C). GLUT5 inhibitor decreased the uptake of fructose by 38% in the 
presence of (poly)phenol mixture (D). Each data point represents the mean 
of 3 replicates (of 3 oocytes), normalized to control for each condition, ± SEM. 
* p ≤ 0.05 
 
Fructose uptake by GLUT5 was significantly decreased by 38% in the presence of 
L-sorbose-Bn-OZO and the (poly)phenol mixture (Figure 4.15 D). As there was no 
inhibition attributed to the (poly)phenol mixture alone, one can conclude this 
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decrease is attributed to the specific inhibitor L-sorbose-Bn-OZO (Figure 4.15 C). 
Although the presence of a mixture of different compounds did not seem to be 
blocking the binding site of specific inhibitors, these GLUT5 inhibitors have high 
affinity for the transporter and were engineered with the sole purpose of inhibiting 
fructose uptake by structural similarities with this sugar, allowing them to compete 
for the binding site. Therefore, it was considered that the incubation conditions 
could be masking some potential subtler inhibition by individual compounds or 
extracts, structurally more dissimilar to the substrate, for reasons discussed 
previously (see section 3.5.1). Henceforth, all additional uptake experiments with 
individual pure compounds were conducted at the following incubation conditions; 
0.1 mM fructose incubation solution, for 5 min at 25 °C. Compounds tested under 
these specific incubation conditions were apigenin, EGCG, quercetin, hesperetin 
and hesperidin. 
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Figure 4-16 Effect of pure compounds on fructose uptake by GLUT5. One day post 
GLUT5 mRNA microinjection oocytes were incubated in 0.1 mM fructose 
solution containing [14C] fructose with increasing concentrations of apigenin 
(0-50 µM) (A), EGCG (0-500 µM) (B) and quercetin (0-100 µM) (C) for 5 min 
at 25 °C. There was no significant change in uptake of fructose by the oocytes 
in the presence of quercetin under these conditions (C). GLUT5-mediated 
fructose uptake was significantly decreased in the presence of Apigenin 
(IC50= 40 ± 4 µM) (A) and EGCG (IC50= 72 ± 13 µM) (B). Each data point 
represents the mean of 6 replicates (of 3 oocytes), normalized to control for 
each condition, ± SEM. ** p ≤ 0.01  
 
GLUT5-mediated fructose uptake was significantly inhibited in the presence of 
apigenin (IC50= 40 ± 4 µM) (Figure 4.16 A), EGCG (IC50 = 72 ± 13 µM) (Figure 4.16 
B) and hesperidin (IC50 = 264 ± 72 µM) (Figure 4.17 A). Neither quercetin nor 
hesperetin had any effect on fructose uptake by this protein, under the conditions 
tested (Figure 4.16 C and 4.17 B, respectively).  
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Figure 4-17 Effect of pure compounds on fructose uptake by GLUT5. One day post 
GLUT5 mRNA microinjection oocytes were incubated in 0.1 mM fructose 
solution containing [14C] fructose with increasing concentrations of hesperidin 
(0-500 µM) (A) and hesperetin (0-500 µM) (B) for 5 min at 25 °C. GLUT5-
mediated fructose uptake was significantly decreased in the presence of 
hesperidin (IC50 = 264 ± 72 µM) (A) but not of hesperetin (B). Each data point 
represents the mean of 12 replicates (of 3 oocytes), normalized to control for 
each condition, ± SEM. * p ≤ 0.05, ** p ≤ 0.01 
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Figure 4-18 Effect of acarbose on fructose uptake by GLUT5. One day post 
GLUT5 mRNA microinjection oocytes were incubated in 6 mM fructose 
incubation solution containing [14C] fructose for 15 min at 37 °C (A) or 0.1 mM 
fructose solution containing [14C] fructose for 5 min at 25 °C. (B) with 
increasing concentrations of acarbose (0-1 mg/ml). There was no change in 
GLUT5-mediated uptake of fructose in the presence of acarbose (A) (B). 
Each data point represents the mean of 3-6 replicates (of 3 oocytes), 
normalized to control for each condition, ± SEM.  
 
Acarbose, a synthetic drug used in the management of diabetes by slowing 
digestion of carbohydrates down, is a potent inhibitor of -amylase and -
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glucosidase enzymes (Zeymer, 2006). The effect of this drug on intestinal 
membrane transporters has not been previously established. For this reason, 
varying concentrations of acarbose were used in the uptake experiments to 
determine its effect on GLUT5-mediated fructose transport. As this is a potent drug 
its effect on both incubation conditions of high and low fructose concentration, at 
different temperatures and different incubation times, was investigated (Figure 
4.18 A and B). Acarbose did no inhibit GLUT5 uptake of fructose.     
 
4.5.3 Summary of results from fructose uptake experiments  
GLUT5-mediated fructose transport was inhibited under both incubation conditions 
(high and low fructose concentration) by their specific inhibitors L-sorbose-Bn-OZO 
and 2,5-anhydro-D-mannitol. The structure of these inhibitors is similar to that of 
the substrate fructose (Figure 4.19 and Table 4.1). The affinity of 2,5-anhydro-D-
mannitol is almost identical to that of D-fructose and the modifications in the 
compound’s 1 hydroxyl group (OH) bind to the site normally occupied by 6-OH 
position of fructose molecule (Yang et al., 2002). The binding to this compound is 
well tolerated by GLUT5, which has evolved to recognize furanose and pyranose 
ring forms of D-fructose while completely excluding D-glucose (Tatibouet et al., 
2000). As for L-srobose-Bn-OZO, it is hypothesised that the bulky benzyl group of 
this compound binds to a position out of the binding site, potentially in the binding-
site cleft where steric restrictions do not pose a critical problem. In addition, the 
oxygen molecule in the OZO derivation increases hydrogen interactions with the 
protein, allowing for a better binding (Girniene et al., 2003). 
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Figure 4-19 Structure of GLUT5 substrate, D-fructose, and specific inhibitors. 
Hydroxyl group of 2,5-anhydro-D-mannitol binds to the active site of GLUT5, 
replacing fructose. Bulkier groups of L-sorbose-Bn-OZO compound bind to 
an alternative site off the active site (Girniene et al., 2003), (Tatibouet et al., 
2000). 
 
Fructose uptake by GLUT5 was also inhibited by the pure compounds apigenin, 
EGCG and hesperidin. An inhibition was also achieved in the presence of German 
chamomile extract, which has apigenin as one of its main components after 
apigenin-7-O-glucoside. Interestingly, although EGCG proved to be a potent 
inhibitor of GLUT5, confirming previous reports (Slavic et al., 2009), and is one of 
the main components of green tea, this extract did not have an effect on fructose 
uptake, suggesting that impurities in the extract could be masking some inhibition 
detection by the oocyte model. A previous investigation of the effects of the main 
components on green tea on GLUT5 concluded that fructose inhibition was 
achieved by the gallated catechins (−)-Epicatechin-gallate (ECG) and EGCG, but 
not the ungallated catechins (−)-epicatechin (EC) and (−)-epigallocatechin (EGC) 
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(Slavic et al., 2009). Similarly, an inhibition of fructose uptake was attributed to 
hesperidin, but not to its aglycone hesperetin. This  suggests that the gallate group 
and glycoside potentially aid interactions with the GLUT5 protein, perhaps by 
binding to the binding-site cleft as the bulkier groups of the L-sorbose-Bn-OZO 
inhibitor. This hypothesis, however, does not necessarily fit with the concentration 
dependent inhibition of GLUT5 in the presence of German chamomile extract (IC50 
= 0.73 ± 0.18 mg/ml; equivalent to 75 µM apigenin) which has as its main 
component apigenin-7-O glucoside, as apigenin alone was a more powerful 
inhibitor (predicted 50% inhibition at 40 µM). Lastly, presence of sugar-free 
pomegranate extract, composed in majority by the hydrolysable tannin punicalagin 
and phenolic acid elagic acid, resulted in a concentration dependent inhibition of 
GLUT5. The effective inhibition by this extract suggest that the structure of its main 
components interact strongly with the protein. All compounds which significantly 
inhibited uptake of fructose by GLUT5, including their structure, are shown in Table 
4.2. Extracts which significantly inhibited GLUT5-mediated fructose uptake when 
incubated in a low fructose concentration, namely 0.1 mM fructose (for 5 mins at 
25 °C), are shown in Table 4.3. The structure of the main component of each 
extract is also shown in this table. 
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Table 4-2 Compounds and their respective inhibition on fructose uptake by GLUT5 
Compound Experimental 
condition 
Inhibition1 Structure 
2,5-anhydro-
D-mannitol 
6 mM fructose 
for 15 mins at 
37 °C 
0.1 mM 
fructose for 5 
mins at 25 °C 
54% and 61% 
inhibition of 
uptake with high 
and low fructose, 
respectively, at 
7.6 mM  
 
Apigenin 0.1 mM 14C-
fructose for 5 
mins at 25 °C 
IC50 = 40 ± 4 µM 
 
EGCG 0.1 mM 
fructose for 5 
mins at 25 °C 
IC50 = 72 ± 13 µM 
 
Hesperidin 0.1 mM 
fructose for 5 
mins at 25 °C 
IC50 = 264 ± 72 
µM 
 
L-sorbose-
Bn-OZO 
6 mM fructose 
for 15 mins at 
37 °C 
53% inhibition of 
uptake at 6 mM 
 
1 compounds for which a single concentration was tested were attributed a 
percentage inhibition at that concentration. 
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Table 4-3 Extracts and their respective inhibition on fructose uptake by GLUT5. 
Experimental condition was 0.1 mM fructose for 5 mins at 25 °C 
Extract Composition1 Inhibition Structure2 
German 
chamomile 
12.32% 
apigenin-7-O-
glucoside; 
0.28% 
apigenin 
0.13% luteolin-
7-O-glucoside; 
0.07% 4,5-
dicaffeoylquini
c acid 
IC50 = 0.73 
± 0.18 
mg/ml 
 
Pomegranate  121 mg/g 
punicalagin; 
6 mg/g 
puricalin;  
5.9 mg/g 
ellagic acid 
hexose;  
101 mg/g 
ellagic acid 
IC50 = 0.48 
± 0.22 
mg/ml 
 
1 analysis of extracts were performed previously; please refer to Chapter 2, section 
2.1 
2 structure of the component present at the highest concentration in the extract is 
shown. 
  
From the results presented in this chapter it can be concluded that uptake inhibition 
experiments were successfully conducted on the oocyte model of GLUT5 
expression. Data shown here supports previous reports of no GLUT5-mediated 
fructose uptake inhibition by phloretin and quercetin (Burant et al., 1992), (Song et 
al., 2002), while confirming that the presence of specific inhibitors L-sorbose-Bn-
OZO and 2,5-anhydro-D-mannitol, as well as of the pure compound EGCG, do 
lead to an inhibition of fructose uptake by this protein (Slavic et al., 2009), (Girniene 
et al., 2003), (Yang et al., 2002).  
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Moreover, additional novel GLUT5 inhibitors were revealed from fructose uptake 
inhibition experiments discussed in this chapter, namely; German chamomile 
extract and sugar-free pomegranate extracts, as well as pure compounds apigenin 
and hesperidin. These findings highlight the potential of these specific compounds 
and plant extracts to have a positive effect on the attenuation of disease risk factors 
and propose a benefit of their inclusion in interventions aimed at disease 
prevention.  
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Chapter 5  
Glucose and fructose uptake inhibition of heterologously 
expressed hGLUT2 by (poly)phenols 
 
5.1 Abstract 
Fructose uptake into the liver and small intestine is mediated by GLUT2, alongside 
the fructose specific transporter GLUT5. To add to that, once absorbed fructose is 
released into the blood by GLUT2 present on the basolateral membrane of the 
enterocyte (Kellett and Brot-Laroche, 2005). In order to investigate the effect of 
pure compounds and (poly)phenol rich extracts on  sugar uptake by this 
transporter, human GLUT2 (hGLUT2) gene was expressed in X. laevis oocytes. 
Expression of GLUT2 on X. laevis membranes was confirmed using automated 
western blotting (Wes), which identified a product of 53-60 kDa in size, and 
internalized sugar uptake was determined by scintillation spectrometry. Uptake of 
14C-glucose by GLUT2 was significantly inhibited by known inhibitors of this 
protein, phloretin (81% inhibition at 100 µM, p ≤ 0.0001) and cytochalasin B (70% 
inhibition at 100 µM, p ≤ 0.0001). Glucose uptake by GLUT2 was also significantly 
reduced in the presence of four plant extracts, namely, green tea (IC50 = 0.13 ± 
0.02 mg/ml), German chamomile (IC50 = 0.49 ± 0.24 mg/ml), oleuropein-rich 
Bonolive extract (IC50 = 0.03 ± 0.002 mg/ml) and sugar-free pomegranate extract 
(IC50 = 0.05 ± 0.01 mg/ml). In addition, the pure compound hesperetin significantly 
decreased GLUT2-mediated glucose uptake (IC50 = 30 ± 9 µM), its glucoside 
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hesperidin also having an inhibitory effect (IC50 = 219 ± 40 µM). Furthermore, the 
rate of uptake inhibition of glucose and fructose transported by GLUT2 was 
determined through oocyte uptake experiments with each individual sugar in the 
presence of increasing concentrations of the pure compounds EGCG, apigenin 
and quercetin. The known GLUT2 inhibitor quercetin decreased the uptake of 
glucose (IC50 = 7 ± 1 µM) and of fructose (IC50 = 8 ± 2 µM) by a comparable rate. 
Apigenin and EGCG also significantly reduced the uptake of both sugars in a 
similar fashion; IC50 values for glucose uptake were of 27 ± 4 µM and 72 ± 16 µM, 
and of 28 ± 10 µM and 93 ± 16 µM for fructose uptake, as seen by presence of 
apigenin and EGCG, respectively. These results show that some plant extracts and 
pure compounds may be useful in dietary interventions focused on disease 
prevention in healthy individuals, as well as disease management in diabetic 
patients. 
  
5.2 Introduction 
The membrane-bound facilitative sugar transporter, GLUT2, is expressed most 
abundantly in the small intestine, but also in the kidney, pancreatic islets, liver and 
brain (Lacombe, 2014). Active transport of glucose through the apical membrane 
of enterocytes is conducted by the sodium-dependent transporter, sodium-glucose 
cotransporter 1 (SGLT1), by means of the downward sodium gradient managed by 
Na+/K+/ATPase on the basolateral membrane (Hediger et al., 1987), (Thorsen et 
al., 2014). GLUT2, on the basolateral membrane, is responsible for facilitative 
transport of both fructose and glucose, as well as galactose and glucosamine from 
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the cytosol to the blood (Ferraris, 2001). Therefore, complete absorption of dietary 
glucose in the small intestine is attributed to the sodium dependent active 
transporter SGLT1 and the facilitative transporter GLUT2 (Wright et al., 2007). 
 
Nevertheless, in addition to the active transport of glucose across the enterocyte, 
it is now widely accepted that a facilitative transport, mediated by trafficking of 
basolateral GLUT2 to apical surface in response to high glucose levels, also takes 
place and contributes to higher levels of transport than sugars transported by 
SGLT1 alone (Kellett et al., 2008). Studies conducted in diabetic rats demonstrated 
that GLUT2 was able to traffic to and from the basolateral membrane in those rats 
fed a normal diet (Helliwell and Kellett, 2002). Insertion of GLUT2 into the apical 
membrane happens quickly (T1/2 approximately 3.5 minutes) and has been 
associated with protein kinase C (PKC) βII activation (Helliwell et al., 2003). This 
rapid movement of GLUT2 from one membrane to another allows this protein to 
contribute to the absorption of fructose alongside its specific transporter, GLUT5 
(Helliwell et al., 2000). Secondary transport of fructose is attributed to GLUT2, 
which is able to recognize fructose in its furanose form (Manolescu et al., 2007b). 
To add to that, in the small intestine, following apical transport of fructose by 
GLUT5, this sugar is then transported across the basolateral membrane by GLUT2 
(Kellett and Brot-Laroche, 2005). Absorption of fructose from the dietary 
components is regulated in the small intestine, which also controls the availability 
of fructose to other tissues (Douard and Ferraris, 2008), (Blakemore et al., 1995). 
Higher levels of glucose and fructose have been associated with a higher 
localisation of GLUT2 by PKC to the apical membrane, while SGLT1 is integral and 
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remains on the apical membrane regardless of sugar level (Morgan et al., 2007). 
Interestingly, human intestinal cells cultured under sodium free conditions show 
that apical sugar transport is mediated by GLUT2 only, with its basolateral function 
remaining unchanged (Manzano and Williamson, 2010). In addition, knock down 
of β cell GLUT2 in mice by homologous recombination created a diabetic 
phenotype with mice experiencing hyperglycaemia, high levels of circulating fatty 
acids, hyperglucagonemia, hyperinsulinemia as well as a loss in pancreatic first 
phase insulin secretion in response to glucose (Thorens, 2001).  
 
T2DM is considered to be a progression of postprandial hyperglycaemia, or 
increased blood glucose levels (Zeymer, 2006). In pancreatic β-cells a rise in blood 
sugar level triggers insulin secretion. In the absence of GLUT2, however, insulin 
secretion by pancreatic β-cells in response to glucose is not detected (Marty et al., 
2007). Furthermore, functional studies reveal that GLUT2 is essential for glucose-
sensing in the brain, where it supresses glucagon secretion during the fed state 
(Burcelin and Thorens, 2001). These findings highlight the importance of GLUT2 
as a glucose transporter and the potential benefits of reduction of glucose and 
fructose uptake into enterocytes. GLUT2 is a high capacity and low affinity 
transporter for both glucose and fructose (KM = ~ 17 mM and ~76 mM for glucose 
and fructose, respectively) (Cura and Carruthers, 2012), (Mueckler and Thorens, 
2013). The high KM values attributed to GLUT2 allows it to transport glucose and 
fructose in amounts proportional to the levels available in the circulation, meaning 
that sugar transport varies as a results of sugar concentration in physiological and 
diabetic conditions (Morgan et al., 2007), (Mueckler and Thorens, 2013).  
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Antidiabetic drugs, such as acarbose, inhibit the sugar digestive enzymes α-
amylases and α-glucosidases, leading to less sugar production and, thereby, 
aiding in the regulation of post-prandial sugar excursions associated with impaired 
glucose tolerance (IGT) and the development of diabetes (Williamson, 2013). 
Another class of drugs used in the treatment of diabetes, shown to be effective at 
reducing CVD mortality in diabetic patients, targets sodium-glucose cotransporter 
2 (SGLT2), responsible for the reabsorption of glucose by the kidneys following 
intestinal absorption by SGLT1 and GLUT2 (Baud et al., 2016). Plant-derived 
(poly)phenols, which are present in our daily diet, have the potential to limit post-
prandial sugar excursions by inhibiting sugar digestive enzymes, leading to a 
decrease in sugar production, and inhibiting sugar transporters, thus reducing 
sugar absorption (Williamson, 2013). For instance, human α-amylase is inhibited 
by flavonols and (poly)phenols present in tea (Forester et al., 2012), (Goto et al., 
2012). Transporters GLUT2 and SGLT1 were both inhibited by tiliroside in 
experiments conducted in Caco-2 human intestinal cell model (Goto et al., 2012). 
Furthermore, it has been previously reported that quercetin is a particular strong 
inhibitor of GLUT2 glucose and fructose uptake and it was determined that this 
flavonoid achieved its effects through non-competitive inhibition. In other words, 
quercetin binds to an alternative site to the binding site of substrate on this 
transporter, implying that binding sites for this flavonoid are a characteristic of the 
GLUT2 transporter itself rather than the membrane it is expressed in (Kwon et al., 
2007), (Song et al., 2002). Inhibition of GLUT2-mediated fructose and glucose 
uptake has also been achieved with the apple (poly)phenol, phloretin, and 
quercetin’s glucoside precursors isoquercetin and spiraeoside. Other flavonoids 
are likely to exert inhibition on GLUT2 in a non-competitive manner as well (Kwon 
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et al., 2007), (Lin et al., 2016). The inhibition studies mentioned here conducted 
using a range of (poly)phenols suggest that a lifetime of dietary (poly)phenol intake 
could have an effect on disease risk reduction comparable to that of synthetic drugs 
such as acarbose (Williamson, 2013).  
 
This Chapter aims to determine the direct effect of additional (poly)phenols and/or 
plant extracts on the GLUT2-mediated transport of not only glucose, but also of 
fructose. In addition, as GLUT2 is responsible for secondary uptake of fructose the 
characterization of an inhibitor for this transporter, which is also able to inhibit the 
main fructose transporter GLUT5 (see Chapter 4), would shed light onto what 
compounds would be most beneficial in an intervention aimed at the control of 
fructose uptake and post-prandial distribution of sugars. Uptake experiments were 
performed using the X. laevis oocyte expression model with oocytes expressing 
human GLUT2 (hGLUT2). Following the incubation of cells in a fructose or glucose 
incubation solution containing radiolabelled sugars and varying concentrations of 
different compounds and/or plant extracts, internalized radioactivity was measured 
using liquid scintillation counting (LSC).     
   
5.3 Validation of GLUT2pBF plasmid construct functionality 
5.3.1 Confirmation of adequate placement of hGLUT2 gene in 
expression vector 
Human GLUT2 gene was inserted into pBF expression vector using the methods 
described in Chapter 2 (see section 2.3). Successful ligation of the sequences of 
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the gene of interest and the expression vector was confirmed through digestion of 
individually selected colonies from ligation reaction with HindIII restriction enzyme. 
This enzyme has a single restriction site in the pBF sequence as well as a single 
restriction site embedded in the sequence of the GLUT2 gene. Therefore, upon gel 
electrophoresis a positive product for the presence of GLUT2 produced two district 
bands, one at a size equivalent to 3909 bp (digestion at the pBF restriction site) 
and another at a size comparable to 970 bp (digestion at the GLUT2 gene 
restriction site). Only one single band was produced for the control digestion 
containing pBF plasmid without the gene insert, as can be seen in Figure 5.2. Of 
the fifteen individual colonies extracted, eight were considered positive for the 
presence of the GLUT2 gene and were sequenced in full (refer to Chapter 2 section 
2.3.1 for list of primers used).   
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Figure 5-1 Illustration of the GLUT2pBF plasmid and theoretical gel 
electrophoresis products upon digestion of plasmid with HindIII restriction 
enzyme. Varying key attributes of the full GLUT2pBF sequence are shown 
including SP6 promoter (green) region, PmlI restriction site (pink) and PolyA 
tail (light purple), as well as the location of the inserted GLUT2 gene (orange) 
and specific homologous primers used in ligation reaction (light grey). 
Location of HindIII restriction sites in the GLUT2pBF sequence (dark grey) 
and the theoretical digestion of the sequence, including electrophoresis 
products, are shown around the circular plasmid structure.  
 
Figure 5.1 illustrates the complete GLUT2pBF sequence with its key attributes, 
including the SP6 promoter site where in vitro transcription begins (green) and PmlI 
restriction site (pink) where transcription ends (Beckert and Masquida, 2011). The 
GLUT2 gene (orange) was positioned in between the promoter site and the PolyA 
tail site (light purple), a stretch of sequence containing only adenosine bases that 
aids with stability of mRNA and nuclear export (Fuke and Ohno, 2008). The site of 
specific primers with homology to pBF and GLUT2 sequences used in the ligation 
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of the gene to the expression vector are shown in light grey (for full sequences 
refer to Chapter 2, section 2.3.3.2). Specific position of restriction sites of HindIII 
(dark grey) are shown in relation to the rest of the plasmid sequence and to each 
other. To add to that, the same figure shows a theoretical digestion of GLUT2pBF 
with this enzyme and the derived gel electrophoresis products based on the DNA 
sequence. A table, also shown in this figure, lists the precise location in the 
sequence for each of the HindIII restriction sites (third column), which in turn 
determine the sizes (in bp) of each digest (first column), as well as the percentage 
of the total mass for which the digest products account for (sixth column). 
 
Restriction enzyme digest products produced from each individual colony 
extracted after ligation reaction, obtained by gel electrophoresis, are shown in 
Figure 5.2. Colonies 4, 5, 7, 8, 12, 13, 14 and 15 (Figure 5.2 A and B) were 
considered positive for the presence of GLUT2 gene as they generated products 
around 4000 bp and 1000 bp in size, which are comparable to the expected product 
sizes of 3909 bp and 970 bp. Control digestion of pBF plasmid without GLUT2 
insert produced a single band product only, as expected. Sequencing results from 
these colonies showed that the sequence from all positive colonies matched with 
the expected sequence of GLUT2pBF. One single colony was randomly chosen 
for propagation (colony 5) and used for all subsequent experiments.  
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Figure 5-2 Gel electrophoresis image showing digestion of GLUT2pBF colonies 
with HindIII after ligation of GLUT gene to expression vector. A colony positive 
for the presence of GLUT2 gene produced two individual bands [colony 4, 5, 
7, 8 (A), 12, 13, 14 and 15 (B)]. Control (c) (B), consisting of pBF plasmid 
without gene insert, produced a single band product. Product sizes are 
comparable to the theoretical sizes of digestion of this sequence with HindIII, 
namely around 3909 bp (digestion at the pBF restriction site) and 970 bp 
(digestion at the GLUT2 gene restriction site). Size of products was 
determined against a DNA hyperladder (HL). 
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5.3.2 Confirmation of specificity and quality of mRNA product 
The IVT reaction was carried out with linearized GLUT2pBF plasmid obtained from 
digestion with PmlI restriction enzyme, for its restriction site is located after the 
gene of interest and PolyA tail. As previously discussed in Chapter 4 (section 
4.3.2), circular plasmid DNA migrates through agarose gels in a district manner, 
producing two band products corresponding to the nicked DNA (higher molecular 
weight product) and the supercoiled DNA (lower molecular weight product) 
(Sambrook and Russell, 2001). Linear DNA migrates through the gel at a slower 
rate than circular DNA, producing a band at a size comparable to the full plasmid 
sequence, which in the case of GLUT2pBF is 4879 bp. The migration pattern of 
the circular GLUT2pBF and the linearized digest are shown in Figure 5.3.  
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Figure 5-3 Gel electrophoresis of circular and linear GLUT2pBF. GLUT2pBF 
plasmid was linearized by digestion with PmlI restriction enzyme before IVT 
reaction. Circular GLUT2pBF plasmid (circ.) produced bands on the gel 
characteristic of its structure, whereas linear plasmid (lin.) produced a single 
band corresponding in size to the sequence of the full plasmid (4879 bp). Gel 
electrophoresis confirming linearization of plasmid was performed for every 
new mRNA sample prepared. 
 
After the IVT reaction is performed the mRNA product was analysed in a 
denaturing RNA gel (see Chapter 2 section 2.3.5) in order to confirm that the 
product size was consistent with the expected size derived from the plasmid 
sequence (2296 bp). The mRNA product obtained from IVT of GLUT2pBF 
produced two band products following gel electrophoresis on RNA denaturing gel, 
one at a lower molecular weight in agreement with that expected of the mRNA from 
the plasmid sequence (around 3000 bp), and one at a higher molecular weight 
(Figure 5.4 A). According to the IVT kit user guide, provided with the product, a 
migration pattern such as this may occur due to persistent secondary structure 
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(mMessage mMachine ® Kit User Guide, Ambion). In order to confirm this 
possibility both bands were cut from the gel, RNA was extracted, and gel 
electrophoresis of extracts was performed on another denaturing gel. The RNA 
extracted from the higher molecular weight band migrated through the gel 
producing a faint band consistent in size to that expected of the GLUT2 mRNA. In 
addition, the RNA extracted from the lower molecular weight band (expected size 
for GLUT2 mRNA) migrated through the gel as a doublet, as with the original 
sample (Figure 5.4.B). Migration patterns from both extracted RNA samples 
confirm that the higher molecular weight band produced by the mRNA following 
IVT is indeed leftover secondary structure brought about as a consequence of the 
electrophoresis reaction. Secondary structure can also contribute to the improper 
denaturing of samples in the gel causing it to migrate abnormally or at an improper 
size to that expected. The size of the band produced by GLUT2 mRNA (3000 bp), 
when compared to the ssRNA ladder, was similar to that expected from the plasmid 
sequence (2296 bp). However, the presence of left over secondary structure could 
explain the more pronounced gap between expected and actual sizes.  
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Figure 5-4 Gel electrophoresis of the GLUT2 mRNA product from IVT on RNA 
denaturing gel. After IVT reaction the mRNA product was run on a 
formaldehyde denaturing gel to confirm that its size matched that expected 
from the plasmid sequence (2296 bp). mRNA produced two bands, one at a 
size corresponding to that expected and one at a higher molecular weight (A). 
Individual bands were cut from the gel, RNA was extracted, and gel 
electrophoresis of extracts on denaturing gel was performed. Migration 
pattern of each extract on the gel confirms that the higher molecular band 
(H.MW) consists of left over secondary structure while the lower molecular 
weight band (L.MW) corresponds to the mRNA product size (B). Size of 
products was determined against an ssRNA ladder. Gel electrophoresis of 
mRNA on RNA denaturing gel was performed for every new mRNA sample 
prepared. 
 
5.4 Validation of X. laevis model functionality 
5.4.1 Glucose uptake by GLUT2-expressing oocytes and inhibition by 
known specific inhibitors 
Uptake experiments with both fructose and glucose on oocytes expressing GLUT2 
were carried out under the same conditions discussed previously in Chapter 4, 
namely, oocytes were incubated at 25 °C in a 0.1 mM fructose/glucose solution. 
Incubation time remained at 5 min, as preliminary uptake experiments 
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demonstrated no significant increase in uptake at longer incubation periods (Figure 
5.5). Water injected oocytes were used as controls in all uptake experiments. 
Results of uptake by GLUT2-expressing oocytes are shown normalized to the 
uptake observed by their respective water injected controls, unless otherwise 
stated. 
 
Figure 5-5 Uptake of 0.1 mM fructose/glucose over different incubations times. 
Two days post GLUT2 mRNA microinjection oocytes were incubated in 0.1 
mM fructose/glucose solution containing [14C] fructose/glucose over 5-20 min 
at 25 °C. Each data point represents the mean of 6 replicates (of 3 oocytes), 
normalized to control for each condition, ± SEM. There was no statistical 
difference between the incubation times tested, however, less variability was 
attributed to 5 min incubation.  
 
Oocytes were exposed to two known inhibitors of GLUT2, added to the incubation 
solution to serve as positive controls and to confirm that inhibition was achievable 
with this expression model. Uptake of glucose by GLUT2 was significantly 
decreased in the presence of 100 µM of phloretin (Figure 5.6 A) and 100 µM 
cytochalasin B (Figure 5.6 B). Phloretin inhibited GLUT2 uptake of glucose by 81% 
(p ≤ 0.0001), while cytochalasin B reduced glucose uptake by 70% (p ≤ 0.0001). 
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Figure 5-6 Inhibition of GLUT2 glucose uptake by known inhibitors. Two days post 
GLUT2 mRNA microinjection oocytes were incubated in 0.1 mM glucose 
solution containing [14C] glucose with and without 100 µM phloretin (A) and 
100 µM cytochalasin B (cytoB) (B) for 5 min. Internalized sugar uptake was 
determined by scintillation spectrometry for protein expressing oocytes (black 
bars) and water injected controls (open bars). Net change in uptake, Δ, (grey 
bars) was determined by normalizing the uptake observed by GLUT2 to 
control uptake. The mean ± SEM of 12 replicates (of 3 oocytes) is shown per 
individual condition. Phloretin reduced GLUT2 uptake of glucose by 81% (A) 
and cytochalasin B decreased glucose uptake by GLUT2 by 70% (B) when 
added to the 0.1 mM glucose incubation solution. **** p ≤ 0.0001. 
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5.4.2 Determination of expression of recombinant hGLUT2 on oocyte 
membrane extracts 
The expression of hGLUT2 on oocyte membranes was determined through 
automated capillary Western blot, Wes (see Chapter 2 section 2.4.7). Membranes 
were extracted from three oocytes for analysis with Wes following one to three 
days post microinjection with GLUT2 mRNA or water (Figure 5.7 A). Images show 
the presence of GLUT2 protein on membranes extracted from oocytes 
microinjected with GLUT2, and on positive control HepG2 cell lysate, but not in 
water injected controls. This is also made clear by the electropherogram of extracts 
from day 2 (Figure 5.7 B). All oocyte membrane extracts were treated with 
PNGase, a glycosidase, before imaging. This could explain the shift in size of 
GLUT2 observed between oocyte membranes (between 54-60 kDa in size) and 
the HepG2 cell lysate (around 63 kDa in size) (Figure 5.7 C). Differences in protein 
glycosylation across species could also contribute to sizes marginally diverging 
from the oocyte membrane extract and mammalian cell lysates. Due to the 
abundance of protein present two days post microinjection with GLUT2 mRNA, all 
further uptake experiments were carried after out after oocytes had an expression 
period of 48 hrs. GLUT2 antibody used for protein detection was raised against an 
internal region of the human protein, reported to recognize a GLUT2 protein 
product of 53-61 kDa in size. Optimal GLUT2 antibody dilution of 1:50 for Wes 
experiments was determined by Dr. S. Tumova. 
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Figure 5-7 Confirmation of expression of GLUT2 on oocyte membrane extracts by 
Wes. Membranes extracted from three oocytes one to three days post 
injection with GLUT2 mRNA (day1-day3), as well as water injected control 
membranes, were analysed using automated capillary Western blot (Wes). 
Analysis of a membrane extract sample shown as a gel-like image, together 
with a HepG2 cell lysate positive control (A). A comparison of GLUT2 mRNA 
injected and control water injection membrane extracts two days post 
microinjection (day2) is shown as an electropherogram (B). The shift in 
GLUT2 size between oocyte membrane extracts and HepG2 cell lysate is 
highlighted as an electropherogram (C). Detected protein size for GLUT2 was 
53-60 kDa for oocyte membrane extract and 63 kDa for HepG2 cell lysate. 
Concentration of oocyte membrane extracts and HepG2 cell lysate loaded 
was 0.5 mg/ml. Antibody dilution was 1:50. This image represents one of 3 
replicates. 
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5.5 Uptake experiment results and discussion 
In order to attribute inhibition of GLUT2-mediated glucose/fructose transport by a 
specific compound or extract oocytes expressing this transporter were incubated 
in a sugar solution, containing 14C-glucose/fructose, in the presence and absence 
of each compound/extract. Uptake inhibition experiments were conducted using 
plant extracts and compounds also used in GLUT5 uptake inhibition studies, in the 
previous chapter (Chapter 4), with the aim to identify common inhibitors of both 
transporters. Due to the amount of time required for oocyte microinjections and to 
perform inhibition studies, not all the extracts tested for GLUT5 inhibition potential 
could be used in the experiments presented in this chapter. For this reason, 
extracts which were being used, or would in the future be used, in human studies 
conducted by other individuals in the research group were prioritized (e.g. German 
chamomile, green tea and pomegranate) (Villa-Rodriguez et al., 2017a), (Nyambe-
Silavwe and Williamson, 2016). Similarly, compounds incorporated by other 
individuals in the group for in vitro cell culture work, as well as compounds shown 
to inhibit GLUT2 from the literature, were also investigated using the oocyte model. 
In other words, extract and compounds were chosen with the aim to validate results 
within the research group and to attribute inhibition to specific transporters. All 
extracts and compounds used in the uptake inhibition studies by GLUT2 described 
in this chapter are listed in Table 5.1. Inhibition of GLUT2 uptake by two of its 
substrates, namely fructose and glucose, was conducted with three pure 
compounds, marked in Table 5.1 with an asterisk.   
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Table 5-1 Compounds/extracts used in GLUT2-mediated glucose/fructose uptake 
inhibition studies described in this chapter 
Compound/ extract Inhibition of GLUT2 mediated sugar uptake 
Acarbose Glucose 
Apigenin * Glucose and fructose 
Bonolive Glucose 
Cytochalasin B Glucose 
EGCG * Glucose and fructose 
German chamomile Glucose 
Green tea Glucose 
Hesperidin Glucose 
Hesperetin Glucose 
Phloretin Glucose 
Pomegranate Glucose 
Quercetin * Glucose and fructose 
* compounds for which investigation of uptake inhibition was carried out with two 
GLUT2 substrates. 
 
The pure compounds apigenin, EGCG and quercetin were chosen to conduct 
GLUT2-mediated fructose uptake inhibition, as well as glucose uptake inhibition, 
for two of these compounds were shown to inhibit fructose uptake by GLUT5 
(apigenin and EGCG, Chapter 4). Although quercetin did not inhibit GLUT5 it is a 
known potent inhibitor of GLUT2 (Kwon et al., 2007), (Song et al., 2002). 
Considering the research objective of investigating the inhibition profiles of GLUTs 
and identifying novel inhibitors of these two transporters and GLUT7, which like 
GLUT2 also transports glucose and fructose, these compounds were thought to be 
good candidates. Once again, due to the time consuming nature of experiments 
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other pure compounds could not be investigated for inhibition of GLUT2 using 
fructose as a substrate.    
 
5.5.1 Effect of extracts on glucose uptake by GLUT2 
The effect of plant extracts on glucose uptake by GLUT2 was investigated by 
incubation of the oocytes in a 0.1 mM glucose solution, containing radiolabelled 
glucose, with increasing concentrations of a particular extract for 5 min at 25 °C. 
Green tea and German chamomile extracts both significantly reduced the uptake 
of glucose by GLUT2 in a concentration dependent manner (figure 5.8). IC50 values 
were determined to be 0.13 ± 0.02 mg/ml and 0.49 ± 0.24 mg/ml for green tea and 
German chamomile extracts, respectively.  
 
Oleuropein-rich Bonolive extract and sugar-free pomegranate extract were tested 
for their potential effects on GLUT2-mediated glucose uptake using the same 
conditions. There was a significant decrease in glucose uptake by this transporter 
in the presence of both extracts (Figure 5.9). Glucose uptake reduction followed a 
concentration dependent pattern with the addition of Bonolive extract, IC50 reached 
at 0.03 ± 0.002 mg/ml (Figure 5.9 A). Sugar-free pomegranate extract proved to 
be a very potent inhibitor, leading to a 93% (p ≤ 0.001) reduction in uptake at 0.1 
mg/ml (Figure 5.9 B).  
 
 
 
162 
 
 
Figure 5-8 Effect of green tea and German chamomile extracts on glucose uptake 
by GLUT2. Two days post GLUT2 mRNA microinjection oocytes were 
incubated in 0.1 mM glucose solution containing [14C] glucose with increasing 
concentrations of green tea extract (0-0.25 mg/ml) (A) and German 
chamomile extract (0-1 mg/ml) (B) for 5 min at 25 °C. There was a significant 
concentration dependent change in uptake of glucose by the oocytes in the 
presence of both extracts under these conditions. IC50 = 0.13 ± 0.02 mg/ml 
for green tea extract (A) and IC50 = 0.49 ± 0.24 mg/ml for German chamomile 
extract (B). Each data point represents the mean of 12 replicates (of 3 
oocytes), normalized to control for each condition, ± SEM. ** p ≤ 0.01 and *** 
p ≤ 0.001. 
  
Composition of extracts used here for uptake experiments in GLUT2-expressing 
oocytes are the same as previously stated in Chapter 4 (section 4.5.1).  
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Figure 5-9 Effect of Bonolive and sugar-free pomegranate extracts on glucose 
uptake by GLUT2. Two days post GLUT2 mRNA microinjection oocytes 
were incubated in 0.1 mM glucose solution containing [14C] glucose with 
increasing concentrations of Bonolive extract (0-0.1 mg/ml) (A) and sugar-
free pomegranate extract (0-1 mg/ml) (B) for 5 min at 25 °C. There was a 
significant change in uptake of glucose by the oocytes in the presence of 
both extracts under these conditions. IC50 = 0.03 ± 0.002 mg/ml for 
Bonolive extract (A) and IC50 = 0.05 ± 0.01 mg/ml for sugar-free 
pomegranate extract (B). Each data point represents the mean of 12 (A) 
and 6 (B) replicates (of 3 oocytes), normalized to control for each 
condition, ± SEM. * p ≤ 0.05 and *** p ≤ 0.001. 
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5.5.2 Effect of pure compounds on glucose uptake by GLUT2 
The direct impact of pure compounds on glucose uptake by GLUT2 was measured 
using the same experimental conditions as for the extracts. The two pure 
compounds tested were hesperetin and its glucoside hesperidin. There was a 
significant decrease in GLUT2-mediated glucose uptake in the presence of both 
compounds. However, the aglycone hesperetin provided a much stronger 
inhibition. In the presence of hesperetin glucose uptake was decreased by 82.9% 
(p ≤ 0.0001) at 50 µM of compound (Figure 5.10 B), and IC50 was reached in the 
presence of hesperidin at 219 ± 40 µM (Figure 5.10 A). 
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Figure 5-10 Effect of pure compounds hesperetin and hesperidin on glucose 
uptake by GLUT2. Two days post GLUT2 mRNA microinjection oocytes were 
incubated in 0.1 mM glucose solution containing [14C] glucose with increasing 
concentrations of hesperidin (0-500 µM) (A) and hesperetin (0-500 µM) (B) 
for 5 min at 25 °C. There was a significant change in uptake of glucose by the 
oocytes in the presence of both compounds under these conditions. IC50 = 
219 ± 40 µM for hesperidin (A) and IC50 = 30 ± 9 µM for hesperetin (B). Each 
data point represents the mean of 6 (A) and 12 (B) replicates (of 3 oocytes), 
normalized to control for each condition, ± SEM. * p ≤ 0.05 and **** p ≤ 0.0001. 
 
The synthetic drug acarbose, used in the management of diabetes, has shown 
potent inhibitory effects on enzymes such as of -amylase and -glucosidase 
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(Zeymer, 2006). In the previous Chapter, the effect of this drug on GLUT5-
mediated fructose transport was investigated (Chapter 4, section 4.5.2), 
concluding that acarbose did no inhibit GLUT5 uptake of fructose. In order to 
investigate the effect of this drug on another intestinal membrane transporter, 
increasing concentrations of acarbose were added to the glucose incubation 
solution of GLUT2-expressing oocytes (Figure 5.11). Acarbose did not have any 
significant effect on glucose transport by GLUT2 under the conditions tested.  
 
Figure 5-11 Effect of acarbose on glucose uptake by GLUT2. Two days post 
GLUT2 mRNA microinjection oocytes were incubated in 0.1 mM glucose 
solution containing [14C] glucose with increasing concentrations acarbose (0-
1 mg/ml) for 5 min at 25 °C. There was no significant change in uptake of 
glucose by the oocytes in the presence of acarbose under these conditions. 
Each data point represents the mean of 6 replicates (of 3 oocytes), 
normalized to control for each condition, ± SEM. 
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5.5.3 Comparison of effect of pure compounds on glucose and 
fructose uptake by GLUT2 
Reports have concluded that GLUT2 has high affinity for fructose as well as 
glucose (KM  of  66 mM and 17 mM for fructose and glucose, respectively) (Cura 
and Carruthers, 2012). Translocation of GLUT2 from the basolateral to the apical 
membrane allows it to transport fructose alongside GLUT5, also located on the 
apical membrane (Helliwell et al., 2003). In order to characterize any differences in 
the inhibition pattern of uptake of either sugar by GLUT2, oocytes expressing this 
protein were incubated in a fructose or glucose incubation solution in the presence 
of increasing concentrations of pure compounds. Quercetin is a known inhibitor of 
GLUT2 and a concentration dependent inhibition was observed when this 
compound was added to both the fructose and the glucose incubation solution 
(Figure 5.12). IC50 values in the presence of quercetin were of 7 ± 1 µM and 8 ± 2 
µM for GLUT2-mediated glucose and fructose uptake, respectively.  
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Figure 5-12 Effects of quercetin on glucose and fructose uptake by X. laevis 
oocytes expressing GLUT2. Two days post mRNA microinjection oocytes 
were incubated in either 0.1 mM glucose solution containing [14C] glucose (left 
axis, ●)  or 0.1 mM fructose solution containing [14C] fructose (right axis, ○) 
with increasing concentrations of quercetin (0-100 µM) for 5 min at 25 °C. 
Each data point represents the mean of 6 replicates (of 3 oocytes), 
normalized to control for each condition, ± SEM. IC50 = 7 ± 1 µM and 8 ± 2 
µM for glucose and fructose, respectively, in the presence of quercetin. ** p ≤ 
0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
 
Two other pure compounds were used in the investigation of GLUT2-mediated 
sugar transport inhibition pattern, namely apigenin and EGCG. Apigenin 
considerably inhibited GLUT2-mediated uptake of glucose (IC50 = 27 ± 4 µM) and 
of fructose (IC50 = 28 ± 10 µM) in a concentration dependent manner (Figure 5.13). 
EGCG also showed to be a powerful inhibitor of GLUT2, concentration dependently 
decreasing uptake of both glucose (IC50 = 72 ± 13 µM) and fructose (IC50 = 93 ± 
16 µM) by this transporter (Figure 5.14). 
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Figure 5-13 Effects of apigenin on glucose and fructose uptake by X. laevis 
oocytes expressing GLUT2. Two days post mRNA microinjection oocytes 
were incubated in either 0.1 mM glucose solution containing [14C] glucose (left 
axis, ●)  or 0.1 mM fructose solution containing [14C] fructose (right axis, ○) 
with increasing concentrations of apigenin (0-50 µM) for 5 min at 25 °C. Each 
data point represents the mean of 6 replicates (of 3 oocytes), normalized to 
control for each condition, ± SEM. IC50 = 27 ± 4 µM and 28 ± 10 µM for glucose 
and fructose, respectively, in the presence of apigenin. * p ≤ 0.05,  ** p ≤ 0.01 
and *** p ≤ 0.001. 
 
Apigenin had a greater effect on fructose transport at the highest concentration 
tested, inhibiting transport of this sugar by 85% (p ≤ 0.001) at 50 µM, compared to 
56% (p ≤ 0.01) reduction of glucose uptake at the same concentration (Figure 
5.13). Similarly, fructose transport was inhibited to a greater extent than glucose 
transport in the presence of the highest concentration of EGCG; inhibition was of 
84% (p ≤ 0.0001) and 74% (p ≤ 0.01) for fructose and glucose, respectively, at 500 
µM (Figure 5.14). Of the three compounds tested the most potent inhibitor of 
glucose uptake by GLUT2 was shown to be quercetin, decreasing the transport of 
this sugar by 67% (p ≤ 0.01) at the lowest concentration tested and by 95% (p ≤ 
0.001) at 100 µM. Although a GLUT2-mediated fructose uptake inhibition by 
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quercetin was also observed, this compound was marginally less effective at the 
highest concentration tested than apigenin and EGCG, decreasing fructose 
transport by 80% (p ≤ 0.0001) at 100 µM. Nevertheless, uptake of fructose was 
reduced by 70% (p ≤ 0.0001) at the lowest concentration of quercetin tested and 
by 85% (p ≤ 0.0001) at 50 µM, suggesting a potential plateau in inhibition was 
reached at a lower compound concentration for this sugar (Figure 5.12). 
 
Figure 5-14 Effects of EGCG on glucose and fructose uptake by X. laevis oocytes 
expressing GLUT2. Two days post mRNA microinjection oocytes were 
incubated in either 0.1 mM glucose solution containing [14C] glucose (left axis, 
●)  or 0.1 mM fructose solution containing [14C] fructose (right axis, ○) with 
increasing concentrations of EGCG (0-500 µM) for 5 min at 25 °C. Each data 
point represents the mean of 6 replicates (of 3 oocytes), normalized to control 
for each condition, ± SEM. IC50 = 72 ± 13 µM and 93 ± 16 µM µM for glucose 
and fructose, respectively, in the presence of EGCG. ** p ≤ 0.01 and **** p ≤ 
0.0001. 
 
Oocytes expressing GLUT2 were able to transport more glucose than fructose, at 
an average ratio of approximately 1 to 3. Although all three compounds tested were 
more effective at inhibiting glucose uptake by this transporter, as observed by the 
lower IC50 values, inhibition patterns over the varying concentrations were 
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comparable between both sugars. This suggests that these compounds acted in a 
similar fashion when inhibiting glucose transport or fructose transport by GLUT2.  
 
5.5.4 Summary of results from glucose and fructose uptake 
experiments  
GLUT2-mediated glucose transport in oocytes was significantly inhibited in the 
presence of the known GLUT2 inhibitors phloretin and cytochalasin B, as expected 
(Krupka, 1985). Glucose uptake was also reduced in the presence of the four plant 
extracts tested, namely green tea extract, German chamomile extract, Bonolive 
extract and sugar-free pomegranate extract. Furthermore, a decrease in glucose 
uptake by GLUT2 was also observed when oocytes expressing this protein were 
exposed to hesperetin and its glucoside hesperidin. Cytochalasin B, when tested 
on human erythrocyte membrane samples, was shown to exert a competitive 
inhibition on GLUT2 through interaction with three sites on the protein. Glucose, 
phloretin and other sugars competitively displaced cytochalasin B from one of the 
interaction sites, site 1. This site is suspected not to be the substrate binding site 
as these two sites display varying structure-activity interactions. (Jung and Rampal, 
1977). While the inward-facing form of the protein was determined to support the 
cytochalasin B binding site, phloretin is reported to bind to the external surface of 
GLUT2 (Krupka, 1985). Smaller than cytochalasin B, phloretin is likely to bind to 
the active site of GLUT2 and in this manner compete for the substrate. The 
structures of both inhibitors are shown in Table 5.2. A great addition to what is 
currently known about competitive inhibition of GLUT2 would be the investigation 
of the exact interactions of the main components of each extract with this protein 
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to determine the manner in which they exert their inhibition. The same is true for 
their interactions with hesperetin and hesperidin. All compounds which significantly 
inhibited uptake of glucose and/or fructose by GLUT2, including their structure, are 
shown in Table 5.2. Extracts which significantly inhibited GLUT2-mediated glucose 
uptake and their compositions, as well as the structure of the main component of 
each extract, are shown in Table 5.3. 
 
Table 5-2 Compounds and their respective inhibition on sugar uptake by GLUT2 
Compound Substrate  Inhibition1 Structure  
Apigenin  Glucose and 
fructose  
IC50G = 27 ± 4 
µM 
IC50F = 28 ± 10 
µM 
 
Cytochalasin B Glucose 70% inhibition 
at 100 µM 
 
EGCG  Glucose and 
fructose 
IC50G = 72 ± 13 
µM 
IC50F = 93 ± 16 
µM 
 
Hesperidin Glucose IC50 = 219 ± 
40 µM 
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Hesperetin Glucose IC50 = 30 ± 9 
µM 
 
Phloretin Glucose 81% inhibition 
at 100 µM 
 
Quercetin  Glucose and 
fructose 
IC50G = 7 ± 1 
µM 
IC50F = 8 ± 2 
µM 
 
1 compounds for which a single concentration was tested were attributed a 
percentage inhibition at that concentration. 
 
Table 5-3 Extracts and their respective inhibition on glucose uptake by GLUT2.  
Compound Composition1  Inhibition Structure2  
Bonolive 40% 
oleuropein 
IC50 = 0.03 
± 0.002 
mg/ml 
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German 
chamomile 
12.32% 
apigenin-7-O-
glucoside; 
0.28% 
apigenin 
0.13% luteolin-
7-O-glucoside; 
0.07% 4,5-
dicaffeoylquini
c acid 
IC50 = 0.49 
± 0.24 
mg/ml 
 
Green tea 199.8 ± 6.7 
mg/g (-)-
Epigallocatechi
n gallate 
(EGCG);  
124.4 ± 9.3 
mg/g (-)-
Epigallocatechi
n;  
34.4 ±1.9 mg/g 
(-)-Epicatechin 
gallate; 
23.3 ± 2.4 
mg/g (-)-
Epicatechin 
IC50 = 0.13 
± 0.02 
mg/ml 
 
Pomegranate  121 mg/g 
punicalagin; 
6 mg/g 
puricalin;  
5.9 mg/g 
ellagic acid 
hexose;  
101 mg/g 
ellagic acid 
IC50 = 0.05 
± 0.01 
mg/ml 
 
1 analysis of extracts were performed previously; please refer to Chapter 2, section 
2.1 
2 structure of the component present at the highest concentration in the extract is 
shown. 
 
Inhibition pattern of GLUT2- mediated fructose and glucose transport was similar 
in the presence of pure compounds apigenin, EGCG and quercetin. Oocytes 
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expressing GLUT2 protein were able to transport three times more glucose than 
fructose and all three compounds had greater inhibitory effects on glucose 
transport, as concluded from IC50 values. Nevertheless, the rate of decrease in 
uptake by GLUT2 with increasing concentrations of each compound was 
comparable for both substrates. Inhibition of glucose by German chamomile extract 
and apigenin, one of the most abundant compounds in this extract (Villa-Rodriguez 
et al., 2017a), are both concentration dependent. Taking the composition of the 
extracts into account apigenin (IC50 = 27 ± 4 µM) was better at inhibiting glucose 
transport by GLUT2 than the German chamomile extract (IC50 = 0.49 ± 0.24 mg/ml; 
equivalent to 51 µM apigenin). On the other hand, green tea extract (IC50 = 0.13 ± 
0.02 mg/ml; equivalent to 43 µM EGCG) was a more potent inhibitor of glucose 
uptake by GLUT2 than EGCG alone (IC50 = 72 ± 13 µM), possibly due to the 
presence of other gallated catechins in the extract, also shown to have an inhibitory 
effect on GLUT2 (Johnston et al., 2005).  
 
Variability observed between uptake experiments is likely due to biological 
differences of the varying female ovaries digested to obtain oocytes for 
experiments, husbandry and housing of the animals, developmental stage 
variation, as well as a seasonal component affecting the quality of oocytes and 
their ability to express heterologous proteins (Delpire et al., 2011), (Conn, 1991), 
(Miller and Zhou, 2000). These factors were previously discussed in more detail in 
Chapter 4 (section 4.5.1). To add to that, multiple products were produced following 
IVT reaction with linear GLUT2pBF plasmid. Although this was determined to be 
leftover secondary structure, it still represented a fraction of the overall mRNA 
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concentration, meaning that less translational mRNA was injected into the oocytes, 
potentially leading to less protein expression on membrane of varying oocytes. 
 
Inhibitors of GLUT2-mediated glucose transport German chamomile extract, 
sugar-free pomegranate extract, and hesperidin also inhibited GLUT5-mediated 
fructose transport. Moreover, EGCG and apigenin were able to inhibit GLUT2- 
mediated fructose and glucose transport, as well as inhibit GLUT5. Further 
research with these compounds, including in vivo studies with novel fructose 
uptake inhibitors able to decrease the uptake of fructose by its two major 
transporters, would help determine their potential as active compounds in 
preventive interventions aimed at reducing risk factors associated with CVD, 
diabetes and other health conditions.  
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Chapter 6  
Glucose and fructose inhibition of heterologously expressed 
hGLUT7 by (poly)phenols 
 
6.1 Abstract 
Sugar uptake by the lesser known intestinal transporter GLUT7 has been under 
debate in recent years. As the closest related protein to GLUT5, it has been 
speculated that GLUT7 is also a fructose transporter. Nevertheless, contradicting 
data on fructose and glucose transport capability by this protein have been 
reported. Studies which concluded that GLUT7 can transport sugars have not been 
able to identify any inhibitors of this protein. In order to investigate if GLUT7 does 
in fact transport glucose and/or fructose, and the potential inhibitory effects of 
(poly)phenols, the protein was heterologously expressed in X. laevis oocytes, 
which were then incubated in a 14C-glucose/fructose solution containing individual 
(poly)phenols and extracts. Automated capillary PorteinSimple Western blotting 
confirmed protein expression on oocyte membranes and uptake of internalised 
14C-glucose/fructose was observed by liquid scintillation counting. Results showed 
that GLUT7 expressed in oocytes transports fructose and glucose, uptake of which 
is competitively inhibited in the presence of fructose, but not deoxy-glucose. In 
addition, of the plant extracts and pure compounds tested, only apigenin had an 
impact on sugar transport by this protein, significantly inhibiting glucose uptake 
(IC50 = 38 ± 2 µM) and fructose uptake (IC50 = 16 ± 12 µM) by GLUT7. These 
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results show that, although perhaps not the primary physiological substrates, 
GLUT7 is a transporter for glucose and fructose and that uptake inhibition is 
achieved by the (poly)phenolic compound apigenin. This novel finding may help in 
the further characterization of this transporter in terms of substrate-protein 
interactions and binding.  
 
6.2 Introduction 
The human GLUT7 (hGLUT7) protein is most abundantly expressed in the small 
intestine, colon, testis and prostate (Li et al., 2004). This GLUT transporter is the 
closest relative to GLUT5, also expressed in the gut, sharing 53% sequence 
homology and 68% amino acid identity to the fructose specific transporter (Li et al., 
2004), (Scheepers et al., 2005). Although GLUT7 has yet to be completely 
characterized, due to its similarity to the GLUT5, this protein has been proposed to 
be a fructose transporter (Uldry and Thorens, 2004). It has been determined that 
GLUT7 has high affinity for fructose and glucose (< 0.5 mM), however, the 
physiological substrate for this transporter has not yet been conclusively 
established (Cheeseman, 2008). Affinity of GLUT7 has been reported to be 
marginally higher for fructose (~ 0.1 mM) than glucose (~ 0.3 mM) (Li et al., 2004), 
(Manolescu et al., 2005). Sequencing alignment analysis indicated that GLUTs 2, 
5 and 7 have a conserved isoleucine containing-motif thought to be essential for 
transport of fructose, as it was not observed in other non-fructose transporting 
GLUTs (Doblado and Moley, 2009). To add to that, a study by Manolescu et al 
showed that a single point mutation substituting isoleucine for valine or serine in 
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the sequences of GLUTs 2, 5 and 7 abolished their ability to transport fructose, 
while glucose transport remained unaffected (Manolescu et al., 2005), (Manolescu 
et al., 2007a). GLUT11, a fructose transporter in the heart and skeletal muscle that 
shares 41.7% amino acid identity with GLUT5, has an aspartic acid and serine 
motif in the same position, and is thought to have the same function as the 
isoleucine motif observed in the sequences of GLUTs 2, 5, and 7 (Doege et al., 
2001). Mechanisms of substrate recognition by GLUTs that transport both glucose  
and fructose, e.g. GLUTs 2 and 7, are not yet fully understood. It has been 
suggested that the different binding sites and/or modes are the key to transport of 
multiple substrates (Thompson et al., 2015). Due to GLUT7 protein distribution in 
the gut, and based on its affinity for fructose, it has been speculated that the 
principal role of GLUT7 may be of fructose absorption at the end or after a meal, 
when fructose is present at low concentrations in the intestinal lumen (Drozdowski 
and Thomson, 2006).  The expression of this transporter is highest in the ileum, 
suggesting it potentially works as a scavenger for luminal glucose and fructose in 
the ileum when abundance of sugars are low (Cura and Carruthers, 2012). 
Nevertheless, although some GLUT7 uptake studies have determined that this 
protein transports both glucose and fructose when expressed in X. laevis oocytes 
(Li et al., 2004), (Cheeseman, 2008), others were unable to detect any sugar 
uptake by this transporter (Ebert et al., 2017). In this chapter, uptake experiments 
by heterologously expressed hGLUT7 were executed with the aim to determine if 
GLUT7 can in fact transport glucose and/or fructose. There currently are no data 
on the ability of (poly)phenols to inhibit sugar uptake by GLUT7, and common 
GLUT inhibitors such as phloretin or cytochalasin B did not exert any effect on 
sugar uptake by  this transporter (Li et al., 2004). A study by Thompson et al 
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identified the N-[4-(methylsulfonyl)-2-nitrophenyl]-1,3-benzodioxol-5-amine 
(MSNBA) compound as a specific GLUT5-mediated fructose inhibitor in 
proteoliposomes, which was speculated to perhaps inhibit GLUT7 as well based 
on the sequence similarity between the  two transporters (Thompson et al., 2016). 
Nevertheless, further investigations on GLUT7-mediated sugar uptake inhibition 
needs to be conducted in order to conclusively establish an inhibitor of this 
transporter. For this reason, the potential inhibitory effect of plant extracts and pure 
compounds on sugar uptake by GLUT7 will be assessed in this chapter using the 
same model, previously described in earlier chapters, of expression of human 
GLUT7 (hGLUT7) in X. laevis oocytes.    
 
6.3 Validation of GLUT7pBF and GLUT7pGEM-HE plasmid 
construct functionality 
6.3.1 Confirmation of adequate placement of hGLUT7 gene in 
expression vector 
Two plasmid constructs containing the human GLUT7 gene were used for sugar 
uptake experiments, namely GLUT7pBF and GLUT7pGEM-HE. The former was 
designed by myself and the latter was kindly supplied by Debbie O'Neill of Prof. 
Chris Cheeseman’s group (Department of Physiology, Alberta University, 
Canada). Described below are the processes applied to ensure correct positioning 
of the gene in either plasmid.  
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6.3.1.1 GLUT7pBF plasmid construct 
The human GLUT7 gene was inserted into the expression vector pBF through 
methods described previously in chapter 2 (see section 2.3). Confirmation of 
successful ligation of the sequences of expression vector and gene of interest was 
determined by digestion of colonies selected after ligation with the restriction 
enzyme HindIII. This particular restriction enzyme recognizes a single restriction 
site embedded in the sequence of the GLUT7 gene as well as one restriction site 
located in the the pBF plasmid sequence. This means that upon gel electrophoresis 
of digest products, a positive colony for the presence of GLUT7 produced two 
distinct bands, one at a size comparable to 3173 bp (digestion at the pBF restriction 
site) and another at a size equivalent to 1692 bp (digestion at the GLUT7 gene 
restriction site), as determined by a theoretical digestion of the plasmid sequence 
with the restriction enzyme (refer to Figure 6.2). All fifteen individual colonies 
extracted were considered positive for the presence of GLUT7 (Figure 6.1) and 
were sequenced for confirmation (refer to Chapter 2 section 2.3.1 for list of primers 
used). Digestion of colonies 1-10 (Figure 6.1 A) and 11-15 (Figure 6.1 B) with 
HindIII produced bands of around 3000 bp and 2000 bp following gel 
electrophoresis, both of which are comparable to expected product sizes of 3173 
bp and 1692 bp. Sequencing results showed that DNA from all colonies sequenced 
matched that expected for GLUT7pBF plasmid. One single colony was randomly 
chosen for propagation (colony 5) and used for all subsequent experiments. 
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Figure 6-1 Gel electrophoresis image showing digestion of GLUT7pBF colonies 
with HindIII after ligation of GLUT7 gene to expression vector. A colony 
positive for the presence of GLUT7 gene produced two individual bands 
[colony 1-10 (A), 11-15 (B)]. Product sizes are comparable to the theoretical 
sizes of digestion of this sequence with HindIII, namely around 3173 bp 
(digestion at the pBF restriction site) and 1692 bp (digestion at the GLUT7 
gene restriction site). Size of products was determined against a DNA 
hyperladder (HL). 
 
 
183 
 
The complete GLUT7pBF sequence with its key attributes, such as the SP6 
promoter site where in vitro transcription begins (green), is shown in Figure 6.2. 
This plasmid could be linearized using two restriction enzymes prior to the IVT 
reaction, namely MluI and PmlI (pink), as the restriction site for both enzymes is 
found after the PolyA tail (light purple), a stretch of sequence consisting of 
adenosine bases that aids with stability of mRNA and nuclear export (Fuke and 
Ohno, 2008). The site of linearization is where sequence template for the RNA 
polymerase ends, as does the transcription reaction (Beckert and Masquida, 
2011), and hence why it is important to opt for a restriction enzyme site after the 
PolyA tail. The GLUT7 gene (orange) was positioned after the transcription start 
site (SP6 promoter, green) and before the PolyA tail and transcription end site (MluI 
and PmlI, pink). The site of specific primers with homology to pBF and GLUT7 
sequences used in the ligation of the gene to the expression vector are shown in 
light grey (for full sequences refer to Chapter 2, section 2.3.3.2). Specific position 
of restriction sites of HindIII (dark grey) are shown in relation to the rest of the 
plasmid sequence and to each other. The same figure also illustrates a theoretical 
digestion of GLUT7pBF with the HindIII restriction enzyme, giving the theoretical 
products to be expected from gel electrophoresis reaction based on the DNA 
sequence. A table is shown in the same figure listing the precise location in the 
sequence for each of the HindIII restriction sites (third column), which in turn 
determine the sizes (in bp) of each digest (first column), as well as the percentage 
of the total mass for which the digest products account for (sixth column). 
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Figure 6-2 Illustration of the GLUT7pBF plasmid and theoretical gel 
electrophoresis products upon digestion of plasmid with HindIII restriction 
enzyme. Varying key attributes of the full GLUT7pBF sequence are shown 
including SP6 promoter (green) region, PmlI and MluI restriction sites (pink) 
and PolyA tail (light purple), as well as location of the inserted GLUT7 gene 
(orange) and specific homologous primers used in ligation reaction (light 
grey). Location of HindIII restriction sites in the GLUT7pBF sequence (dark 
grey) and the theoretical digestion of the sequence, including expected gel 
electrophoresis products, are shown around the circular plasmid structure. 
 
6.3.1.2 GLUT7pGEM-HE plasmid construct 
This plasmid was transformed into competent cells, propagated, and colonies were 
extracted to be digested with restriction enzymes in order to confirm presence of 
GLUT7 gene. Exact location of GLUT7 gene in expression vector pGEM-HE was 
determined using restriction enzyme and specific primer information previously 
published (Li et al., 2004) and confirmed through sequencing reactions (refer to 
Chapter 2 section 2.3.1 for list of primers used).  
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Figure 6-3 Illustration of the GLUT7pGEM-HE plasmid and theoretical gel 
electrophoresis products upon digestion of plasmid with HindIII and KnpI 
restriction enzymes. Varying key attributes of the full GLUT7pGEM-HE 
sequence are shown including T7 promoter (green) region, NheI restriction 
site (pink) and PolyA tail (light purple), as well as location of the inserted 
GLUT7 gene (orange) and the specific enzyme restriction sites used in the 
original ligation reaction (light grey). Location of HindIII and KpnI restriction 
sites in the GLUT7pGEM-HE sequence (dark grey) and the theoretical 
digestion of the sequence, including expected gel electrophoresis products, 
are shown around the circular plasmid structure. 
 
Figure 6.3 illustrates the complete GLUT7pGEM-HE sequence and its key 
features. The GLUT7 gene (orange) was positioned between the T7 promoter site 
(green) and PolyA tail (light purple) and NheI restriction enzyme site (pink). Specific 
primers used for PCR ligation reaction were designed to include the sequence 
corresponding to the sites of two restriction enzymes, BamHI and EcoRI (dark 
grey). This ensured correct positioning of the gene of interest in relation to other 
features of the expression vector, as previously mentioned in 5.3.1.1. A table is 
shown in the same figure listing the precise location in the sequence for each of 
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the restriction sites of the two restriction enzymes (third column), which in turn 
determine the sizes (in bp) of each digest (first column), as well as the percentage 
of the total mass for which the digest products account for (sixth column). 
 
Much like GLUT7pBF, this plasmid also contains two HindIII restriction sites, one 
in the pGEM-HE sequence and one within the sequence of the GLUT7 gene. 
However, proximity of the two restriction sites meant that the digestion product at 
the expression vector restriction site was 102 bp, which was not very clear on the 
gel following electrophoresis (Figure 6.4). For this reason, the plasmid was 
digested with the addition of another restriction enzyme, namely KpnI, which is only 
present in the pGEM-HE sequence and not in the GLUT7 gene sequence. 
Theoretical digestion of GLUT7pGEM-HE with both enzymes and the theoretical 
products to be expected from gel electrophoresis reaction based on the DNA 
sequence are shown in Figure 5.3. Of the six colonies extracted, only one was 
considered positive for the presence of the GLUT7 gene as it produced two clear 
products upon gel electrophoresis, namely one around 1500 bp, consistent with 
digestion of the sequence at the GLUT7 gene HindIII restriction site, and another 
about 3000 bp in size, corresponding to the digestion at the pGEM-HE KpnI 
restriction site. Control digestion of pGEM-HE plasmid without inserted GLUT7 
produced a single clear band product at around 3000 bp (Figure 6.4 A). DNA from 
the colony deemed positive for the presence of GLUT7 gene was sequenced, 
confirming agreement with the theoretical GLUT7pGEM-HE sequence. This colony 
(colony 5) was propagated and used for all subsequent experiments. Once 
propagated, GLUT7pGEM-HE, as well as pGEM-HE, were digested with HindIII 
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and KnpI and gel electrophoresis confirmed the presence, albeit faint, of the 
smaller product of about 200 bp in size consistent with the 102 bp product of 
digestion at the pGEM-HE HindIII restriction site (Figure 6.4 B).  
 
Figure 6-4 Gel electrophoresis image showing digestion of GLUT7pGEM-HE and 
its colonies with HindIII and KpnI after ligation of GLUT gene to expression 
vector. A colony positive for the presence of GLUT7 gene produced three 
individual bands [colony 5 (A)], while control digestions produced two bands 
(c). Comparison of circular GLUT7pGEM-HE (circ.) and digested product 
(digest) to pGEM-HE following plasmid propagation (B). Product sizes are 
comparable to the theoretical sizes of digestion of this sequence with HindIII 
and KpnI, namely around 102 bp (digestion at the pGEM-HE HindIII restriction 
site), 1541 bp (digestion at the GLUT7 gene HindIII restriction site) and 2930 
bp (digestion at the pGEM-HE KpnI restriction site). Size of products was 
determined against a DNA hyperladder (HL). 
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6.3.2 Confirmation of specificity and quality of mRNA product 
The IVT reactions were carried out  with linearized GLUT7pBF and GLUT7pGEM-
HE plasmids following digestion with restriction enzymes for which restriction sites 
were located after the gene of interest and PolyA tail. GLUT7pBF was linearized 
with either MluI or PmlI, and GLUT7pGEM-HE was digested with NheI. Gel 
electrophoresis of both circular plasmids showed the characteristic migration 
pattern  for the combination of nicked and supercoiled DNA, as previously 
mentioned in Chapters 4 and 5 (section 4.3.2 and 5.3.2, respectively). Linear DNA 
of GLUT7pBF produced by digestion with both MluI and NheI migrated through the 
gel producing a band corresponding in size to that of the full plasmid sequence 
(4865 bp), as did the linear DNA of GLUT7pGEM-HE from digestion with PmlI 
(4573 bp). The migration pattern of circular and linear DNA of both plasmids are 
shown in Figure 6.5. 
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Figure 6-5 Gel electrophoresis of circular and linear GLUT7pBF and 
GLUT7pGEM-HE. GLUT7pBF plasmid (circ.) was linearized by digestion with 
PmlI and MluI restriction enzymes (lin.) before IVT reaction (A). Circular 
GLUT7pGEM-HE plasmid (circ.) was linearized by digestion with NheI 
restriction enzyme (lin.) before IVT reaction (B). Both circular plasmids 
produced bands on the gel characteristic of their structure, whereas linear 
digests produced a single band corresponding in size to the sequence of the 
full plasmid (4865 bp and 4573 bp for GLUT7pBF and GLUT7pGEM-HE, 
respectively). Gel electrophoresis confirming linearization of plasmid and was 
performed for every new mRNA sample prepared. 
 
Once the IVT reaction was performed the mRNA product is analysed in a 
denaturing gel (see Chapter 2 section 2.3.5) in order to confirm that the product 
size was consistent with the expected size determined from the sequence of each 
plasmid. 
 
6.3.2.1 GLUT7pBF derived mRNA 
The mRNA product obtained from IVT of GLUT7pBF produced two band products 
following gel electrophoresis on RNA denaturing gel. Much the same as the GLUT2 
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mRNA which also produced two bands on denaturing gel (Chapter 5, section 
5.3.2), the GLUT7 mRNA produced two distinct bands, one at higher molecular 
weight (around 2000 bp) and one at lower molecular weight (around 1000 bp). 
However, unlike previously the size of the higher molecular weight band was in 
agreement with that expected of the GLUT7 mRNA derived from this plasmid (2276 
bp or 2341 bp by digestion with MluI or PmlI, respectively) (Figure 6.6 A). Bands 
were cut from the gel, RNA was extracted and gel electrophoresis of extracts was 
performed on another denaturing gel. RNA extracted from both the higher and 
lower molecular weight band migrated through the gel in the same manner as when 
present together in the original GLUT7 mRNA sample (Figure 6.6 B), meaning the 
IVT reaction produced two distinct products. The IVT kit user guide states that 
premature termination by the polymerase is the most likely cause for multiple 
products. Potential reasons for early termination by polymerase include sequences 
with resemblance to the polymerase termination signals, GC-rich templates, and 
stretches of a single nucleotide (mMessage mMachine ® Kit User Guide, Ambion). 
Analysis of plasmid sequence determined that GC was 57%, which is within the 
optimal range of 40-60% (Lorenz, 2012) and there were no identified long stretches 
of a single nucleotide. This led to the conclusion that the polymerase must have 
recognized a particular stretch of the sequence as a termination signal. Based on 
the size of the product upon gel electrophoresis this stretch of sequence with 
similarity to the termination site of the enzyme would be located within the GLUT7 
gene sequence, therefore, there was no possibility of adjusting the sequence to try 
and rectify the problem. The IVT reaction temperature was lowered to try and 
alleviate premature termination, however, no changes were observed (RNA 
denaturing gel of IVT reaction at different temperatures can be found in Figure 6.8). 
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Although the GLUT7 mRNA obtained from GLUT7pBF produced two products, 
only one product, where polymerase did not terminate prematurely, would contain 
all the features necessary for translation of product once microinjected. Therefore, 
uptake experiments were still carried out with oocytes microinjected with this 
mRNA. 
 
Figure 6-6 Gel electrophoresis of the GLUT7 mRNA product, derived from 
GLUT7pBF, on RNA denaturing gel. After IVT reaction the mRNA product 
was run on a formaldehyde denaturing gel to confirm that its size matched to 
that expected from the plasmid sequence (2276 bp or 2341 bp by digestion 
with MluI or PmlI, respectively). GLUT7 mRNA produced two bands, one at a 
size corresponding to that expected and one at a lower molecular weight (A). 
Individual bands were cut from the gel, RNA was extracted, and gel 
electrophoresis of extracts on denaturing gel was performed. Migration 
pattern of each extract on the gel showed that RNA from higher (H.MW) and 
lower (L.MW) molecular weight bands migrated through the gel in the same 
way as in original mRNA sample, meaning the IVT reaction produced two 
products (B). Size of products was determined against an ssRNA ladder. Gel 
electrophoresis of mRNA product on RNA denaturing gel was performed for 
every new mRNA sample prepared. 
 
As the GLUT7 gene sequence contained a particular stretch of sequence with 
resemblance to the termination signal of the SP6 RNA polymerase, it is possible 
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that a different polymerase would not recognize any sites in the gene sequence as 
a termination signal, thereby, producing one single mRNA product. This possibility 
was pursued by obtaining the GLUT7pGEM-HE plasmid, which contains the T7 
promoter. 
 
6.3.2.2 GLUT7pGEM-HE derived mRNA 
The mRNA product obtained from IVT of GLUT7pGEM-HE also produced two 
distinct band products following gel electrophoresis on RNA denaturing gel. The 
GLUT7 mRNA produced one higher molecular weight (around 5000 bp) product 
and one lower molecular weight product (around 2000 bp). As seen previously with 
the GLUT2 mRNA, the lower molecular weight band was in agreement with that 
expected of the GLUT7 mRNA derived from this plasmid (1888 bp) (Figure 6.7 A). 
Bands were cut from the gel, RNA was extracted and gel electrophoresis of 
extracts was performed on another denaturing gel. Extracted RNA from both the 
higher molecular weight band and lower molecular weight band migrated through 
the gel in the same manner as in the original GLUT7 mRNA sample (Figure 6.6 B). 
Although this did not confirm that the higher molecular weight product was leftover 
secondary structure, as discussed previously (Chapter 5 section 5.3.2), this is 
extremely likely based on the size of the product (around 4000 bp). Uptake 
experiments were carried out with oocytes microinjected with this mRNA. 
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Figure 6-7 Gel electrophoresis of GLUT7 mRNA product, derived from 
GLUT7pGEM-HE, on an RNA denaturing gel. After IVT reaction, the mRNA 
product was run on a formaldehyde denaturing gel to confirm that its size 
matched  that expected from the plasmid sequence (1888 bp). GLUT7 mRNA 
produced two bands, one at a size corresponding to that expected and one 
at a higher molecular weight (A). Individual bands were cut from the gel, RNA 
was extracted, and gel electrophoresis of extracts on denaturing gel was 
performed. Migration pattern of each extract on the gel confirms that the 
higher molecular band (H.MW) consists of left over secondary structure while 
the lower molecular weight band (L.MW) corresponds to the mRNA product 
size (B). Size of products was determined against an ssRNA ladder. Gel 
electrophoresis of mRNA product on RNA denaturing gel was performed for 
every new mRNA sample prepared. 
 
The GC content of this sequence was within range (57%) and lowering of the IVT 
reaction temperature (usually performed at 37 °C), although seemingly increasing 
specificity, significantly reduced the yield of mRNA product. Lower temperatures 
for IVT reaction also decreased the concentration of mRNA products derived from 
GLUT7pBF plasmid (linearized with either PmlI or MluI restriction enzymes), with 
no conclusive improvements in mRNA quality or specificity (Figure 6.8).  
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Figure 6-8 Gel electrophoresis of GLUT7 mRNA products, derived from 
GLUT7pGEM-HE and GLUT7pBF linearized with PmlI or MluI, on an RNA 
denaturing gel. mRNA products from IVT reactions performed at 10 °C (10), 
20 °C (20) or 30 °C (30) were run on a formaldehyde denaturing gel to 
determine any improvements in specificity and quality of mRNA. Specificity of 
mRNA products derived from GLUT7pGEM-HE plasmid improved, however, 
yield was significantly reduced. There were no changes in specificity of mRNA 
products derived from GLUT7pBF plasmid (linearized with either MluI or 
PmlI), with two distinct products still being produced. Concentrations of mRNA 
products were also reduced for samples derived from this plasmid at the lower 
IVT reaction temperatures.  
 
6.4 Validation of X. laevis model functionality 
6.4.1 Sugar uptake by GLUT7-expressing oocytes and inhibition by 
known specific inhibitors 
There are contradicting reports of what the substrate(s) of GLUT7 may be. While 
some have detected uptake of both glucose and fructose, but not galactose or 
deoxy-glucose, by this transporter (Li et al., 2004) others have not observed uptake 
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of any sugars by oocytes microinjected with GLUT7 mRNA (Ebert et al., 2017). 
Presence of GLUT7 on the membranes of GLUT7-injected oocytes was shown in 
both instances (Li et al., 2004), (Ebert et al., 2017). In order to assess the possible 
transport of sugars by GLUT7 uptake experiments by oocytes expressing GLUT7 
were carried out under conditions previously optimised (Li et al., 2004), namely 
oocytes were incubated at 25 °C in a 0.1 mM sugar solution for 5 min following a 
5 day expression period post-microinjection. For all uptake experiments in this 
chapter one replicate is equivalent to 3 oocytes homogenized together, unless 
otherwise stated. Oocytes microinjected with GLUT7 mRNA derived from 
GLUT7pBF showed a significant uptake of glucose as well as fructose (Figure 6.8 
A). Similarly, significant glucose and fructose uptake, but not of deoxy-glucose 
(70% less uptake than glucose, p ≤ 0.01), was observed by oocytes microinjected 
with GLUT7 mRNA derived from GLUT7pGEM-HE (Figure 6.9 B). In addition, 
glucose uptake by GLUT7 seems to be inhibited in the presence of fructose (42% 
less uptake of glucose in the presence of fructose, p ≤ 0.01) (Figure 6.9 A), which 
is in accordance with previously reported uptake experiments (Li et al., 2004). 
 
To date there have been no accounts of GLUT7 inhibitors, with compounds such 
as phloretin and cytochalasin B having no impact on glucose uptake by this 
transporter, as previously demonstrated  (Li et al., 2004) and assessed here by 
oocytes microinjected with GLUT7 mRNA derived from both the GLUT7pBF 
(Figure 6.10 A) and GLUT7pGEM-HE plasmids (Figure 6.10 B). Water injected 
oocytes were used as controls in all uptake experiments. Results of uptake by 
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GLUT7-expressing oocytes are shown normalized to the uptake observed by their 
respective water injected controls, unless otherwise stated.  
 
Figure 6-9 Uptake of sugars by GLUT7-expressing oocytes. Five days post GLUT7 
mRNA microinjection oocytes were incubated in 0.1 mM glucose/ fructose/ 
deoxy-glucose solution containing the corresponding [14C] sugar for 30 min. 
Internalized sugar uptake was determined by scintillation spectrometry for 
GLUT7-expressing oocytes (black bars) and water injected controls (open 
bars). Net change in uptake, Δ, (grey bars) was determined by normalizing 
the uptake observed by GLUT7 to control uptake. The mean ± SEM of 6 
replicates (of 3 oocytes) is shown per individual condition. There was 
significant uptake of glucose, inhibited by the presence of fructose, by oocytes 
injected with GLUT7 mRNA derived from GLUT7pBF (A). Uptake of glucose 
and fructose, but not deoxy glucose, was observed by oocytes injected with 
GLUT7 mRNA derived from GLUT7pGEM-HE (B). ** p ≤ 0.01 
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Figure 6-10 Inhibition of glucose uptake by GLUT7-expressing oocytes. Five days 
post GLUT7 mRNA microinjection oocytes were incubated in 0.1 mM glucose 
solution containing [14C] glucose for 30 min in the presence of 100 µM 
phloretin or 100 µM cytochalasin B (cytoB). Internalized sugar uptake was 
determined by scintillation spectrometry for GLUT7-expressing oocytes 
(black bars) and water injected controls (open bars) (A). Net change in 
uptake, Δ, (grey bars) was determined by normalizing the uptake observed 
by GLUT7 to control uptake. Neither cytochalasin B nor phloretin inhibited 
uptake of glucose by oocytes injected with GLUT7 mRNA derived from 
GLUT7pBF (A) or GLUT7 mRNA derived from GLUT7pGEM-HE (B). Each 
data point represents the mean of 6 replicates (of 3 oocytes), normalized to 
control for each condition, ± SEM. 
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6.4.2 Determination of expression of recombinant hGLUT7 on oocytes 
membrane extracts 
Automated capillary Western blot, Wes (see Chapter 2 section 2.4.7), was used to 
investigate expression of GLUT7 on oocyte membranes. Membranes were 
extracted from 10 oocytes 5 days post-microinjection with GLUT7 mRNA or water. 
Cell lysate from TC7 cells was used as a positive control for the presence of 
GLUT7. Detection of GLUT7 was only successful in membranes extracted from 
oocytes microinjected with mRNA derived from the GLUT7pGEM-HE plasmid 
(Figure 6.11), with size comparable to protein detected in the TC7 cell lysate. 
Nevertheless, there was substantial non-specific binding from the antibody in the 
membrane extract samples, creating a much stronger signal than that observed for 
GLUT7 (Figure 6.12 A). The GLUT7 antibody used for protein detection targets the 
glycosylated epitope and so membrane extracts, as well as the TC7 cell lysate, 
were treated with the glycosidase PNGase before imaging with the aim to enhance 
detection. A shift in size was clearly observed between PNGase-treated and 
untreated membrane samples from GLUT7-microinjected oocyte membranes (shift 
from about ~ 59 kDa to about ~ 48 kDa after PNGase treatment), serving as further 
confirmation that the peak in question did in fact correspond to GLUT7 protein 
(Figure 6.12 B). Optimal GLUT7 antibody dilution of 1:10 for Wes experiments was 
determined by Dr. S. Tumova. 
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Figure 6-11 Confirmation of expression of GLUT7 on oocyte membrane extracts 
by Wes. Membranes extracted from ten oocytes five days post injection with 
GLUT7 mRNA, as well as water injected control membranes, were analysed 
using automated capillary Western blot (Wes). Analysis of membrane extracts 
of GLUT7 and control injected oocytes (A) and the positive control TC7 cell 
lysate shown as a gel-like imagine (B). The same TC7 cell lysate (C) and 
GLUT7, isolated and magnified from original image, and control injected 
membrane extracts (D) are shown as an electropherogram (C). Detected 
protein size for GLUT7 was 52 kDa for oocyte membrane extract and 50 kDa 
for TC7 cell lysate. Concentration of TC7 cell lysate loaded was 0.5 mg/ml; 
membrane extracts were loaded without dilution. Antibody dilution was 1:10. 
 
The difficulty in obtaining a clear detection of GLUT7 on oocyte membrane samples 
could be explained by the fact that, in general, GLUT transporters are prone to 
aggregation. Although a treatment with detergent is performed on the membrane 
extract samples prior to protein analysis it is possible that the sample is not entirely 
digested and that the antibody binding site on the GLUT7 proteins is not fully 
accessible, causing not all the available protein to be detected. Another possibility 
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is that the unspecific binding sites are preferred by the antibody, decreasing the 
signal for GLUT7 even further. Nevertheless, the lower expression of this 
transporter on oocyte membranes, particularly when compared to other GLUTs 
and cell lysates, is the most likely cause of its weak detection.  
 
A  layer of follicular cells surrounds the oocytes, separating it from the external 
environment, has been reported to express ion channels as well as transporters 
(Miledi and Woodward, 1989a), (Miledi and Woodward, 1989b). Presence of this 
follicular cells interferes mostly with electrophysiological recordings, nevertheless, 
it is removed prior to microinjections by treatment with collagenase (Browne and 
Werner, 1984). This also facilitates the microinjection procedure by eliminating 
some of the resistance when piercing the oocyte cell membrane with the 
micropipette (Bianchi, 2006). Although unlikely, any remaining follicular cells 
present in the membrane extract samples could potentially lead to non-specific 
proteins being recognized by the GLUT7 antibody and contributing to the non-
specific signal observed in these samples.  
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Figure 6-12 Confirmation of expression of GLUT7 on oocyte membranes. 
Membranes, extracted from ten oocytes five days post injection with GLUT7 
mRNA, as well as water injected control membranes, were analysed using 
automated capillary Western blot (Wes). Electropherogram from analysis of 
membrane extracts of GLUT7 and control injected oocytes, displaying the 
antibody un-specific binding in relation to the GLUT7 signal (A). The same 
sample, isolated and magnified from original, compared to itself with (G7 5 
days) and without (mock PNGase) PNGase digestion (B). The shift in size 
from untreated (59 kDa) to treated (48 kDa) confirms that this peak does in 
fact correspond to GLUT7 protein. Membrane extracts were un-diluted. 
Antibody dilution was 1:10. 
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6.5 Uptake experiment results and discussion 
In order to attribute inhibition of GLUT7-mediated glucose/fructose transport by a 
specific compound or extract oocytes expressing this transporter were incubated 
in a sugar solution, containing 14C-glucose/fructose, in the presence and absence 
of each compound/extract. Uptake inhibition experiments were conducted using 
two plant extracts and compounds also used in GLUT5 and GLUT2 uptake 
inhibition studies presented in the previous chapters (Chapter 4 and 5), with the 
aim to identify common inhibitors of all transporters. Furthermore, both plant 
extracts (German chamomile and green tea) were being used, or would in the 
future be used, in human studies conducted by other individuals in the research 
group (Villa-Rodriguez et al., 2017a), (Nyambe-Silavwe and Williamson, 2016). In 
other words, extract were chosen with the aim to validate results within the 
research group and to attribute inhibition to specific transporters. The pure 
compounds apigenin, EGCG and quercetin were also chosen to conduct 
concentration dependent GLUT7-mediated glucose and fructose uptake inhibition 
experiments for two of these compounds were shown to inhibit fructose uptake by 
GLUT5 (apigenin and EGCG, Chapter 4), and all three inhibited GLUT2-mediated 
glucose and fructose uptake (Chapter 5). Considering the research objective of 
investigating the inhibition profile of GLUT2, GLUT5 and GLUT7, and identifying 
novel inhibitors of these transporters, these compounds were thought to be good 
candidates. GLUT7 uptake inhibition studies were only conducted with the plant 
extracts and pure compounds mentioned above due to the amount of time required 
for oocyte microinjections and to perform inhibition studies. All extracts and 
compounds used in the uptake inhibition studies by GLUT7 described in this 
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chapter are listed in Table 6.1. Inhibition of GLUT7 fructose and glucose uptake 
was conducted with pure compounds as previously performed with GLUT2, which 
also transports both sugars (Chapter 5). Compounds used in concentration 
dependent GLUT7-mediated fructose and glucose uptake inhibition studies are 
marked in Table 6.1 with an asterisk.   
 
Table 6-1 Compounds/extracts used in GLUT7-mediated glucose/fructose uptake 
inhibition studies described in this chapter 
Compound/ extract Inhibition of GLUT7 mediated sugar 
uptake 
Apigenin * Glucose and fructose 
Cytochalasin B Glucose 
EGCG * Glucose and fructose 
German chamomile Glucose 
Green tea Glucose 
Phloretin Glucose 
Quercetin * Glucose and fructose 
* compounds for which a uptake inhibition experiments were carried out with two 
GLUT7 substrates. 
 
6.5.1 Effect of extracts on glucose uptake by GLUT7 
The effect of plant extracts on glucose uptake by GLUT7 was investigated by 
incubation of microinjected oocytes at 25 °C in a 0.1 mM glucose solution with 
radiolabelled glucose and increasing concentrations of a particular extract. 
Oocytes were microinjected with GLUT7 mRNA derived from either GLUT7pBF or 
GLUT7pGEM-HE in order to directly compare the quality of both mRNA products 
and their glucose uptake profiles. Presence of German chamomile or green tea 
extracts did not influence the uptake of glucose by GLUT7 in oocytes microinjected 
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with mRNA derived from GLUT7pBF (Figure 6.13 A and C) or GLUT7pGEM-HE 
(Figure 6.13 B and D).  
 
Figure 6-13 Effect of plant extracts on glucose uptake by GLUT7-expressing 
oocytes. Five days post GLUT7 mRNA microinjection oocytes were incubated 
in 0.1 mM glucose solution containing [14C] glucose for 30 min at 25 °C in the 
presence of increasing concentrations of German chamomile (0-1 mg/ml) (A, 
B) and green tea (0-0.25 mg/ml) (C, D) extracts. Neither German chamomile 
nor green tea extract had an impact on glucose uptake by oocytes 
microinjected with mRNA derived from GLUT7pBF plasmid (A, B) or 
GLUT7pGEM-HE plasmid (C, D). Each data point represents the mean of 6 
replicates (of 3 oocytes), normalized to control for each condition, ± SEM. 
 
Variation between replicates was again a substantial problem when it came to 
uptake experiments with GLUT7-expressing oocytes. This variability can be 
partially attributed to the biological differences in oocytes derived from different 
ovaries coming from varying females, as well as the previously discussed  (refer to 
Chapter 4, section 4.5.1) seasonal component affecting the ability of oocytes to 
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express heterologous proteins (Delpire et al., 2011) (Conn, 1991). In addition, the 
quality of the mRNA microinjected into the oocytes may also contribute to the 
observed variability. As an example, GLUT7pBF plasmid produced two distinct 
mRNA products, and while only one could be translated into GLUT7 both 
contributed to the measurement of mRNA concentration. In other words, the 
precise amount of the translatable mRNA in the total mRNA sample was not 
determined and it is likely that only a fraction of the concentration of the total mRNA 
microinjected into oocytes corresponded to the translatable mRNA product. 
Furthermore, multiple products were also produced following IVT reaction with 
linear GLUT7pGEM-HE plasmid. Although this was highly likely leftover secondary 
structure it still represented a fraction of the overall mRNA concentration, meaning 
that less translational mRNA was injected into the oocytes, potentially leading to 
less protein expression on membrane of varying oocytes. 
  
6.5.2 Effect of pure compounds on glucose and fructose uptake by 
GLUT7 
The direct impact of pure compounds on glucose and fructose uptake by GLUT7 
was measured using the same experimental conditions as for the extracts, namely 
oocytes were incubated in a 0.1 mM sugar solution for 30 min at 25 °C. Unlike 
previous uptake experiments with the GLUTs however, where 3 oocytes were 
homogenized together, here 10 oocytes were grouped and homogenized together 
in an effort to potentially decrease variability between replicates. Each data point 
represents the mean of 3 replicates ± SEM. Oocytes were microinjected with either 
water, to serve as controls, or mRNA derived from GLUT7pGEM-HE plasmid. To 
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add to that, mRNA obtained from IVT reaction with GLUT7pBF plasmid linearized 
with either PmlI or MluI were used in oocyte microinjection, in order to rule out any 
potential mRNA quality differences products derived from DNA linearized with 
these enzymes. Uptake of glucose and fructose by GLUT7-expressing oocytes, by 
means of injection with all each individual mRNA product, was unchanged in the 
presence of 100 µM quercetin (Figure 6.14 A and B). Similarly, there was no 
significant change in fructose uptake by GLUT7-expressing oocytes in the 
presence of 500 µM EGCG (Figure 6.15 B). Interestingly, however, there was a 
significant change (46% reduction at 500 µM, p ≤ 0.05) observed in glucose uptake 
from oocytes microinjected with mRNA derived from IVT reaction or GLUT7pBF 
plasmid when it was linearized with MluI restriction enzyme (Figure 6.15 A). Only 
an uptake reduction trend was noted for the GLUT7-expressing oocytes by means 
of microinjection with the other two mRNA products; 39% reduction in uptake  (p = 
0.06) and 30% reduction in uptake (p = 0.07) for GLUT7pGEM-HE plasmid derived 
mRNA microinjected oocytes and oocytes injected with GLUT7pBF plasmid 
linearized with PmlI mRNA, respectively (Figure 6.15 A). Glucose transport by 
GLUT7-expressing oocytes was unaffected by the presence of 50 µM apigenin 
(Figure 6.16 A). Nevertheless, there was a significant decrease in fructose 
transport by oocytes microinjected with mRNA derived from GLUT7pGEM-HE and 
oocytes injected with GLUT7pBF plasmid linearized with PmlI mRNA (53% and 
45% reduction in uptake at 50 µM for GLUT7pGEM-HE and GLUT7pBF mRNA 
injected oocytes, respectively, p ≤ 0.05) (Figure 6.16 B). No significant change in 
fructose uptake by oocytes microinjected with mRNA derived from GLUT7pBF 
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plasmid linearized by MluI was observed. This was predominantly due to the large 
variability observed between the replicates for this particular sample and condition.  
 
Additionally, a concentration dependent uptake experiment in the presence of 
apigenin was carried out with oocytes microinjected with mRNA derived from 
GLUT7pGEM-HE plasmid. Apigenin significantly, and concentration dependently, 
inhibited GLUT7-mediated fructose uptake (IC50 = 16 ± 12 µM) (Figure 6.17 B). In 
this experiment, GLUT7-mediated glucose uptake was also significantly inhibited 
by apigenin, at its highest concentration (IC50 = 38 ± 2 µM) (Figure 6.17 A). 
Differences in protein expression, brought about by biological variations between 
oocytes, and affinity of GLUT7 for glucose and fructose could help explain why 
fructose uptake by this protein was more prominently affected in the presence of 
apigenin. Similar experiments with GLUT2-expressing oocytes have observed 
significant differences in inhibition of glucose and fructose uptake with the same 
inhibitor (Kwon et al., 2007). For instance, the quercetin precursors isoquercitrin 
and spiraeoside were almost twice as effective at inhibiting GLUT2-mediated 
fructose uptake when compared to glucose uptake. To add to that, quercetin and 
phloretin almost completely inhibited GLUT2-mediated glucose uptake, being not 
as potent inhibitors of fructose uptake by this same transporter (Kwon et al., 2007). 
Uptake experiments in cells overexpressing GLUT7 could help determine if higher 
levels of protein expression are needed in order for an inhibition of glucose uptake 
by apigenin to be detectable.  
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Figure 6-14 Effect of quercetin on sugar uptake by GLUT7-expressing oocytes. 
Five days post GLUT7 mRNA microinjection oocytes were incubated in 0.1 
mM glucose/fructose solution containing the corresponding [14C] sugar for 30 
min in the presence of 100 µM quercetin. Internalized sugar uptake was 
determined by scintillation spectrometry for protein expressing oocytes and 
control oocytes in sugar solution only (black bars) and in the presence of 100 
µM quercetin (grey bars). Quercetin did not have an effect on either glucose 
uptake (A) or fructose uptake (B) by oocytes microinjected with mRNA 
derived from GLUT7pGEM-HE plasmid (T7) or mRNA derived from 
GLUT7pBF plasmid following linearization with PmlI or Mlul restriction 
enzymes. Each data point represents the mean of 3 replicates (of 10 oocytes) 
± SEM. 
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Figure 6-15 Effect of EGCG on sugar uptake by GLUT7-expressing oocytes. Five 
days post GLUT7 mRNA microinjection oocytes were incubated in 0.1 mM 
glucose/fructose solution containing the corresponding [14C] sugar for 30 min 
in the presence of 500 µM EGCG. Internalized sugar uptake was determined 
by scintillation spectrometry for protein expressing oocytes and control 
oocytes in sugar solution only (black bars) and in the presence of 500 µM 
EGCG (grey bars). EGCG significantly inhibited glucose uptake by oocytes 
microinjected with mRNA derived from GLUT7pBF linearized with Mlul (46% 
reduction at 500 µM, p ≤ 0.05) and an inhibition ‘trend’ was observed for the 
other mRNA samples (A). EGCG had no effect on fructose uptake by oocytes 
microinjected with mRNA derived from GLUT7pGEM-HE plasmid (T7) or 
mRNA derived from GLUT7pBF plasmid following linearization with PmlI or 
Mlul restriction enzymes (B). Each data point represents the mean of 3 
replicates (of 10 oocytes) ± SEM. * p ≤ 0.05 
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Figure 6-16 Effect of apigenin on sugar uptake by GLUT7-expressing oocytes. 
Five days post GLUT7 mRNA microinjection oocytes were incubated in 0.1 
mM glucose/fructose solution containing the corresponding [14C] sugar for 
30 min in the presence of 50 µM apigenin. Internalized sugar uptake was 
determined by scintillation spectrometry for protein expressing oocytes and 
control oocytes in sugar solution only (black bars) and in the presence of 50 
µM apigenin (grey bars). Apigenin did not have an effect on glucose uptake 
or by oocytes microinjected with mRNA derived from GLUT7pGEM-HE 
plasmid (T7) or mRNA derived from GLUT7pBF plasmid following 
linearization with PmlI or Mlul restriction enzymes (A). Apigenin significantly 
inhibited fructose uptake by oocytes microinjected with mRNA derived from 
GLUT7pGEM-HE (53% reduction in uptake at 50 µM) and oocytes injected 
with GLUT7pBF plasmid linearized with PmlI mRNA (45% reduction in 
uptake at 50 µM) (B). Each data point represents the mean of 3 replicates 
(of 10 oocytes) ± SEM. * p ≤ 0.05 
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Figure 6-17 Effect of apigenin on sugar uptake by GLUT7-expressing oocytes. 
Five days post GLUT7 mRNA microinjection oocytes were incubated in 0.1 
mM glucose/fructose solution containing the corresponding [14C] sugar for 30 
min in the presence of increasing concentrations of apigenin (0-50 µM). 
Apigenin significantly inhibited glucose uptake (66% inhibition at 50 µM) (A) 
and fructose uptake (IC50 = 29 ± 10 µM) (B) by oocytes microinjected with 
mRNA derived from GLUT7pGEM-HE. Each data point represents the mean 
of 3 (A) or 6 replicates (B) (of 10 oocytes), normalized to control for each 
condition, ± SEM. * p ≤ 0.05 
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Figure 6-18 Dot plot representing values for uptake by control oocytes in single 
uptake experiments with 3 and 10 oocytes. This figure represents the uptake 
by water injected control oocytes after incubation in [14C] sugar, for 30 min, in 
the absence of any (poly)phenol or extract. Each individual dot represents 
one replicate. Uptake by samples containing 10 oocytes homogenized 
together was higher than that observed by samples of 3 oocytes only, as 
expected. Variation in uptake is similar for both groups.  
 
A dot plot of the specific uptake by water-injected control oocytes in single sugar 
uptake experiments with 3 and 10 oocytes, in the absence of any (poly)phenol or 
extracts, is shown in Figure 6.18 above. Sugar uptake by individual samples 
containing 10 oocytes homogenized together was higher than that observed by 
samples of 3 oocytes only, as expected. Some biological variation is observed, 
however, this is relatively comparable between the two groups. It can be 
concluded, therefore, that the variation is an attribute of varying levels protein 
expression in the oocytes.  
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6.5.3 Summary of results from glucose and fructose uptake 
experiments 
The results presented here show that GLUT7, when expressed in oocytes, is able 
to transport both glucose and fructose. This goes against previous findings by 
Ebert at al, where sugar uptake by oocytes expressing GLUT7 was not detected 
(Ebert et al., 2017). Nevertheless, experiments executed by this group were 
performed using oocytes microinjected with less GLUT7 mRNA (13.8 ng as 
opposed to 50 ng microinjected into oocytes used in the experiments above) and 
with a shorter expression period post-microinjection, namely, 4 days. To add to 
that, oocytes were incubated in a sugar solution of higher concentration (1 mM) for 
a shorter period of time of 10 min only. Other differences between experiment 
protocols include digested oocyte storage conditions, radiolabelled substrate 
concentration, and wash solution. Furthermore, non-injected oocytes, instead of 
water injected oocytes, were used as controls in experiments performed by this 
group, which does not properly control for the microinjection procedure itself and 
the oocyte pigmented ring scar caused by the micropipette prick (O'Connell et al., 
2011). The quality of the oocytes could also have affected membrane protein 
expression, a problem which was faced when expressing the GLUTs during this 
project as well. An investigation of husbandry facilities by Delpire at al found that 
animals kept in static water facilities, as opposed to recirculating water facilities, 
led to a much more robust and reproducible expression of the heterologously 
expressed transporter of interest. In addition, oocytes isolated from females kept 
in recirculating facilities showed a significant deterioration during the summer 
months (April to August) (Delpire et al., 2011), an issue previously reported by 
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other researchers (Conn, 1991). To add to this, once the oocytes are extracted 
from the ovary they are susceptible to microbial contaminations, leading to black 
foci on the oocyte animal pole and deterioration in the health of the oocyte 
(O'Connell et al., 2011). This group found that bacteria, which become associated 
with oocytes are susceptible to amikacin and ciprofloxacin, which should be added 
to oocyte storage solution to avoid contamination of oocytes (O'Connell et al., 
2011). Oocytes used for the experiments presented in this chapter were obtained 
by extraction from ovaries of females kept in a recirculating facility (European 
Xenopus Resource Centre, University of Portsmouth, UK), which most likely played 
a role in the variability seen between individual experiments, based on the 
observations discussed above. Moreover, oocyte storage solution contained 
amikacin and ciprofloxacin, however, contaminations did occasionally occur, in 
which case oocytes were not used for experiments and disposed of. Oocytes at 
stage V-VI of development were visually selected for uptake experiments as 
endogenous transporter activity is not only variable between batches of oocytes 
but in oocytes of different developmental stages. This has a particular impact on 
membrane permeability, intracellular ion concentrations and surface pattern of 
extracellular currents (Miller and Zhou, 2000). Nonetheless, as the method of 
selection is purely visual it is possible that oocytes in transition to or from stage V-
VI were selected for uptake experiments, adding another factor that could 
contribute to variability between experiments. This again highlights the importance 
of a control from the same batch of eggs injected with a similar volume of water.   
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The concluding findings that GLUT7 does in fact transport glucose and fructose 
corroborated previous observations by Li et al, where GLUT7 microinjected 
oocytes were incubated at similar conditions to those applied to uptake 
experiments presented in this chapter, namely oocytes were incubated in 0.1 mM 
sugar solution for 30 min 5 days post-microinjections (Li et al., 2004). Furthermore, 
the determinations that GLUT7 is not inhibited by either phloretin or cytochalasin 
B, and that glucose uptake by the transporter is significantly inhibited in the 
presence of fructose are in agreement with previous observations by the same 
group (Li et al., 2004).  By confirming that fructose is in fact transported by GLUT7 
these results also fit with the hypothesis that a conserved isoleucine-containing 
motif present in GLUTs 2, 5 and 7 may be essential for the transport of fructose 
(Manolescu et al., 2005). 
 
Detection of GLUT7 protein on oocyte membrane samples was only achieved in 
samples microinjected with mRNA derived from GLUT7pGEM-HE plasmid. 
Nevertheless,  non-specific binding signal was high in both mRNA injected and 
water injected oocyte membrane samples. This suggests that the antibody used 
for protein detection recognises a particular protein(s) present in the oocyte 
membrane. It is also possible that this unspecific binding site is preferred by the 
antibody, meaning that effectively less GLUT7 than is available is detected. In other 
words, the antibody is ‘used up’ by the non-specific band. In addition, as GLUT 
transporters are prone to aggregation, the binding site of the antibody on GLUT7 
could have not been fully accessible. These observations could explain why no 
GLUT7 was detected in oocyte membrane samples following microinjection with 
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GLUT7pBF plasmid derived mRNA. Nonetheless, the lower expression of this 
protein when expressed on oocytes membranes, particularly when compared to 
the other GLUTs, is likely to be the main cause of limited protein detection.  
 
A novel finding from the GLUT7 uptake experiments in the presence of individual 
compounds was that apigenin significantly inhibited the uptake of fructose (IC50 = 
16 ± 12 µM) and glucose (IC50 = 38 ± 2 µM) by this transporter. The structure of 
this compound is shown in Table 6.2. Initially, a reduction in GLUT7-mediated 
uptake was only observed for fructose, and not for glucose. Moreover, although 
there was a decrease in GLUT7-mediated glucose uptake by oocytes microinjected 
with PmlI linearized GLUT7pBF plasmid derived mRNA, this was not significant. In 
a subsequent concentration dependent uptake experiment, however, there was a 
significant decrease in glucose uptake by GLUT7 following oocyte microinjection 
with mRNA derived from GLUT7pGEM-HE plasmid. This occurrence could be 
explained by differences in protein expression, attributed to biological variations 
between oocytes, as well as the affinity of GLUT7 for glucose and fructose. The 
pure compound EGCG also demonstrated potential as an inhibitor of glucose 
uptake by GLUT7. Presence of quercetin had no impact on either glucose or 
fructose uptake by GLUT7. Although apigenin did not significantly inhibit fructose 
uptake by GLUT7-expressing oocytes following microinjection with MluI linearized 
GLUT7pBF plasmid derived mRNA, this was due to the high variability between 
the experimental replicates. In the same way, when microinjected with this same 
mRNA, oocytes incubated in the presence of EGCG demonstrated a significantly 
reduced uptake of glucose (p ≤ 0.05), while only a trend (p = 0.06) was observed 
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for the other two mRNA products. Even though sugar uptake confirms GLUT7 
expression on oocyte membranes following GLUT7pBF plasmid derived mRNA 
microinjection, regardless of which restriction enzyme was used in the linearization 
step, protein was not detectable by automated Western blotting (Wes). For this 
reason, the overall conclusions of the effect of pure compounds on GLUT7 sugar 
uptake were a consequence of the analysis of results obtained from oocytes 
microinjected with mRNA derived from GLUT7pGEM-HE plasmid. The plant 
extracts German chamomile and green tea did not have any effect on glucose 
uptake by GLUT7-expressing oocytes, although these experiments had a high 
variability between replicates which could have masked an inhibition by these 
extracts. Overall it can be concluded that the GLUT7 in X. laevis oocytes 
expression model was successful at determining the sugar transport capability of 
this protein as well as a novel inhibitor. The structure of apigenin could be 
considered in conjunction with sequence alignment results and point mutation 
studies for the further characterization of this transporter in terms of substrate-
protein interactions and substrate binding. 
 
Table 6-2 Structure of apigenin and its inhibition of GLUT7 sugar uptake 
Compound Substrate Inhibition Structure 
Apigenin Glucose and 
fructose 
IC50G = 38 ± 2 
µM 
IC50F = 16 ± 12 
µM 
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Chapter 7  
Summary discussion, future perspectives and conclusions 
 
7.1 Research rationale and objectives  
7.1.1 The role of (poly)phenols in CVD and T2DM prevention 
CVD is the number one cause of death worldwide, with coronary heart disease 
(CHD) alone being responsible for over 1 million deaths annually within the 
European Union (Nichols et al., 2014). Nonetheless, the rates of CVD progression 
in many developed European countries, including the UK, are in decline (Gale et 
al., 2012), (Threapleton et al., 2013). This reduction in CVD has been attributed to 
improvements in risk factors for CVD, particularly by means of lifestyle changes 
(Unal et al., 2004), (Jennings et al., 2009). One of the main risk factors associated 
with CVD is diabetes, with diabetic patients being classed as at high risk of CVD 
regardless of other potential risk factors (Jennings et al., 2009). Nearly 5% of the 
world’s population is affected by diabetes, with T2DM accounting for 90-95% of 
cases worldwide (Hajiaghaalipour et al., 2015). According to the World Health 
Organisation’s projections the number of people suffering from diabetes will reach 
more than 300 million by 2025 (Fayaz and Suvanish Kumar, 2014). Lifestyle 
intervention, risk factor management and cardioprotective drugs are able to 
significantly reduce morbidity and mortality in patients with established CVD and 
those at high risk of developing disease (Wood et al., 2008), (Jennings et al., 2009). 
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Nevertheless, pharmaceutical drugs used in the treatment of diabetes in many 
countries worldwide, such as acarbose an metformin, are commonly accompanied 
by side effects and discomfort, such as nausea, flatulence and diarrhoea 
(Chiasson, 2006), (Coniff et al., 1995), (Holman, 2007). Although the clinical 
benefits of metformin were confirmed in clinical trials, such as the UK Prospective 
Diabetes Study, up to 25% of patients suffered from metformin-associated 
gastrointestinal side effects, with approximately 5% not being able to tolerate the 
drug (McCreight et al., 2016), (Dujic et al., 2015). This has contributed to a rise in 
use of herbal medicine in the treatment of diseases in recent years, particularly 
due to their natural origin and reduced side effects (Modak et al., 2007). Dietary 
intake of (poly)phenols is estimated to be of ~ 1 g/day per person, with many of 
these compounds having a positive effect on reduction of disease risk factors 
associated with CVD and diabetes, as previously described in Chapter 1 (de Bock 
et al., 2012), (Lim et al., 2010). For instance, administration of green tea 
significantly reduced blood pressure after a three week period (Nantz et al., 2009), 
with a  reduction in LDL-cholesterol also being attributed to compounds in this 
beverage (Maron et al., 2003). In addition, total and LDL-cholesterol were 
decreased after consumption of a controlled diet with black tea (Davies et al., 
2003). Coffee has also been linked to T2DM reduction, possibly due to LDL-
cholesterol and fasting glycaemia lowering properties (van Dam and Feskens, 
2002), (Pimentel et al., 2009), (Manach et al., 2004). Furthermore, cocoa 
(poly)phenols have been shown to increase HDL-cholesterol, decrease blood 
pressure, as well as reduce relative risk of CVD (Buijsse et al., 2010), (Mellor et 
al., 2010). 
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7.1.2 Effect of (poly)phenols on carbohydrate uptake and digestion  
Many (poly)phenols have been shown to have an effect on sugar digestion, as well 
as uptake and post-prandial distribution of glucose and fructose, as previously 
discussed in Chapter 1. For instance, (poly)phenol consumption has been shown 
to have a positive impact on glycaemic control in several meta-analysis studies, 
(Liu et al., 2014), (Hooper et al., 2012), (Zheng et al., 2013), (Shrime et al., 2011), 
(Palma-Duran et al., 2017), (Muraki et al., 2013). Furthermore, compounds present 
in green tea, strawberry, raspberry, blueberry and blackcurrant have been shown 
to be potent inhibitors of α-amylase and α-glucosidase (McDougall et al., 2005), 
(Nyambe-Silavwe et al., 2015). These enzymes, responsible for sugar production, 
are also the target of the anti-diabetic drug acarbose, meaning that a long-term 
consumption of (poly)phenols could have a comparable effect to this drug on 
reducing diabetes risk (Williamson, 2013). To add to that, certain compounds, such 
as quercetin, have been shown to lower glucose absorption by inhibiting GLUT2-
mediated glucose uptake, in cell and oocyte models (Kwon et al., 2007), (Johnston 
et al., 2005). Expression of the facilitative sugar transporters GLUT2 and GLUT5 
is elevated in the diabetic state, meaning that sugar metabolism is permanently 
increased in diabetic patients (Legeza et al., 2014), (Cohen et al., 2014). For this 
reason these transporters are possible targets for slowing down the rate of sugar 
absorption in the gut, and its associated responses (Williamson, 2013). In vivo, a 
(poly)phenol-rich intervention, with compounds that inhibit digestive enzymes and 
sugar transporters, was shown to have an impact on postprandial blood glucose 
by significantly reducing the area under the curve (Nyambe-Silavwe and 
Williamson, 2016). In this project, direct inhibition of transporters expressed in the 
gut, able to transport fructose, by specific (poly)phenols was investigated. This 
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research aspired to identify specific compounds or extracts that could potentially 
be added to interventions aimed at improving health markers, control of fructose 
uptake and post-prandial distribution of sugars in both healthy volunteers and 
patients with CVD or diabetes.  
 
7.2 Discussion of research outcomes and novelty of findings 
7.2.1 Characterization of hGLUT7 
Expression of both GLUT2 and GLUT5 has been shown to be increased in the 
presence of glucose and fructose, respectively (Legeza et al., 2014), (Cohen et al., 
2014), suggesting that expression of sugar transporters could be modulated by 
sugars. Glucose and fructose uptake by heterologously expressed GLUT7 in the 
X. laevis oocyte model has been previously observed (Li et al., 2004), and 
confirmed in this study through expression of GLUT7 mRNA derived from two 
distinct plasmids (Chapter  6). As fructose was identified as a substrate for this 
protein the effects of this sugar on the expression of GLUT7 was investigated in 
this project. There was a significant increase in mRNA and total protein expression 
when cells were grown in media supplemented with fructose, compared to glucose 
only. Nevertheless, increase in GLUT7 protein expression was more extreme than 
changes in mRNA levels. This suggests that perhaps the increase in protein 
expression is not a direct effect of the marginally elevated GLUT7 mRNA levels, 
but rather, due to post-translational modifications (PTMs). Chemical modifications 
brought about by PTMs may impact localization and activity of proteins, as well as 
their interactions with other cellular molecules (Lodish et al., 2008). There are over 
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300 different types of PTMs known, some occurring shortly after translation and 
impacting protein folding and stability, while others take place after folding and 
localization, thereby affecting the biological activity of the protein (Jensen, 2004). 
The dynamic activity of the human proteome in response to different stimuli is 
commonly mediated through PTMs, which aim at cellular activity regulation (Lodish 
et al., 2008), (IHGSC, 2004). Glycosylation, or the attachment of sugar moieties to 
proteins, is a PTM that can affect protein-protein interactions, due to the increase 
in size and ‘bulkiness’ of the protein, by facilitating or preventing protein binding to 
similar interaction domains (Rudd and Dwek, 1997). Changes in protein solubility 
are also correlated to glycosylation (Jensen, 2004). In the endoplasmic reticulum 
(ER), protein glycosylation ensures that only properly folded proteins are trafficked 
to the Golgi, serving as a quality control for the protein folding process (Wormald 
et al., 2002). Therefore, it is possible that in the presence of fructose, more GLUT7 
protein is glycosylated, and hence, transported to the Golgi for secretion into the 
cytoplasm (Lodish et al., 2008). Another possibility is that GLUT7, stored in 
vesicles responsible for transport of proteins between the Golgi compartments, is 
more readily released in the presence of fructose, leading to higher expression 
levels of this protein being detected (Nelson and Cox, 2008), (Cooper, 2000). One 
of the most common types of glycosylation is N-glycosylation, where the glycan is 
attached to the carboxamido nitrogen on asparagine residues (Trombetta, 2003). 
GLUT7 protein, expressed in the oocytes and Caco-2/TC7 cell models, is N-
glycosylated, as determined by a shift in size following treatment with the 
peptide:N-glycosidase (PNGase) F (Chapters 3 and 6). The interaction of lectins, 
glycan-binding proteins, with glycosylated proteins are a commonly used tool for 
glycoprotein identification and purification (Varki et al., 2009). To add to that, the 
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isotope-coded glycosylation-site-specific tagging (IGOT) technique, which is based 
on lectin column-mediated affinity binding with glycoproteins followed by specific 
incorporation of a stable isotope tag into the N-glycosylation site, allows for peptide 
identification by LC-MS. Differences in the absolute amounts of glycosylated 
GLUT7 following treatment with and without fructose, using imaging or LC-MS 
techniques, would help to further characterize the role that this sugar plays in the 
regulation of fructose uptake.   
 
7.2.2 Sugar uptake experiments  
Uptake of sugar by heterologously-expressed human proteins was successfully 
observed using the X. laevis oocyte model. This expression model targeted each 
individual GLUT transporter on their own, allowing for a precise characterization of 
inhibitors for each transporter. Biological variation between oocytes was expected, 
and changes in level of protein expression by this model are likely to be attributed 
to the seasonal variations and husbandry facilities, as discussed previously in 
Chapters 4-6 (Delpire et al., 2011), (Conn, 1991), (Miller and Zhou, 2000). 
Fructose-specific transporter, GLUT5 was significantly inhibited in the presence of 
sugar analogue inhibitors L-sorbose-Bn-OZO and 2,5-anhydro-D-mannitol, as 
expected (Girniene et al., 2003), (Yang et al., 2002), (Tatibouet et al., 2000). 
Inhibition of fructose uptake by this transporter was also achieved in the presence 
of EGCG, as previously reported (Slavic et al., 2009). In addition, through the 
expression model created and used for uptake experiments in this project, novel 
GLUT5 inhibitors were determined, namely, apigenin, hesperetin, and its glycoside 
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hesperidin. Sugar-free pomegranate and German chamomile plant extracts also 
significantly inhibited GLUT5-mediated fructose uptake in this model (Chapter 4).  
 
Confirmation of hGLUT2 expression model functionality was achieved through 
observed inhibition of this transporter in the presence of known inhibitors phloretin, 
quercetin and cytochalasin B (Kwon et al., 2007), (Song et al., 2002), (Jung and 
Rampal, 1977), (Krupka, 1985). Using the oocyte expression model, novel 
inhibitors of GLUT2-mediated glucose uptake, in the form of plant extracts and pure 
compounds, were also determined. Inhibitors of GLU2-mediated glucose uptake 
are as follows; German chamomile, green tea, sugar-free pomegranate, and 
oleuropein-rich (Bonolive) extracts, as well as pure compounds hesperetin and 
hesperidin. Furthermore, glucose and fructose uptake by this transporter was 
shown to be significantly inhibited in the presence of apigenin, EGCG and 
quercetin (Chapter 5).  
 
Expression of hGLUT7 in oocytes has previously produced controversial results, 
with some groups being able to identify uptake of glucose and fructose by this 
transporter, while others observed no sugar uptake (Li et al., 2004), (Ebert et al., 
2017). To date, there have been no reports of specific inhibitors of this proteins. In 
this project, uptake of fructose and glucose by hGLUT7 expressed in oocytes was 
observed with mRNA derived from two independent plasmid constructs. 
Furthermore, neither phloretin nor cytochalasin B were shown to inhibit GLUT7 
sugar uptake, however, a competitive inhibition of glucose uptake by this 
transporter was associated with presence of fructose, as previously reported (Li et 
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al., 2004). In this project, an inhibition trend of GLUT7-glucose mediated uptake 
was observed in the presence of EGCG. Moreover, apigenin, at high 
concentrations, significantly decreased the uptake of fructose by GLUT7. These 
observations were comparable for the two individual hGLUT7 expression models, 
derived from microinjections with mRNA obtained from two separate hGLUT7-
containing plasmids, used in the uptake experiments (Chapter 6). The observation 
that GLUT7 is able to transport fructose is in agreement with the hypothesis that a 
conserved isoleucine-containing motif in the sequence of GLUTs 2, 5 and 7 is 
responsible for the transport of this sugar (Manolescu et al., 2005). GLUT5 
inhibition by the compounds identified in this research project are likely to act by 
competitive inhibition, through binding to the active site and/or binding-site cleft, 
where bulkier groups are able to bind and potentially lead to a stronger inhibition 
of this protein (Yang et al., 2002), (Girniene et al., 2003). Molecular docking 
analysis of well characterized GLUT2 inhibitors have shown that while phloretin 
binds extracellularly to this protein, where glucose also binds, cytochalasin B binds 
to an intracellular binding site (Salas-Burgos et al., 2004). Furthermore, reported 
KM values for uptake of sugars by GLUT2 in the presence and absence of quercetin 
suggests that binding site for sugar and this compound are different (Kwon et al., 
2007). A comparison of inhibition profiles, obtained from analysis of sugar uptake 
in the presence of different concentrations of these well-established inhibitors, 
could help identify the specific binding site of (poly)phenols and plant extracts 
shown to significantly inhibit sugar uptake by GLUT2 and GLUT5. In addition, a 
linear-regression analysis of data from uptake experiments with varying 
concentrations of sugars, as well as (poly)phenols, could help confirm the 
hypothesis that these compounds and extracts exert their effects through 
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competitive inhibition of these transporters. This would, of course, require 
optimization of uptake experiments as too high a sugar concentration might not 
lead to any inhibition being detected, as was the case for GLUT5 inhibition 
experiments with high fructose concentrations (refer to Chapter 4). Moreover, 
structure based molecular docking and molecular dynamics studies could also help 
identify the type of inhibition exerted by compounds tested in this research, as well 
as determine the stability of their interactions with the transporters (Garcia-Mora et 
al., 2017). Nevertheless, this would require a precise structure of the GLUT 
transporters to be identified, an extremely challenging task for membrane-bound 
proteins due to their flexibility, lack of stability and partially hydrophobic surfaces 
(Carpenter et al., 2008). Development of a photoaffinity probes for the systems of 
interaction between the GLUT transporters and their inhibitors, identified in this 
research, would also help to establish the molecular interactions of the compounds 
with the transporters (Smith and Collins, 2015), (Tatibouet et al., 2000). Moreover, 
probing of the structure and steric factors that manage the interactions of glucose 
and fructose with GLUT7 would provide invaluable information about the binding 
potential of these sugars, and offer a stepping stone for the development/discovery 
of new inhibitors of this transporter (Smith and Collins, 2015). The pure compounds 
apigenin, quercetin and EGCG were used in sugar uptake inhibition studies on 
GLUT2, GLUT5 and GLUT7. In addition, these three compounds were used in 
experiments with two substrates of GLUT2 and GLUT7, namely fructose and 
glucose. Table 7.1 summarizes the results of the sugar uptake inhibition studies 
conducted with these compounds on all three GLUTs. Uptake experiments carried 
out in Chapters 4 and 5 identified that fructose uptake by GLUT2 and GLUT5 was 
significantly inhibited by apigenin, EGCG, hesperidin, German chamomile extract, 
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and sugar-free pomegranate extract. Apigenin also significantly inhibited fructose 
uptake by GLUT7 (Chapter 6). The potential of an additive inhibition induced by 
these compounds could be identified through co-expression of proteins in the X. 
laevis oocyte model. Further investigations of the impact of these compounds and 
extracts using other models, including in vivo work, would help determine their 
direct impact on the responses associated with sugar absorption.  
 
Table 7-1 Summary of inhibition of GLUT2-, GLUT5- and GLUT7-mediated sugar 
uptake by pure compounds apigenin, quercetin and EGCG 
 GLUT2 GLUT5 GLUT7 
glucose fructose fructose glucose fructose 
Apigenin 
(µM) 
27 ± 4 28 ± 10 40 ± 4 38 ± 2 16 ± 12 
Quercetin 
(µM) 
7 ± 1 8 ± 2  NI NI NI 
EGCG 
(µM) 
72 ± 13 93 ± 16  72 ± 13 NI NI 
* NI = no inhibition 
 
The flavonoids listed in Table 7.1 above, investigated for their inhibitory potential 
on GLUT2, 5 and 7- mediated sugar uptake in this project, have been previously 
reported to have an inhibitory impact on other sugar transporters as well, with 
EGCG inhibiting GLUT1 and SGLT1 (Slavic et al., 2009), (Johnston et al., 2005) 
and apigenin downregulating GLUT1 mRNA and protein expression (Melstrom et 
al., 2008). Quercetin has been shown to inhibit GLUT1 sugar transport as well as 
insulin-mediated GLUT4 translocation in adipocytes (Xu et al., 2014), (Strobel et 
al., 2005), which like GLUT2, belong to class 1 in the GLUT classification (Mueckler 
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and Thorens, 2013). Together with the data presented here this suggests that 
flavonoids have the potential to be used as inhibitors of multiple GLUT transporters. 
The interaction of flavonoids with GLUTs is likely exerted through binding on a site 
that differs from the binding site of the sugar, and inhibitory potential could be 
additionally linked with the sequence similarities between GLUTs. For instance, 
quercetin has been shown to inhibit GLUTs 1, 2 and 4 (Xu et al., 2014), (Kwon et 
al., 2007), (Strobel et al., 2005), all of which belong to class 1. Furthermore, it was 
concluded from sugar uptake experiments presented in Chapter 6 that GLUT7 is 
able to transport both glucose and fructose, supporting the hypothesis that an 
isoleucine-containing motif present in GLUTs 2, 5 and 7 could be essential to 
fructose transport (Manolescu et al., 2005). Considering GLUT protein sequence 
may dictate which substrates are recognized by GLUT transporters, it could also 
be important in the potential binding and inhibitory effects of flavonoids.  
 
7.3 Future research perspectives  
7.3.1 Cell culture studies 
Inhibition of GLUT2 and GLUT5-mediated sugar uptake by specific compounds is 
associated with binding at the same site as the substrates, we well as additional 
binding to other sites on the protein (Yang et al., 2002), (Girniene et al., 2003), 
(Salas-Burgos et al., 2004). Similarly, GLUT7-mediated glucose uptake was 
significantly inhibited by presence of fructose, likely due to competitive inhibition 
(Li et al., 2004), (Chapter 6). Although it is thought that (poly)phenols would exert 
inhibition of sugar uptake by this protein in the same manner, it is possible that 
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certain compounds also have an effect on protein expression levels. For this 
reason, analysis of GLUT7 protein and mRNA expression in cells grown in the 
presence of apigenin, shown to significantly inhibit fructose uptake by this protein 
(Chapter 6), would help to determine the mode by which this compound bestows 
inhibition. Trafficking of the protein to the membrane, or re-internalization of 
membrane bound protein, could also be a potential target for inhibitors. Therefore, 
quantitative analysis of cell surface GLUT7 expression, using the cell surface 
biotinylation technique, following treatment with apigenin would help provide 
further information as to the potential inhibitory mechanisms of this compound.   
 
7.3.2 Human intervention studies 
(Poly)phenols have been shown to impact carbohydrate digestion and sugar 
absorption by the intestine through their inhibition of digestive enzymes and sugar 
transporters, as previously discussed (Manzano and Williamson, 2010), 
(McDougall et al., 2005), (Hanhineva et al., 2010). To add to that, data has 
demonstrated that dietary (poly)phenols maybe have potential prebiotic effects, 
promoting the growth of particular bacteria in the gut that have been linked to 
improved glucose tolerance (Jin et al., 2012), (Vendrame et al., 2011), (Kim et al., 
2016). This research project focused on identifying potential inhibitors of specific 
sugar transporters expressed in the gut with the aim to instigate human intervention 
studies that would then investigate the effects of the novel inhibitors identified in 
vivo, using concentrations achievable through the diet or supplementation. 
Intervention studies looking at the effects of long and short-term (poly)phenol 
exposure suggests a protective effect against many different conditions through 
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attenuation of risk factors (Arts and Hollman, 2005), (Williamson and Manach, 
2005), (Shi and Williamson, 2016). A study looking at the effects of acute and 
chronic black tea consumption, for instance, showed a reversal of endothelial 
dysfunction in patients with coronary artery disease (Duffy et al., 2001). 
Furthermore, an investigation of the acute effects of a (poly)phenol-rich 
intervention on glycaemic response showed that (poly)phenols had an effect on 
postprandial blood glucose in vivo, by reducing the area under the curve (Nyambe-
Silavwe and Williamson, 2016). Short and long-term administration of apigenin, 
shown in this study to inhibit three fructose transporters, in the form of a human 
intervention, would help determine the potential effect of this compound on 
postprandial glycaemic response. Isotopic tracer studies could be used to measure 
changes in fructose levels in the plasma following consumption of apigenin as a 
supplement or dietary form, eg. German chamomile extract (Sun and Empie, 
2012b). In addition, analysis of faecal samples following interventions with apigenin 
could establish the presence of Bifidobacteria, a genus of bacteria associated with 
improved glucose tolerance and lowered inflammatory markers (Vendrame et al., 
2011), (Cuervo et al., 2015). Investigating the potential effects of apigenin by 
different methods of delivery, namely through the diet or supplementation, would 
also provide valuable information about the functionality of this compound as a 
sugar absorption inhibitor in vivo.  
 
 
 
 
 
231 
 
7.4 Overall conclusion 
One of the novel findings of this research was that expression of GLUT7 was 
significantly increased in the presence of fructose, as seen in the Caco-2/TC7 cell 
model. This project identified that only apical and basolateral fructose, and not the 
other sugars tested, induced both GLUT7 mRNA and total protein in differentiated 
Caco-2/TC7 cells. The increased protein concentration in the cell did not change 
the ratio between surface-expressed and total protein, implying that increases were 
due to more protein synthesis or less degradation, and not enhanced trafficking 
per se. This observation beckons for additional studies to further characterize the 
lesser known GLUT7, with the aim to establish the role it plays in the regulation of 
sugar uptake. Another overall objective of this project was to determine the direct 
impact of specific (poly)phenols and food extracts on fructose and glucose uptake 
by GLUT2 and GLUT7 transporters, as well as their effect on sugar uptake by the 
fructose specific transporter GLUT5. Differentiated Caco-2 and Caco-2/TC7 cell 
monolayers, as for the intestine in vivo, express a variety of GLUTs and other sugar 
transporters, which makes them unsuitable for determination of the role of 
individual transporters. Therefore the Xenopus laevis expression system was used 
to elucidate effects of (poly)phenols as inhibitors on individual functional GLUTs. A 
successful quantitative model was set up, through heterologous expression of 
human transporters present in the gut in X. laevis oocytes, with the outlook to 
quantify the inhibition of sugar transporters by polyphenols. Through this, novel 
inhibitors of GLUT2-mediated glucose and fructose transport, as well as GLUT5-
mediated fructose transport, were established. Furthermore, one compound 
(apigenin), able to significantly inhibit fructose uptake by GLUT2, 5 and 7, was 
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identified. The results from uptake experiments using the X. laevis oocyte model 
obtained in this project can be used to validate cell culture and in vivo studies, as 
well as inspire future studies using these models. In addition, this research 
highlights the potential that (poly)phenols have to modulate sugar transport by 
inhibition of GLUT transporters, and that the specificity of inhibition could be 
exploited in mechanistic studies to examine the role of sugar transporters in cells. 
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Appendix A   pBF plasmid sequence 
 
    XbaI restriction site    PolyA tail    SP6 promoter 
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Appendix B   GLUT5pBF sequence 
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Appendix C   GLUT2pBF sequence 
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Appendix D   GLUT7pBF sequence 
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Appendix E   GLUT7pGEM-HE sequence 
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Appendix F   Confocal images of GLUT2 with WGA 
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Appendix G   Confocal images of GLUT7 with WGA 
 
 
